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Anand Kulanthaivel 
STUDYING RARE PATIENTS WITH COMMONLY-AVAILABLE INFORMATION: 
SOCIAL MEDIOMICS FOR RESEARCHING PATIENT HISTORIES IN AUTOIMMUNE 
HEPATITIS (AIH) 
 
Autoimmune Hepatitis (AIH), an incurable chronic condition of unknown cause where 
the body attacks its own liver, is a rare disease, with a current diagnosed worldwide prevalence of 
< 150,000.  Inadequately treated, AIH can cause progressive liver damage and ultimately liver 
failure. A wide variety of symptoms are associated with AIH including severe fatigue, joint pain, 
depression, anxiety, and insomnia. 
While precision medicine’s genomics has attempted to shed light on the disease, other 
non-molecular “-omics” approaches can be taken in studying AIH patients, who often utilize 
social media to gather information from other patients or care providers to apply to their own AIH 
disease course.  It is proposed that these patient-generated social mediomes can create self-report 
health records for patients – and facets of their lives - otherwise unreachable by conventional 
research. 
In this feasibility study, I examined in an exploratory fashion the social mediome of a 
large (N > 1000) gathering of AIH patients and caregivers as present on a Facebook Group to 
determine the potential of mining various types health-related user information.  The following 
types of information were mined, with feasible indicating a reliability of F >= 0.670: 
 
1) Types of health information shared and structures of information sharing (Feasible) 
2) Types and directionality of support provided by and to users (Portions feasible) 
 
 
 
vi 
3) Clinical factors (AIH-related and otherwise) disclosed by users 
a. Medication intake (Feasible) 
b. Signs and symptoms (including pain and injury) and diagnosed comorbidities 
(Portions feasible) 
c. Results of disease monitoring blood tests (Portions feasible) 
4) Contextual (non-clinical; environmental; social) factors disclosed by users (Detection of 
which type of factor discussed occasionally feasible). 
 
The resulting knowledge is required to adequately describe the disease not only clinically, but 
also environmentally and socially, and will form part of the basis for future disease studies. 
 
Josette F. Jones, R.N., Ph.D., Chair 
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LIST OF DEFINITIONS & ABBREVIATIONS 
 
 AIH (Autoimmune hepatitis): a disease where the body’s own immune system attacks the 
liver.  Unrelated to viral hepatitis disorders.  Occasionally known as Autoimmune Liver 
Disease (ALD; AILD), Hepatic Lupus, or Liver Lupus. 
 AC: Stands for “administering colleague” and refers to a hepatologist colleague of the 
author’s, who administers the researched Facebook™ group. 
 Annotation (also “annotating”, “annotated”, etc.): The procedure of a human reading a 
document and marking features about it. 
 Autoimmune: Indicating any disorder where the body’s own immune system attacks other 
parts of the body. 
 Comment: On Facebook™, refers to a reply made to a post. 
 Corticosteroid(s): A class of immunosuppressive medications related to cortisol, a natural 
human hormone. 
 Emotional Support: A type of verbal support given to enhance the receiver’s emotions.  
Used here as well as a synonym for social support. 
 Etiology: The root cause(s) of a condition 
 Facebook™: The world’s largest online social media (SM) venue. 
 FML: In this dissertation used to refer to Facebook Metalayer Language, a novel format 
used to store data and metadata about user-generated content from Facebook™. 
 Genotype: A genetic characteristic of a person, determined by DNA sequence. 
 Hepatic: Refers to things that have to do with the liver 
 Immunosuppressant (also “immune suppressant” or “immunosuppressive”): Refers to a 
drug that reduces the functioning of the immune system. 
xii 
 IPI (Identifiable Private Information): referring to information that can be used to contact 
an individual.  The exact categorization of what does and does not constitute IPI may vary by 
jurisdiction. 
 Mediate (also “mediated” or “mediates”): To have a role in the occurrence of something.  
If A mediates B, this indicates that A has a role in B’s occurrence. 
 Morbidity: Suffering, both subjective and objective, caused by a condition 
 Mortality: Death caused by a condition 
 NLP (Natural Language Processing): referring to a variety of tools and algorithms that 
mine, process, and classify large bodies of text. 
 Pathogenesis: The way by which a disease starts. 
 Phenotype: Something about a person or organism that is not described by a gene sequence 
(common examples include hair color and laboratory test result values). 
 Post: On Facebook™, refers to a top-level posting.  Comments are replies made to these 
posts. 
 Rare disease(s): Conditions that each affect fewer than 1 in 1,500 Americans but together 
affect over 10%.  Also known in some parlances as rare disorder(s) and/or rare condition(s). 
 SM (Online social media): a diverse set of Internet-based sites and services that offer 
platforms for anybody to communicate and publicize.  Venue is a suffix that refers to a 
specific instance of online social media. 
 User-generated content: Content (text postings) made by everyday users over online social 
media (SM).  Similar to patient-generated data, except the users are not necessarily patients 
and what they post is usually free text. 
 User narrative: In this dissertation, refers to the entire communication text of a single social 
media venue user over that venue, compiled into a single, human-readable file. 
xiii 
 Xenobiotic: Referring to any substance or chemical that is foreign to the human body.  Most 
xenobiotics studied in medicine are pharmaceutical products (drugs), but other important 
classes of xenobiotics are over the counter medications and certain chemicals (vitamins, 
minerals, and various other organic small molecules) present in foods and herbal 
supplements. 
  
1 
CHAPTER 1. INTRODUCTION TO THE PROJECT 
 
1.1 Summary Introduction 
 
The increasing globalization and inter-connectedness of shared information has benefits 
and disadvantages.  The inter-connectedness of information shared in the non-research realm, 
while leveraged by major corporations for profit, is insufficiently leveraged by the biomedical 
field for underserved communities, including those with conditions (i.e., rare diseases) that are 
neglected by the current research establishment. 
Autoimmune Hepatitis (AIH) is an example of a rare disease that is underserved by 
current research: Different from the more commonly known viral hepatitis disorders, it is a 
chronic, immune-mediated, and incurable disease of the liver that creates significant morbidity in 
affected patients.  Studying patients with this disease is difficult due to the fact that its rarity 
creates inherent geographic barriers.  Furthermore, the etiology of AIH is multifactorial and 
includes variables that are beyond reach of detection by clinicians during office visits.   
Online social media (SM) consists of a set of Internet-based venues that allow for peer-
to-peer and global sharing of communications; SM has a very high global rate of usage.  SM has 
been shown to be a productive and non-invasive venue for gathering patient-generated data 
pertaining to disorders both rare as well as common. Particularly prevalent are online SM venues 
that cater to specific patient disease groups. 
It is therefore hypothesized that histories of patient clinical variables, including 
medication usage, AIH-related symptoms, self-reported clinical comorbidity, and clinically 
relevant environmental factors can be discovered via reading the posts of affected individuals 
over social media.  Due to the importance of the provision of social support in the care of rare 
diseases, it is also important to study how social support is offered to and between those affected 
by AIH and the effects of the social support offered.   
2 
Most importantly, a colleague of the author’s, know here as AC (Administering 
colleague), administers and moderates a Facebook™ group online social venue1 for patients with 
AIH. Because online SM venues are frequently used to share condition-related information, the 
types of AIH-related information shared between patients, caregivers, researchers, and providers 
can be assessed via analysis of this Facebook™ group.  
 
1.2 Goal & Purpose 
 
Thus, by utilizing patient-generated data from an AIH-specific SM venue, the 
overarching goal is to assess if social media communications can be analyzed to enhance the 
body of knowledge that surrounds this disorder, and therefore create a knowledge framework that 
may one day be used to improve clinical and everyday care of those with AIH.   
 
1.3 Aims & Hypotheses 
 
Specific Aim A: To identify and categorize the body of information that is distributed via a large 
AIH-related SM venue and communication structures by which this information is shared.  The 
information that are shared over SM are diverse and may include personal patient stories, general 
advice from practitioners, research-related information, and health-related advertising.  
Describing the types of information found as well as finding out how it is shared is expected to 
help enhance future patient disease resources. 
 
1 Note: The identity of this Facebook™ group is withheld from this dissertation for 
reasons of privacy. 
 
3 
Specific Aim(s) B1/B2/B3: To determine the feasibility of analyzing AIH-related social media 
content from an AIH-related Facebook group better inform the clinical and social research 
community about the disorder, enhancing knowledge of:  
 Sub-Aim B1: Pharmaceutical treatments discussed by AIH patients 
 Sub-Aim B2: Clinical symptoms and comorbidities that impact quality of life of AIH 
patients 
 Sub-Aim B3: Contextual and environmental factors that could potentially correlate with 
the AIH disease process  
 
Specific Aim C: To determine the structures and types of social support offered to and between 
AIH patients and caregivers over SM communications on an AIH-associated SM venue.  Due to 
the importance of social support provision in the care of incurable diseases such as AIH, it is 
required to study the types of and quantity of social support that is offered to and between AIH 
affected individuals over SM communications.   
 
The hypotheses of this dissertation’s research are in a one-to-one relationship with the 
specific aims.  Because the research conducted in this dissertation is of the exploratory proof-of-
concept nature, hypotheses are all alternate and center on feasibility goals and not explanatory 
ones. 
 
Specific Aim A Alternate Hypothesis: The health-related information communicated between 
patients, caregivers, clinicians, and researchers over an AIH-associated SM venue can be 
analyzed in order to determine its origin and subject matter. 
 
Specific Aims B 1/2/3 Alternate Hypotheses: The alternate hypotheses for each sub-aim under 
Specific Aim B are similar; they all state that a certain type of factor (pharmaceutical product 
4 
usage, symptoms, or contextual/environmental factors) can be discovered through studying social 
media communications of users in an AIH-associated SM venue. 
 
Specific Aim C Alternate Hypothesis:  Types and contents of, and communication metrics of, 
social support given between AIH patients and caregivers can be detected via analysis of an AIH-
associated SM venue. 
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CHAPTER 2. GENERAL BACKGROUND & LITERATURE REVIEW 
 
2.1 Rare Diseases: An Introduction 
 
As defined by the National Organization for Rare Disorders (NORD), rare diseases 
comprise conditions that each affect fewer than 1 in 1,500 Americans (i.e., fewer than 200,000 
individuals across the US population) 1. Over 7,000 rare diseases are recognized by NORD and 
the total prevalence of diagnosed Rare diseases is estimated to be approximately 10%.2  Rare 
diseases are, for the most part, not curable.  This problem, combined with the fact that Rare 
diseases may present extreme morbidity and often premature mortality to patients, makes rare 
diseases a significant nationwide burden on quality and quantity of life.  
The situation of rare disease patients is exacerbated due to the fact that although current 
research in Rare diseases is progressing well, it still lacks optimal quality and quantity. Writing 
for Clinical Pharmacology & Therapeutics, Smith (2016) states that rare disease is a topic where 
“there are no experts among us” (p. 312)3. The inherent rarity of these conditions creates major 
barriers to recruiting and retaining patients in research and treatment.  It is also noted that rare 
disease patients themselves have geographical disadvantages: rare disease patients also often 
travel large geographic distances in order to participate in research and even to seek treatment. 4, 5 
 
2.2 Autoimmune Hepatitis (AIH): Epidemiological, Etiological, Clinical 
 
Next, it is elaborated the clinical entity that is the object of this dissertation: Autoimmune 
Hepatitis (AIH), being a rare disease, inherits the research and treatment issues seen with other 
rare diseases.  Its extreme rarity (less than 1.2 out of 100,000 in the US are diagnosed6)  and 
exceptional burden of morbidity create further significant difficulties in studying populations with 
the disease and can also make treatment and daily life with the disease very difficult for patients.  
6 
Differences in researching adequate sample sizes of AIH patients are exacerbated by its 
multifactorial etiology. 
One factor proposed to be involved in the etiology is viral disease.  Infectious diseases 
that may predispose individuals to AIH include prior infections including Epstein-Barr Virus 
(EBV) and Hepatitis C Virus (HCV), but It has notably been observed that correlation of AIH to 
EBV and HCV infection is difficult due to the small sample size of available AIH patients for 
direct study.7  Similarly, one case report series discussed a potential association of AIH with 
human immunodeficiency virus (HIV), but with only three case studies.8 
Non-AIH autoimmune disorders are widely thought to be found at a much higher rate in 
AIH patients than in the general population.  The disorder most commonly thought to be 
comorbid with AIH is autoimmune thyroiditis (also known as Hashimoto thyroiditis), considered 
comorbid by Wong & Heneghan’s review with between 8% and 20% of all AIH cases.9  
Rheumatoid arthritis (RA) was also noted by this review to be comorbid, with an estimated 
prevalence of 4-6% in the AIH population.  The association between AIH and celiac disease (a 
form of autoimmune-mediated gluten intolerance) was demonstrated in one case study.10  
Furthermore, researchers claimed the development of AIH in a patient with psoriasis not 
controlled by immunosuppressants.11   
Genetic correlates exist for AIH, but the literature evidence from the author’s perspective 
appears to still be sparse.  One study showed that alpha1-antitrypsin (A1A) deficiency phenotypes 
were more prevalent in patients diagnosed with Type 1 AIH (a subtype of AIH).12  The 
expression of TIPE2, a tumor necrosis factor-induced protein, was found to be altered in a mouse 
model of autoimmune hepatitis, but as of that study (March 2017), no human correlation had been 
reported. 13  In humans, genetic culprits invoked by researchers include certain human leukocyte 
antigen (HLA) subtypes, with several anomalous variants of these genes being modestly 
correlated in one genome-wide association study with the presence of AIH.14 Therefore, studying 
AIH beyond the patient genome is desired. 
7 
Xenobiotics, a collective group of chemicals encompassing most pharmaceutical 
products, many nutritional supplements, and most environmental toxins, are defined as 
compounds or substances that are foreign nature to the body.15  Researchers have positively 
correlated intake of various xenobiotics with the development of AIH.  Antibiotics (in particular, 
preparation combinations thereof) are perhaps the largest treatment group of medications known 
to correlate with AIH development.  The antibiotic combination preparation trimethoprim-
sulfamethoxazole (TMP-SMZ; TMP-SMX) has also been associated with the development of 
AIH.16  Another common antibiotic combination, amoxicillin with clavulanic acid 
(AUGMENTIN; Amox-Clav; Amoxicillin-Clavulanate) has been hypothesized to increase the 
chances of developing AIH.  Similarly, tetracycline antibiotics have been implicated in the 
pathogenesis of drug-induced AIH in a series of case studies and also in single, modestly sized 
AIH cohort. 17   
Other medication families and medications have been suggested by researchers as AIH 
triggers.  Case reports long implicated the statin family of drugs in the pathogenesis of AIH.16, 18-
20  In addition, use of the drug nitrofurantoin was found to precede a form of drug-induced liver 
injury with microscopic features of AIH.21  A separate review of hepatotoxic medications also 
implicated the pharmaceutical products carbamazepine, chlorpromazine, methotrexate (a 
treatment option for rheumatoid arthritis, commonly comorbid with AIH), ibuprofen, and 
valproates.22 
Variables influencing and confounding the etiology of AIH are hypothesized to reach 
beyond what is detectable in the clinic and extend into the patient’s environment; these variables 
often are also associated with xenobiotic exposure.  The common herbal supplement black cohosh 
has been implicated in the pathogenesis of AIH.23 Another environmental variable is 
hypothesized to be exposure to environmental pollution; trichloroethylene (TCE), present in low 
levels in much of the United States’ water supply, has been implicated in autoimmune liver 
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diseases including AIH 24, and the organic compound vinyl chloride has been suggested to 
increase the risk of liver lesions (including those that are autoimmune-mediated). 25   
Diet, an important part of the patient environment, may also have a role in the 
pathogenesis of AIH.  Due to the aforementioned finding of celiac disease association with AIH, 
it is hypothesized that gluten consumption could be an etiological or aggravating factor in some 
patients with AIH.10  A population-based study in New Zealand found that positive past histories 
of alcohol usage, despite that chemical’s well-known hepatotoxic effects, were correlated with a 
lower prevalence of AIH. 16 
In summary, the diversity of etiological variables – particularly those seen outside of 
genetics -- correlated to AIH makes it significant to study every potential factor that surrounds the 
AIH group user; clinically-oriented data such as drugs, signs, and symptoms are unlikely to 
divulge a full picture of the AIH group user.  Furthermore, the clinical environment usually 
cannot ascertain environmental factors, making the study via social media of AIH patients’ day to 
day lives of potential benefit. 
The possibility exists that xenobiotics other than those currently implicated may still be 
implicated in AIH’s pathogenesis. General liver toxicity due to medications is known as drug-
induced liver injury (DILI), but the International Autoimmune Hepatitis Group (IAIHG) states 
that DILI must be excluded from the diagnosis of AIH and yet simultaneously state that there 
exists no means by which DILI should be excluded.26, 27   Furthermore, the concept of drug-
induced autoimmune liver disease (DIAILD) does exist; it biochemically and clinically bridges 
AIH (and similar disorders) with DILI.  The main anomaly in the relationship is that some forms 
of DIAILD are acute and resolve with drug discontinuation.  Nonetheless, checkpoints of 
molecular cascades are shared in common between DILI, DIAILD, and AIH28  Therefore, it is of 
interest to study the use of a general corpus of xenobiotics as potential triggers of AIH. 
In addition, treatments (such those for AIH) that have a high side effect burden may in 
turn incur an even higher burden of xenobiotic load by convincing the patient, provider, or both 
9 
that more medications and/or supplements are needed.29  Therefore, the potential for both 
beneficial and adverse polypharmacy may be studied by using a wide net across all potentially 
consumed xenobiotics. 
Other substances whose use is not easily ascertainable in the clinic are also known to 
participate in AIH’s etiology.  The common herbal supplement black cohosh has been implicated 
in the pathogenesis of AIH.23  Another published compendium22 implies a larger list of 
supplements that may be responsible for DILI and DIAILD types of liver damage; the list 
includes not just black cohosh but also common supplements such as ginseng, ephedra, 
chamomile, milk thistle, kava kava, and pennyroyal.  
Although medications (xenobiotics) are correlated with AIH etiology, more obvious 
correlates in the usage of xenobiotic pharmaceutical products by AIH patients exist as the 
disorder requires medical treatment with regimens of immunosuppressants.  Pharmaceutical 
products commonly prescribed for AIH treatment include azathioprine, mechanistic Target of 
Rapamycin (mTOR) inhibitors, ursodiol (ursodeoxycholic acid), mycophenolate, and a variety of 
corticosteroids (chiefly prednisone, budesonide, and prednisolone).  The use of cyclosporine is 
also common after liver transplant, a procedure required in the most severe cases of AIH.30   
Comorbidities of AIH include recognized hepatobiliary sequelae as well as frequently co-
occurring autoimmune diseases.  Well-recognized hepatobiliary sequelae occur in autoimmune 
hepatitis (AIH) and, secondary to hepatic destruction, are comparable to those found in other 
hepatic diseases.  Widespread and greatly feared is cirrhosis, a permanent gross scarring and 
damage of liver tissue. 31  Hepatic encephalopathy (HE), a form of dementia secondary to the 
liver’s failure to properly filter out neurotoxic metabolites, may be found in more severe AIH 
cases.32  Certain hepatobiliary tract autoimmune comorbidities, whose presence are frequent 
enough to have titular AIH-overlap syndrome designations33, include the rare conditions primary 
sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC)34, the latter of which 
significantly increases the risk of cirrhosis in AIH.33   
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Autoimmune comorbidities outside the hepatobiliary tract are also noted.  A more recent 
and exceptionally wide-ranging study by Baven-Pronk et al (2018) discovered multiple 
comorbidities, with at least 2 (N > 150) patients each reporting autoimmune thyroiditis, celiac 
disease, scleroderma (systemic sclerosis), ulcerative colitis, diabetes mellitus, Crohn disease, and 
systemic lupus erythematosus (SLE).35 The latter finding is unsurprising knowing that the anti-
nuclear antibody (ANA) is noted to be one of those that may attack the liver in AIH.  Similarly, 
Karp et al (2010) assembled a sizable electronic medical record (EMR) cohort involving over 200 
AIH patients and found a strong association between AIH and Sjörgen Syndrome, an oral 
autoimmune condition.36 
The disorder most commonly thought to be comorbid by Wong & Heneghan’s review is 
in fact autoimmune thyroiditis (also known as Hashimoto thyroiditis or Hashimoto 
hypothyroidism), occurring in this opinion between 8% and 20% of all AIH cases.9   An 
association between AIH and celiac disease (a form of autoimmune-mediated gluten intolerance) 
was demonstrated in one case study. 10  Furthermore, the development of AIH has been 
documented in a patient with psoriasis not controlled by immunosuppressants. 11   
Comorbidities with no direct known relationship to AIH are also observed.  Physical pain 
is likely to be significant (see below section on physical pain in AIH), and the exceptionally high 
risk of disease-related psychological trauma may lead to increased experiences of reactive anxiety 
and depression in AIH patients.   Diabetes Mellitus (DM) is a common disease that can affect the 
liver via fibrosis37, steatosis38, and generalized hepatic destruction.39    AIH patients are equally 
prone to disorders that affect non-AIH-impacted patients, and it is uncertain how other disorders 
may influence the clinical course or quality of life of affected individuals. 
Adverse drug effects (ADEs) are symptoms attributable by the clinician as secondary to 
medication intake.  Typical ADEs are also known as side effects while less expected ADEs are 
known as adverse drug reactions (ADRs).  Corticosteroids, a mainstay of AIH treatment, have a 
heavy burden of ADEs, some of which (such as edema, weight changes, and impaired WBC 
11 
function40) are common to original disease symptoms.  Despite the beneficence of the treating 
clinicians, corticosteroids have been shown by at least one healthcare utility review to actually 
decrease quality of life of treated AIH patients compared to alternately-treated AIH patients.41   
Immunosuppressive regimens with corticosteroids and other potent immunosuppressants 
such as azathioprine (AZA) also contribute to an increased risk of infectious diseases.  In 
addition, such drugs and regimens are known to aggravate the paralyzing fatigue and 
psychological risks42 already observed in untreated disease.  As noted in the next section, pain is a 
common indirect sequela of AIH treatment. 
Most importantly, this dissertation notes mentions of potential user ADEs (including pain 
ADEs; see below) as simply symptoms and not in a special ADE class.  Specifically, the 
relationship will be viewed not in a clinical cause-and-effect knowledge framework, but instead 
in a scientific and associative one that is more suited the author’s academic training expertise.  
Associative analyses43 between drug intake (from the previous chapter) and signs and symptoms 
(from this chapter) can instead help elucidate (although not confirm) the relationships between 
drug intake and associated symptoms, which may or may not be ADEs. 
In all chronic disease patients, pain (referring to physical pain in this article) is a 
significant negative impactor of quality of life.  Pain has been hypothesized to be a significant 
ADE of AIH treatments.  Although the reasons are poorly known, immunosuppressants such as 
mycophenolate44,45 have been blamed as the cause for new-onset arthralgia in smaller studies. 
Indirectly, corticosteroids have been observed in non-AIH cohorts to increase pain burden by 
raising the risk of bone and joint degeneration, resulting in increased rates of painful injury 
including soft tissue injuries (bruises, sprains, strains, and similar)42 and osteonecrosis-induced 
bone fractures.46  The usage of some corticosteroids is strongly associated with other 
hepatobiliary derangements such as pancreatitis47, which are often extremely painful. 
Pain also occurs in AIH in manners that is currently not attributed to medication therapy.  
Likely due to hepatic inflammation and subsequent impingement on nearby sensory nerves, right 
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upper quadrant (RUQ) abdominal pain is frequently noted, and this pain may radiate to nearby 
regions of the abdomen.  Autoimmune comorbidities of AIH include joint diseases11 such as 
rheumatoid arthritis (RA) and psoriatic arthritis (PA), both of which feature arthralgia as a 
cardinal symptom.    
Pain, referring to discomfort in the purest sense, is not just physical but also can be 
mental (psychological).  Pain in the form of psychological distress (and potentially 
psychosomatic physical pain) is seen in AIH, which has neuropsychiatric disorder prevalence 
significantly higher than that of the general population and on par with infectious liver diseases 
(i.e., the viral hepatitides).48   Mental depression is a significant QOL-limiting factor in AIH and 
other inflammatory liver diseases49 and among the more feared of its neuropsychiatric sequelae.50  
Furthermore, immunosuppressant therapies (in particular, corticosteroids51) are associated with 
similar adverse neuropsychiatric effects.   
Other psychologically-mediated inhibited states are noted.  Fatigue (tiredness) is 
attributed to overall heavy illness burden but its specific etiology is still in the process of 
attribution.52, 53   Fatigue is also commonly attributed as an ADE. 42  Finally, cognitive 
impairment is also noted as in AIH and can be a direct consequence of the sequela of hepatic 
encephalopathy,32 and is also associated with depressed mood and fatigue.54 
AIH-relevant disease characteristics range beyond symptoms and extend into objective 
laboratory signs, which are correlated with mortality and objective outward signs but less so with 
burdens of pain and fatigue.  The monitoring of serum hepatic enzyme levels, conducted as the 
battery of liver function tests (LFTs), is the most significant cornerstone of AIH surveillance and 
management.  Enzymes typically assayed in LFT batteries include alanine transaminase (ALT), 
aspartate transaminase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transpeptidase 
(GGT).55  In the setting of AIH, the lowering of these enzymes’ levels close to normal baselines is 
the cardinal diagnostic measure for judging cycles of disorder remission and exacerbation. 
13 
Other hepatorenal parameters measured as surrogate remission measures include bilirubin 
and creatinine protein kinase (CPK).  Another important object of monitoring are titers of 
autoantibodies, atypical proteins that form the basis for the body’s autoimmune attack on itself.  
Seroprevalences of different antibodies, including anti-nuclear antibody (ANA), perinuclear anti-
neutrophil cytoplasmic antibody (PANCA), and anti-liver kidney microsomal type 1 (anti-LKM-
1) antibody are far in excess of those observed in the non-AIH population and in seropositive 
AIH patients are assayed as a surrogate for potential remission and exacerbation56 even though 
seropositivity is not an explicit required criteria for AIH diagnosis. 
 
2.3 Out of and Beyond the AIH Clinic: Contextual Factors 
 
In disorders such as AIH where researchers believe to have weak clinical etiological 
correlates and protean signs and symptoms, the diametric opposite of biomarkers may be 
entertained; patient contextual factors are also investigated.  Relating to the concepts of 
environmental factors and virtually a synonym to social factors and social determinants of health 
(SDH), contextual factors for purposes of this discussion are non-clinical factors present in any 
individual or population thereof.  Commonly studied contextual factors include demographics 
(race/ethnicity, sex, gender, age), physical environment (geographic location environmental toxin 
exposures), economic factors (income, employment) and lifestyle-related factors (dietary 
behavior, use of recreational drugs, exercise/physical activity).  Some contextual factors (in 
particular demographics) are easily and commonly ascertained at routine clinical visits, but a 
majority can only be elucidated with specific inquiry during studies or via observation of patients.  
Other contextual factors, often classified under quality of life (QOL) and health-related quality of 
life (HRQOL), focus on the patient’s psychological and social well-being.  Regardless of the type 
of contextual factor being investigated, the casual nature of social media allows for the potential 
of ascertaining non-clinical factors of a body of AIH patients.   
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In order to cast a broad net around potential contextual factors associated with AIH’s risk 
profile, an exhaustive systematic review is performed on the literature regarding AIH risk factors 
in order to filter out the contextual risk factors that have thus far been elucidated by research. 
The query (AIH risk) OR (AIH factor)2 was over conducted over PubMed with a 10-year 
publication date filter with the intention of removing purely clinical articles from the search.  334 
article abstracts were returned.  Abstracts were then excluded by these criteria by the titles’ 
indications, being assigned codes for reason of rejection: 
 NHWRH: No focus on any liver disease at all (chiefly due to the authors using another 
meaning of the term AIH) (37/334; 11.1%) 
 WRHEP: Sole focus on non-autoimmune hepatitides. (10/334; 3.0%) 
 MCB: Only cell and molecular (including genomic and proteomic aspects) were being 
studied, and these aspects were not known to be environmentally influenced. (91/334; 
27.3%) 
 CLIN: Only clinical environmental factors (e.g., medication exposure, comorbid 
illnesses) were being studied (152/334; 45.5%) 
 DEMOF: Contextual factor study in AIH, but only the study of demographic factors 
already ascertainable in the clinic (6/334; 1.8%) 
 
After abstract filtering, 38/334 (11.4%) of articles remained; these were subject to full-
text filtering by the same criteria as above.  The following exclusions (in Table 1) were noted, 
with an additional criterion (ADVOC) to mark full texts that were not about contextual factors 
but advocated that contextual factors must be studied in addition.  
 
 
2 Note: As of the date it was searched, PubMed automatically expanded AIH into AIH, 
autoimmune hepatitis, autoimmune liver disease, hepatic lupus, and liver lupus. 
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Table 1. Exclusion of Articles Irrelevant to Contextual Factors 
 
Excluded Included 
CLIN DEMOF ADVOC (Fully Relevant) 
13/38 (34.2%) 4/38 (10.5%) 3/38 (7.9%) 18/38 (47.4%) 
 
 
Synthesis 
The remaining articles, in the categories Fully Relevant and ADVOC (21/38; 55.3%) are 
subject to a thematic synthesis.  The themes to be entertained are diet-related factors, treatment 
noncompliance (patient-initiated withdrawal), physical environment, psychological quality of life, 
recreational substance usage, and research advocacy of more contextual factors research 
(ADVOC). 
The most common theme was noted to be diet-related factors, defined as factors that are 
dependent upon the foods (and nutritional supplements) consumed by the patient (or other model 
organism).    The interactions of the fatty liver syndromes non-alcoholic steatohepatitis (NASH) 
and non-alcoholic fatty liver disease (NAFLD) with AIH are documented.  The interactions are 
important because poor diet (too high in caloric energy from fat and/or carbohydrates) is a prime 
suspect in the pathogenesis of these disorders.38  Muller et al (2016)57 demonstrated that NAFLD 
aggravated AIH in an anti-CYP2D6 murine (mouse) model.  A study on humans (Himoto et al, 
2017)58 also suggested that fatty liver and AIH interact; this study found a deleterious effect on 
insulin resistance in patients with autoimmune liver features and NASH and also patients with 
combined autoimmune liver features and hepatitis C (HCV)-induced liver disease.   
Outside NASH and NAFLD, epigenetic changes (changes in genetic expression) are 
hypothesized to affect the pathophysiology of AIH.59  Although these changes are inherently 
genetic, they are byproducts of the environment directly modifying genetic expression: Common 
triggers for such changes include environmental exposure and SDH stressors, including but not 
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limited to dietary intake.  The intestinal microbiome, heavily influenced by diet, may also 
mediate AIH’s pathogenesis; Czaja (2017)60 in fact recommends that dietary surveys of AIH 
patients be undertaken for this reason.  As per Silva (2014),61 adiponectin, a molecule synthesized 
by adipose (fat) tissue (which is increased by poor diet) has been correlated in increased levels 
with the development of hepatic cirrhosis, including AIH-related cirrhosis.  Finally, a series of 
rodent models as reviewed by Luong et al (2013)62 suggested links between dietary vitamin D 
consumption and a reduced risk of developing AIH-pathognomic histologic features. 
Another salient theme observed was treatment noncompliance (also referred to here as 
patient-initiated withdrawal), defined for these purposes as a patient being unwilling or unable to 
take a medication required for AIH treatment.  Van Gerven et al (2016)63 note that many AIH 
patients become noncompliant with treatment due to the severe side effects of corticosteroids and 
other treatment immunosuppressants.  These authors further state that withdrawal, regardless of 
the initiator, can lead to severe deleterious consequences for the health of the AIH patient.  
Because patient-initiated withdrawals are often not documented in the clinic due to the patient 
masking their noncompliance, the phenomenon is important to study as a contextual factor.  
Studies have explored the frequencies of patient-initiated withdrawal in various withdrawal 
studies, although the estimates vary highly.  The most extreme documented rate of patient-
initiated vs. all-cause withdrawals was 713/844 (84.5%) (Van Gerwen et al, 2013).64  Hoeroldt et 
al (2011)65, in a United Kingdom-based AIH study, noted that 29/84 (34.5%) of withdrawals from 
an AIH treatment trial were patient-initiated and due to side effects.  The lowest rate of voluntary 
withdrawal was observed was 1/14 withdrawals (7.1%) (De Luca-Johnson et al, 2016).66 
The physical environment, defined as the physical surroundings (including geographic 
surroundings) of the patient, is another often-studied contextual factor.67  A meta-analysis by Wen 
et al (2018)68 discovered that two geographic factors played a role in the mortality of hospitalized 
patients with AIH; patients residing in metropolitan areas of under 250,000 population 
experienced significantly higher mortality rates than those residing in large metropolitan 
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(population > 1,000,000) regions, and patients residing in the western region of the United States 
had significantly higher mortality rates than the nation overall. Substance exposure, another 
element of the environment, may also modulate the pathogenesis of AIH; Ngu et al (2013) 16 
suggested a role for exposure to wood smoke (via wood-powered heating systems) in decreasing 
the future relative risk of developing AIH. 
Environmental research in AIH has taken the first steps in extending beyond the physical 
environment and has also encompassed the psychological environment, in particular patient 
quality of life.  A Russian study (Golovanova, 201069) compared quality of life in AIH-PBC 
overlap patients across different medical treatments (combination ursodiol and prednisone vs. 
monotherapy ursodiol) and utilized the 36 item Short Form general (mental and physical; SF-36) 
survey to differentiate quality of life in these cohorts.  This research concluded that combination 
ursodiol-prednisone therapy was associated with higher SF-36 scores (and therefore a greater 
estimated quality of life) than what was seen with ursodiol monotherapy.  In addition, Srivastava 
and Boyer (2010)70 conducted survey-based and qualitative psychology analyses on AIH patients 
and controls.  Using the psychological stress instrument Social Readjustment Rating Scale 
(SRRS), they determined that while AIH patients did not score significantly higher than matched 
controls for psychological stress.  However, when AIH patients with at least one relapse were 
compared to controls, it was noted these relapsing AIH patients have significantly higher 
psychological stress scores via SRRS.  The qualitative analysis in this study revealed that stress 
experienced by AIH patients was due to reasons that were similar to that seen in the general 
population.  The major difference in reasons for stress focused on daily living, with AIH patients 
expressing trouble with work, school, and exercise due to the fatigue inherent in the disease. 
Exposure to other substances, including recreational drug products, may also modulate 
AIH’s pathogenesis.  Smyk et al (2012)71 suggested that first-hand tobacco smoke exposure 
correlated with an increase in the development of primary biliary cirrhosis (PBC) and by indirect 
conjecture hypothesized that it may also play a role in the pathophysiology of AIH.  A New 
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Zealand-based survey by Ngu et al (2013)16, in contrast, rather interestingly discovered a decrease 
in the risk of developing AIH risk in those with a history of regular ethanol (beverage alcohol) 
consumption. 
Finally, some articles subject to full-text filtering did not explicitly research contextual 
factors but advocated the use of contextual factors to supplement their research.  Clinical research 
focused on de novo (transplant-induced) AIH (Visseren & Darwish-Murad, 2017)72 has advocated 
for the addition of non-clinical factors into determining outcome influencers.  Informatics-based 
researchers have also called on the addition of contextual factors to analysis: Sonnenberg and 
Naugler (2010)73 called for a very detailed analysis of patient “social factors” (p. 722)73 to add to 
their existing mathematical model of liver disease prediction, which only used clinical factors.  
Mells et al (2013)74, after conducting a genome-wide association study (GWAS) to attempt 
discovery of AIH genomic correlates, found only weak genetic evidence and called for the 
incorporation of contextual factors as additional variables into GWAS and other bioinformatics-
based genomic studies.  
In addition to having potential contextual etiological factors, AIH, like other diseases, 
affects the whole life of the patient, including in non-medical (contextual) areas.  Therefore, a 
search is undertaken to determine the impact of quality of life (QOL), a very important contextual 
factor domain encompassing psychological and functional facets of life, in AIH patients.  The 
query AIH quality of life was utilized in PubMed and retrieved 19 results. 
It was noted that the impact of AIH on global quality of life scales (those that combined 
physical, mental, and social aspects of QOL) was significant.  Janik et al (2018)75 noted that Short 
Form 36 (SF-36) global QOL responses were inferior in AIH patients versus controls.  Via 
analysis of Modified Fatigue Impact Scale (MFIS) results, the impact of fatigue was seen to be 
higher in AIH than in matched controls.  Psychosocial QOL factors were overall the least 
impacted.  Furthermore, prevalence of anxiety and depression was found to be higher in AIH 
patients than in matched controls in this survey-based study.  Objective signs, symptoms, and 
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comorbidities, including cirrhosis, pain, and jaundice, were also demonstrated to adversely affect 
QOL in a pediatric study; furthermore, this study found that severe grade AIH more negatively 
affected pediatric QOL.76  
Psychologically-specific sequelae were noted in one study75, which used the Personal 
Health Questionnaire 9th Edition (PHQ-9) to assess psychological QOL in AIH patients and also 
clinical correlates of QOL.  General psychological QOL was adversely affected by female sex 
and usage of the drug prednisolone.  A more specific and qualitative observation, furthermore, 
was an increase in anxiety regarding the stigmatization of AIH due to its hepatic nature and 
untoward associations with infectious and alcoholic hepatitides. 
Overall, it can be concluded from this brief synthesis that contextual factors are a nascent, 
albeit insufficiently studied, modifier of AIH’s patient course.  Further research is therefore 
necessary to record and classify contextual factors experienced by AIH patients. 
 
2.4 Patient Activation & Engagement: Social Media 
 
In order to extend the case of AIH into that of social media research, I now turn to 
molding literature regarding an existing framework to social media.  It is a generally accepted 
principle that patients are best to be involved in their own care (i.e., self care).  This onus is most 
likely stronger in patients with rare disease, who in many cases have insufficient time to discuss 
their entire life situations with providers during brief and sparse office visits.  For purposes of this 
discussion, patient activation and engagement (PA and PE respectively; here together PA&E) will 
be defined as a motivation for patient attitude in self care and the ability to change patient 
behavior, respectively.  The two are interdependent and therefore treated as one concept (PA&E) 
here.  Most importantly, PA&E will be explored as it relates to social media in healthcare in order 
to create a grounded initial case for studying social media for healthcare research purposes. 
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The terms as explicitly used were searched on PubMed, with a restriction to articles 
published in the past ten years.  The query “social media” AND (“patient engagement” OR 
“patient activation”) was utilized.  Nine articles resulted, of which five were removed due to not 
discussing patient impact or due to being large-scale reviews.  In this brief thematic synthesis, the 
four remaining articles are assessed to examine the effects of social media on PA&E.   
Collier’s article (2014)77 took the form of an editorial covering the marketing aspects of 
pharmaceutical companies using social media to inform patients of products and help them 
manage disease.  Liddy (2017)78 covered an example of a Facebook page used to raise electronic 
primary care virtual consult (eConsult) awareness.  Meanwhile, Rozenblum et al (2017)79 discuss 
the current status of social media use in healthcare.  Finally and perhaps most poignantly, Dhar et 
al (2018)80 put forth an exploratory research study in the field of liver transplant (a procedure 
coincidentally performed on a significant proportion of AIH patients), where a controlled, closed 
Facebook group is utilized to facilitate patient information sharing. 
The first theme noted in these articles is the benefactor.  For purposes of this discussion, 
the benefactor is the primary party (outside the researchers and authors) benefitting from the 
social media venue(s) in question; ideally, one benefactor will be the patient.  Significantly, 
Collier (2014)77 noted that pharmaceutical corporations would be benefactors in social media 
usage, with (in this use case) patients taking a second priority.  This editorial specifically noted 
that one scenario in which patients can be directly engaged (and therefore benefitted) is the 
provision of disease management portals (albeit ones that focus on the company’s drug products).  
This observation is significant because in patient-centered medicine, patients are inherently the 
chief benefactors.  Fortunately, in contrast, Liddy (2017)78’s study implies that patients will 
benefit from the eConsult services advertised on their Facebook page and could also leave 
feedback about the services.  Dhar et al (2018)80 were at the other pole of patient-centered 
approaches, allowing most discussion to be held between patients for purposes of mutual advice 
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and social support, leaving patients as virtually exclusive benefactors of the study; this structure 
is what is eventually observed in this dissertation’s research. 
The next theme to be explored is the nature of information to be gained by the benefactor 
(which in turn is defined as the previous concept).  The nature of information to be gained is tied 
to the nature of the benefactor.  Business-oriented organizations such as pharmaceutical 
corporations and eConsult services primarily gain information that is best categorized as 
feedback.  Collier77 notes that pharmaceutical companies stand to gain information about adverse 
drug events (ADEs; including side effects) and drug efficacy.  Liddy78, although implying more 
benefit to the patient, also notes that feedback on eConsult services is gained via consumer 
(patient) reviews, which can be posted to their social media venue.  Dhar et al80 and Rosenblum et 
al79 both propose that patient contextual factors (social and environmental health-impacting 
factors not ascertained in the clinic) can be obtained from.  Patient contextual factors, which 
surround the patient more often than the clinic does, intuitively will impact PA&E and clinician 
knowledge of these factors will be important in improving PA&E.  Dhar et al80 further find that 
(similar to Collier’s77 pharmaceuticals editorial) ADE and treatment efficacy opinions can be 
gained, and further notes that symptoms (related and unrelated to liver transplant) can be 
surveyed via their social media venue.  However, Dhar et al80 strongly imply that the information 
gained is to be used directly in the body of knowledge of engaging and activating patients, as 
opposed to simply a business strategy. 
The final theme noted is the dyad of communication.  The dyad is an ontological concept 
defined here as the subjects and objects of the verb communication.  Greater patient involvement 
in communication dyads is a cornerstone of increasing PA&E.81  Rozenblum et al79 propose that 
the dyad is chiefly patient-to-provider (or patient-to-researcher) communication, forming 
unidirectional structures with the patient as subject. Collier77 proposes that a communication dyad 
is created between patients and pharmaceutical companies.  In the given scenarios, the dyad is 
bidirectional, with one party as subject and the other as object.  Pharmaceutical companies are 
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expected to advertise product information to patients; on the other hand, patients communicate 
their opinions about the product to the companies responsible for the social media venues, so both 
actors in the dyad may be subject or object.   Liddy78 notes a similar bidirectional dyad, with 
organizations increasing patient awareness of eConsult services, and patients providing feedback 
about such services.  PA&E here occurs most significantly in the form of increasing patient 
awareness about a service that can improve their health.  In contrast, Dhar et al’s80 study notes 
that the primary observed dyad was patient-to-patient, with patients engaging each other.  
Occasionally, a patient education dyad of provider-to-patient would be observed, and finally, the 
dyad of patient-to-provider via research observation may increase the body of knowledge 
surrounding PA&E. 
In this thematic synthesis, multiple themes affecting patient activation and engagement 
(PA&E) were noted across four relevant publications.  The identity of the social media venue’s 
benefactor, the nature of information to be gained, and the nature of the dyad of communication 
all affect PA&E, whether directly or indirectly.  These and similar themes are important in 
assessing the role of social media in rare disease research; I will therefore address such items in 
the forthcoming sections. 
 
2.5 Social Media: An Introduction 
 
This dissertation earlier has noted that patient activation and engagement (PA&E) are 
amenable to social media use; here I provide a brief background prior to proceeding in deeper 
discussion on social media in rare disease research.  Online social media, often known simply as 
social media or SM, encompasses a wide variety of Internet-based venues dedicated to the mutual 
sharing of information between friends and across the world.  Many types of SM qualify and are 
more often known as social networking sites (SNSs) due to their ability to facilitate direct 
interactions between different users. 
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Facebook™ (http://www.facebook.com/)82 is an SM venue used by over half of the US 
adult population and reaches penetrations of 73% among Internet-using adults ages 30-49. 83 As 
such, it is arguably the world’s most popular social media venue.  Facebook™ provides support 
for individual personal walls, where users can post things that are on their minds and also solicit 
reactions from individuals they have designated as friends.  Posts on walls can also be shared 
globally if an individual chooses to do so.  Facebook™ functionality is extended by Facebook 
Groups, where groups of people with similar interests can create a common wall on which to post 
and share thoughts.   
In contrast, the online blog (short for weblog) is a service that is typically owned by 
private individuals.  Most blogs focus on the owner’s thoughts and writings, and also offer a place 
for viewers to react by commenting.  The corporate run service Twitter™ is a form of blog 
(microblog, as posts are limited to 140 character tweets) that is popular for sharing brief thoughts 
on a global basis. 84  The final common form of online social media consists of Internet forums, 
also known as web forums, online forums, message boards, or simply forums.  These venues are 
almost always privately run and allow for textually rich communication that is organized into 
posts (initial communications) and comments (reactions to the initial communications).85   
 
2.6 Social Media for Studying Patients with Rare and Common Diseases 
 
Initially, I conducted a brief systematic review of the literature to assess the current 
(2007-2017 as of review) state of social media in general health and biomedical research.    
PubMed was queried for the term social media (all fields; no quotes).  Only results within the past 
ten years of query (i.e., those published during or after 2006) were included.  Further filtering was 
performed to only include articles of types study, comparative study, observational study, and 
clinical trials, thereby excluding articles such as reviews and editorials. 568 articles were 
returned in the search results, which were downloaded in the form of PubMed/Medline XML.  
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XSLT (XML Stylesheet Translation) was used to parse out pairs of PubMed IDs and the titles 
that the IDs represented.  I then performed a systematic qualitative analysis on the resulting titles, 
marking whether the title of each article indicated that it was actually an original study in the 
healthcare field that related to patients participating in online social media.   
In order to determine relevant article titles at this stage, articles were excluded if it was 
clearly evidenced by the title that one of the following exclusion criteria were relevant: 
 Criterion 1 (NHC; N=14 excluded): The title evidences a definite lack of relationship to 
health or healthcare 
 Criterion 2 (NSTD; N=7 excluded): From the title, it is clear that the article is not an 
actual study (i.e., it is a review, proposal, or editorial) 
 Criterion 3 (CSTD; N=52 excluded): The title clearly shows that the article involved only 
the study of clinicians (and not patients/lay consumers). 
 Criterion 4 (NICT; N=364 excluded): It is obvious from the title that the article does not 
deal with information and communicating technologies (ICTs; virtually all of these 
articles dealt with non-ICT based materials including print-based, television-based, and 
face to face interventions). 
 Criterion 5 (OWC; N=52 excluded): The title clearly shows that the study did not include 
patient-generated communication as valuable input; most of these were one-way 
educational platforms for communication of information to patients). 
Of note, the criteria were sought in consecutive order during the review of each title, so if 
the article was clearly not about health (Criterion 1), the assessment for further criteria was not 
conducted.  Hence, all of the exclusion criteria counts add up to the total number of titles that 
were excluded.  The final title analysis therefore excluded 489 articles (82.6% of the articles 
returned by PubMed) and similarly included 79 articles (17.4% of articles returned). 
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I then performed further exclusion analysis via qualitative interpretation of the abstracts 
of the 79 remaining articles.  The same criteria in the title analysis were applied in an identical 
consecutive fashion.  One article excluded due to lack of relationship to health, 4 articles were 
excluded due to not being actual studies (NSTD), 2 articles were excluded due to being solely 
about clinicians (CSTD), 3 articles were excluded due to not having an ICT-related component 
(NICT), and 29 articles were excluded due to having no patient-generated communication 
component (OWC).  Therefore, in the abstract analysis phase, 39 articles (49.4% of those that 
passed the title analysis) were excluded, while 40 (50.6%) of these articles were included.  
Because the articles have been filtered to only the ones that will be relevant for future 
discussion, a narrative review can now be performed.  The knowledge gap is evidenced in that the 
systematic review demonstrated that there were only 40 articles published between 2006 and 
2016 that fit the criteria of engaging and researching patients via social media tactics.  The next 
and final step in filtering involved judging by the article introduction full text sections if the 
article focused on rare diseases.  Out of the 40 articles, eight did, an amount sufficient for a 
narrative review, which is discussed further. 
Given the wide reach and content diversity of social media, it is not surprising to note 
that several studies have shown that social media is popular in the rare disease community in 
attracting and coalescing groups of rare disease patients.  Significantly, the social media venue 
Facebook™ has shown a very strong trend towards attracting those with rare diseases, 7, 86 and 
part of this trend is, as hypothesized by Davies (2016)18 in one proposal on SM use in Rare 
diseases, due to the fact that there are 1.7 billion individual (non-group) user accounts on that SM 
venue.87   
More specifically, Schumacher et al86 detail the problems of finding patients with post-
Fontan procedure plastic bronchitis (PFP-PB) and protein-losing enteropathy (PFP-PLE), two 
rare complications of a surgery (the Fontan procedure) that itself is rarely performed.  These 
authors were able to discover via Facebook™ and online surveys what is believed at the time to 
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be the world’s largest ever study cohort of PFP-PB and PFP-PLE patients.  Similarly, Greeley et 
al (2011) discovered, researched, and have been following up with a cohort of over 700 patients 
recruited from various Facebook™ patient support groups; these patients had monogenetic 
diabetes, a rare subtype of the disorder.88   
Health-related information is commonly shared across rare disease-related online SM 
venues; therefore, determining the types of health-related information shared is important to not 
just research AIH, but also to determine the types and quality of information that are shared on 
the AIH-related SM venue of study. 
Rare disease-related blogs (a subcategory of SM venues) often focus on material that 
directly relates to health information.  Evidence exists in using SM as a venue for clinicians to 
disseminate useful, reliable health-related information to patients, lowering barriers to clinician-
patient communication.  Hawn89 has proposed that patients are directly engaged, taking the first 
step to be activated in their own healthcare, by using social media as a venue of receiving health-
related information.  One study found that blogs run by parents of children with Hirschsprung’s 
Disease (HD) were effective in answering questions of fellow parent caregivers and moreover, in 
quickly attracting thousands of views from around the world.90  One physician has found that the 
blog is a highly effective medium over which to distribute information and answer patient 
questions about pheochromocytoma, a rare endocrine tumor.91  In another observation, a group of 
PF-related blogs allowed for high volumes of patient communication, and that the most popular 
topic in patient-generated content related to the symptoms patients were experiencing.92 
The microblog service Twitter has also shown to be of use for increasing societal 
awareness of the rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN), as 
shown by Pemmaraju et al (2016).  This study has shown that multiple types of health 
information can be disseminated over a Twitter-based system; recipients of information are 
patients, clinicians, and other stakeholders concerned about the disorder.93  
27 
An overall survey of social media sites performed by Winchester et al94 sought to 
describe the quality of information regarding cardiac stress testing disseminated over these 
venues.  These authors found that a commonly discussed topic was the Choosing Wisely 
campaign, a clinically-approved movement that advocated for patients and doctors to wisely 
choose whether or not stress testing was necessary.  This study therefore demonstrated that 
information regarding proper healthcare protocols was being disseminated to patients. 
Finally, it was also found that an online focus group geared towards patients with rare 
cancers allowed patients to discuss their issues in a more honest fashion.  One specific benefit of 
using an SM venue was noticed as the fact that patients, as users, were masked by screen names 
and did not reveal their true identities, allowing for greater transparency. 95   
 
2.7 Online Patient Support in Rare Disease 
 
Patients with rare diseases, including AIH, travel great distances to seek presence of a 
provider, both for treatment and advice. 4, 5  It was noted in the previous chapter that contextual 
factors also related to the ways in which patients emotionally behave and react to their disease.  
Knowing these facts, it is understood that patients with AIH (and other rare diseases) will 
inherently face a shortage of support, both socially and informationally, and literature indicates 
that patients of many rare diseases turn in addition to their peers for support. 
Much prior research on peer support over social media has been performed over online 
health communities (OHCs), which for this purpose are defined as Internet-based communities of 
individuals affiliated as patients or caregivers of various disorders.  It is theorized that the 
exchange of support of all types is facilitated by the post-and-response (or in Facebook’s case, 
post-and-comment) nature of the OHC.96  Significantly, the social media (SM) venue Facebook 
has shown a very strong trend towards attracting those with rare diseases, 7, 86 and part of this 
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trend is, as hypothesized by Davies (2016)18 in one proposal on SM use in rare diseases, due to 
the fact that there are 1.7 billion individual (non-group) user accounts on that SM venue.87   
From an analysis of the literature, two types of (emotional/social and 
advice/informational) as well as two directions of (inbound and outbound) were noted.  Wang et 
al, furthermore, proposed a comprehensive, computationally-based classification system of the 
types of social support given over OHCs; these authors propose that seeking and providing 
informational support, seeking and providing emotional support, and seeking and providing 
companionship (ie, social/emotional support) are major areas in social support offered over 
OHCs.97 
Advice and/or informational support (here abbreviated AIS) is defined here as the 
provision or receiving of objective information or suggestions as a form of help.  The presence of 
this type of support is particularly important because rare disease patients have relatively sparse 
visits with their providers and require other sources of information.  PatientsLikeMe, a forum-
based website for patient support, was observed to be useful in facilitating exchange of 
knowledge about treatments. 98  In a qualitative review of pulmonary fibrosis (PF)-related blog 
postings, sharing health-related information as support was reported to be the most common type 
of support found. 92 One study found that blogs run by parents of children with Hirschsprung’s 
Disease (HD) were effective in answering questions of fellow parent caregivers, in the process 
providing informational support.90  In addition, it has been found that patients with rosacea, a 
relatively uncommon skin disorder, actively seek information and advice through online health 
communities.99  More saliently, a publication on online health communities catering to rare 
vascular diseases claimed that AIS was the most important kind of support exchanged over rare 
disease-oriented online health communities due to the inherent lack of availability of external 
advice and information regarding such conditions.100 
Social/emotional support (here abbreviated EMO) is considered here as support that does 
not have objective information or recommendations but instead are essentially kind words given 
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to help someone’s emotional status.  Inherent in rare and incurable diseases is grief that the body 
will never return to normal; indeed, a study regarding online support in grief discovered support 
content to be almost entirely emotional in nature.101  Similar findings were obtained in a study of 
another psychological problem, postpartum depression.102  PatientsLikeMe in one case was also 
found to allow for the exchange of emotional support for patients with various uncommon (and 
common) chronic conditions. 98  The aforementioned study of PF-related blogs found that the 
second most popular type of discussion (behind sharing health-related information) involved the 
solicitation and provision of social (ie, emotional) support. 92 A study from Spain, furthermore, 
found that Facebook pages that are administered by official rare disease advocacy organizations 
also facilitate the provision of information as well as social support to patients. 7  A Dutch survey 
on breast cancer patients and survivors seeking online support, meanwhile, reported that 
emotional and social support predominated among the support needs and capabilities of affected 
women.103 
Support can also be designated not just by subject type, but also by its direction and 
structure, although this aspect of support is less well-studied.  In another breast cancer study, the 
provision (here known as offering and abbreviated OFF) and acceptance (the initial stage, 
requesting, abbreviated here as REQ) of support were demonstrated, although the utility on 
psychiatric clinical outcome of the patients who provided support was debatable.104  A Chinese 
study of online Acquired Immunodeficiency Syndrome (AIDS) patients on the microblogging 
service Weibo demonstrated the importance of dyads in provision, acceptance, and reciprocation 
of all types of disease-related support.105  A contingency management intervention in tobacco 
smoking cessation demonstrated the importance of bilateral support in disease management, 
especially in situations such as contingency management here group reward and punishment are 
present.106  Finally, a computational linguistics-based study of a Norwegian online support group 
demonstrated that the group’s content changed semantically over time to represent a more 
egalitarian structure of support, which was considered a positive development by the authors.107 
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2.8 Social Media & Autoimmune Hepatitis 
 
Autoimmune hepatitis (AIH), being among the rarest of rare diseases, inherits from other 
rare diseases all onuses for social media-based study; indeed, this condition has a significant 
online support community.  A colleague of the author’s, who cannot be named due to concerns 
over his patients’ privacy and will be referred to as “AC” (administering colleague), is a 
hepatologist who administers an (also unnamed for the same reason) Facebook™-based group 
that allows informational communications between researchers, patients, and clinicians. During 
the time span between May 2015 and May 2017, 1,052 users (excluding the administering 
colleague) have been active in this group.   
In his experience moderating this group over the past three years, the administering 
colleague believes that the majority of users of the group are actual AIH patients or caregivers for 
those with AIH.  The primary author, furthermore, has performed preliminary computational 
topic modelling studies on the content generated by the group’s users over the two-year timespan.  
These studies have shown that topics represent discussion of personal histories of disease, 
treatments, and also the provision of social support.  Most importantly, this group comprises 
corpus of users and communications that will be of study in this dissertation. 
 
 
 
2.9 Barriers to Health Research via Social Media and Overcoming Them 
 
In light of the desire to study AIH via social media-based methods, caution must be 
exercised to potential barriers to researching health via social media; these may broadly be 
classified into technical and social/ethical barriers.  Intuitive concerns exist because the proposed 
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research involves acquiring large quantities of unstructured, personally-identifiable user-
generated content from a website with proprietary access controls and structuring it in a manner 
that could allow those with access to the resulting structured data to easily identify individual 
users.   
Technical barriers exist, and these barriers are most often socially-grounded.  Since 2010, 
Facebook™ has banned a majority of automated information collection (scraping) via application 
program interfaces (APIs), which used to be a mainstay for mining Facebook data.108  Extant 
Facebook Apps (applications) and application programming interfaces (APIs), including the 
Graph API109 and content feeds allow for some collection of user information, but not universal 
access to consenting users’ private, full text communications.  Privacy and ethics issues also 
exist: Regardless of how the data are collected, Facebook™ screen names are valid e-mail 
addresses and considered identifiable private information (IPI) by most institutions, including that 
of the authors’.110    In addition, users’ expectations of privacy on Facebook™ Groups may vary, 
especially if the group content is set to closed (i.e., only admitted members may view and create 
group content).  Given that back-end downloading is prohibited, researchers may only work with 
the source code of the website (that which is available from any common web browser).  This fact 
implies that researchers must work to determine the regular source code expressions in which the 
necessary data and metadata are stored so that users can be related to their communications and to 
each other. 
A review by Abedin et al (2017) 111 surveyed literature regarding social media use for 
research; this review synthesized that researchers and SM users believe that de-identification of 
information is mandatory in order for such research to be ethically and legally conducted.  A 
general study of the ethics of SM information extraction, furthermore, found that the use of 
informed consent is important, particularly in utilizing information that users may believe has a 
modicum of privacy.112  (For the reader’s reference, a Facebook example of such information 
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would include that present on a private group, which is a group that is only accessible to those 
whom an administrator approve.) 
However, even users on publicly accessible social media venues have experienced 
objections to being studied.  A seminal 2004 study by Hudson & Bruckman113 discovered the 
pitfalls of using publicly accessible but moderated chat rooms (SM venues where users could 
communicate in real time by typing text to each other): After entering a chat room, the 
researchers would announce their identity as researchers; in over 63% of chat rooms studied, the 
researcher was subsequently ejected and permabanned (permanently banned) from the chat room 
by a moderator.  Nonetheless, with disclosure of researcher status and absent any external 
moderator or administrator objection, both of which are precautions being taken in the course of 
this dissertation’s research, it is noted that research of the SM venue is much more acceptable to 
users. 111 
Furthermore, specific local policy to the author is mediated by the organization (Indiana 
University Institutional Review Board; IU IRB) responsible for approving the protocols in this 
study.  Specifically, the IU IRB classifies Facebook™ screen names as identifiable private 
information (IPI)110, that which is not protected health information (PHI) but whose release would 
allow subject identification outside the social media venue in question.  In particular, the IPI 
classification is given because these screen names are actually valid email addresses that link to 
the users’ respective Facebook messaging accounts. 
Without overcoming the barriers explained just prior, utilizing social media data to 
elucidate AIH would be unethical or entirely impossible.  There are, however, ways to mitigate 
these barriers with appropriate technical and ethical controls.  Therefore, I developed and 
executed a front-end data mining method to acquire data from a colleague-administered 
Facebook™ group pertaining to AIH, and further describe security and de-identification protocols 
to remain within bounds of commonly accepted research ethics.  Analysis of the extracted data 
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then confirms many of the putative benefits of using social media in order to research “digital 
cohorts” 85 (p. 614) of rare disease patients.114   
Finally, the group comprises an excellent convenience sample that may in fact encompass 
a significant portion of the global AIH population.  Being led by researchers, these groups are 
open to observation for research without any risk of the researcher being ejected.  The chosen 
group, with the moderators (including AC) taking active roles in preventing spam posting.  Users 
in these groups communicate openly knowing that only fellow group members and researcher 
administrators have access to the content they post in context of their personal identities.   
 
Note: Specific technical data mining techniques and ethical measures, including consent protocols 
and IU IRB approval, are entertained in forthcoming Chapter 3 of this dissertation. 
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CHAPTER 3. ACQUISITION, STRUCTURING, AND PROTECTION OF AIH-
RELATED FACEBOOK DATA 
 
3.1 Introduction 
 
As discussed prior, utilizing social media data to elucidate AIH would be unethical or 
impossible without adequate technical methodology and ethical controls.  Technical issues, many 
of which are socially-grounded, exist; furthermore, there are ethical issues that relate to the usage 
of identifiable private information (IPI).85 
Therefore, I developed and executed a front-end data mining method to acquire data from 
an IU Health-sponsored Facebook™ group pertaining to AIH, and further describe security and 
de-identification protocols to remain within bounds of commonly accepted research ethics.  
Analysis of the extracted data then confirms many of the putative benefits of using social media 
in order to research “digital cohorts” 85 (p. 614) of rare disease patients.  
 
3.2 Methodology 
 
Facebook codes its front end (web interface) in XHTML (eXtensible HyperText Markup 
Language).  Because back-end downloading of such detailed Facebook data is prohibited, data 
were acquired by the entire group page into the browser front-end.  Posts on the page were then 
expanded to reveal all comments by using an open source JavaScript bookmarklet.  Finally, the 
browser’s view source feature was used to download the full XHTML source code.  The XHTML 
file’s document object model (DOM) was elucidated manually to determine the locations of 
posts, post authors, post timestamps, post comments, post comment authors, and post comment 
timestamps.  All were found to be contained in regular XHTML expressions, allowing for 
canonization of the form. 
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A novel canonical metalanguage, the Facebook Metalayer Language (FML), was 
therefore created for this dissertation’s research in order to exclude visual element coding and 
compactly store only the data that are needed for text and network analysis.  The XHTML-to-
FML translation was performed using XML Stylesheet Literal Translation (XSLT) via Oxygen 
XML software.115  Detail and flows are shown in Figures 1 and 2, respectively. 
 
Specifically, FML contains only: 
 Posts: ID, content, author, timestamp 
 For each post, comments: Content, author, timestamp 
 
 
 
Figure 1. RELAX NG (RNG) Metalanguage Schema for FML. 
 
 
 
Figure 2. The XHTML to FML to Ready-to-Analyze Format Workflow 
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For future natural language processing (NLP) analysis, the FML file was parsed via a 
third XSLT sheet into a tag-stripped delimited linear format, with one line for each 
communication and its metadata.  In order to compare communications throughout the population 
as they differed between separate users, the messages were then into files, with each file 
representing every communication a single user made over the two-year course of observation.  
These files are termed user narratives, parsed from the linear file; one is visible in Figure 3.  
Timestamps were also parsed into the number of days past 2014 January 1. 
 
 
 
Figure 3. Partial User Narrative Screenshot 
 
 
Ethical concerns are equal to technical ones.  The group and its administering clinician 
have already gained informed consent to research user communications via a front-panel 
agreement stating that users have no expectation of privacy when posting in the group and that 
communications may be used for research purposes.  However, to avoid further issues with 
privacy and ethics, the following internal study policies were devised by the authors and 
approved by the Indiana University IRB: 
 Any data containing identifiable private information (IPI), including Facebook screen 
names (which are valid email addresses and cognate to real life names), are always stored 
on encrypted media. 
 Any data that leaves an encrypted drive are always de-identified via user name encoding 
to remove PII.   
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 For purposes of research integrity and to comply with Facebook’s terms of service, the 
researching author (AK) is never allowed communication with members of the group. 
 The clinician co-author (AC) is not allowed to view the key that links the Facebook 
screen names of users with their encoded names. 
 
For de-identification, all usernames in the FML file were encrypted numerically by using 
a Java Virtual Machine (JVM) program and fixed key, kept on an encrypted hard drive.  A fixed 
key was chosen in the event that more data from the group were to be added, thus permitting 
referential integrity between group users’ posts. 
 
3.3 Results 
 
Front-end downloading was utilized to acquire 73.1 MB of XHTML data, representing all 
group communications between 1 June 2015 and 31 May 2017.  Via removal of unnecessary 
(visual) XHTML elements over XSLT, the XHTML was condensed into 6.6 MB of FML.   
The integrity of the XHTML-to-FML conversion was validated by randomly sampling 
100 user communications from the FML.  Communications were then searched via the encoding 
key through the XHTML to find whether the user who generated the communication matched 
between the XHTML and FML.  100 (100.0%) of all communications matched the user across 
both formats.  The linear file was validated similarly; this time, the linear file and FML file were 
compared, with a match rate of 100.0% as well.   
 
3.4 Discussion & Conclusions 
 
A proof-of-concept in acquiring user-generated content from an active Facebook™ 
support group for a rare disease, autoimmune hepatitis (AIH) has therefore been demonstrated.  
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Importantly, the required data gathered via a method (front-end download) that, as of this writing, 
is not prohibited by Facebook’s terms of service.  Downloaded data were successfully parsed into 
a more compact form (Facebook Metalayer Language; FML) that maintained full information 
integrity of communication content via metadata.  The resulting data are therefore usable in 
studies of online posting patients with AIH, and these protocols may also be used to gather 
patient-generated online content from users with other disorders of interest. 
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CHAPTER 4. DETERMINING HEALTH INFORMATION SHARING OVER AIH-
RELATED SOCIAL MEDIA 
 
4.1 Introduction 
 
The data acquired in the previous chapter will be subject to meaningful analysis in order to 
attempt detailing the clinical and non-clinical histories of AIH patients.  Health-related 
information is commonly shared across rare disease-related online SM venues; therefore, 
determining the types of health-related information shared is important to not just research AIH, 
but also to determine the types and quality of information that are shared on the AIH-related SM 
venue of study. 85, 116  A model thereof is conceptualized in Figure 4. 
 
 
Figure 4. Conceptual Graphic of Health Information Shared: Clinic vs. Social Media 
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4.2 Methods 
 
The data extracted and used in earlier research117 were re-used for purposes of 
determining health information sharing over the venue.  Importantly, I utilized the user 
narratives, the latter of which each contained the entire communications of its respective user.  In 
order to quantify communication structures within this Facebook group, social network analysis 
(SNA) was performed by transforming the FML into a network (graph) edge list.  SNA itself was 
conducted using Cytoscape.JS118 software.  Edge lists consisted of a giver (commenter) and 
receiver (author of post being replied to).  To confirm reliability of actual user communication (as 
opposed to the reliability of computational methods for mining and transformation), the user 
narratives of 73 randomly selected users were qualitatively annotated to estimate the role of the 
user (patient, caregiver, or other) and gender of user (or patient user represented).  The suspected 
residency of the user (US, non-US, or ambiguous) was also noted by the usage of US brand 
names for medications as well as US word spellings.   
Content was also assessed using a deeper qualitative analysis.  Six (6) randomly selected 
user narratives from the previous pool of 73 were annotated for contextual factors and organized 
with the framework proposed by Holden et al.67  These narratives were then detailed further into 
clinical dossiers; items such as clinical information, demographics, and family history were 
noted; finally, contextual information gained in the step prior was added to the dossiers. 
In order to give an all-encompassing yet quantitative view of the topics discussed, and 
therefore types of information shared, over the group in question, topic modelling (TM) via latent 
Dirichlet analysis (LDA) was performed.  TM via LDA uses an N-incomplete algorithm to 
efficiently sort baskets of words that define the similarities and differences between documents in 
a given corpus.  Documents are then clustered and key topics representing the word baskets are 
assigned a relative strength to each document, creating a document-key topic strength matrix.  
 The LDA implementation used in this case is the Machine Language Learning Toolkit 
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(MALLET).119  Most recently, Jones et al (2018)120 noted that MALLET-based TM was of great 
utility in analyzing a similar corpus, that of breast cancer survivors over an online forum; these 
authors discovered both expected as well as novel topics of patient communication. 
In this case, the corpus consisted of the previously generated user narratives, allowing to 
determine the strength of machine-generated topics across group users.  After the cleaning of the 
corpus via stem word removal, MALLET was run over the corpus and instructed to return 50 key 
topics embodied by respective baskets of words.  Qualitative professional interpretation of the 
topics was then performed by committee member AC, who is an AIH-treating hepatologist.  If 
multiple key topics were found to imply discussion of similar matters, AC grouped these key 
topics into topic groups. 
 
4.3 Results 
 
Group metrics are then calculated via the resulting FML file; these numbers are shown in 
Table 2.  Note that users who neither posted nor commented are excluded from this and further 
analyses because detecting them is physically impossible. 
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Table 2. Group Metrics 
 
Active Users 
Total 1053 
Who made at least one post 478 (45.4%) 
Who made at least one comment 1016 (96.6%) 
Posts 
Total 1479 
Made by AC 71 (4.8%) 
Comments 
Total 16646 
Made by AC 488 (2.9%) 
Received by AC 1798 (10.8%) 
 
Qualitative annotation analysis of 73 randomly selected user narratives revealed the following 
user demographics, as per Table 3. 
 
Table 3. Demographics from Qualitative Annotation 
 
Role 
Patient Caregiver Ambiguous** 
61 (83.6%) 10 (13.7%) 2 (2.7%) 
Gender 
Male Pt./CG of Male Pt. Female Pt./CG of Female Pt. Ambiguous** 
5 (6.8%) 66 (90.4%) 2 (2.7%) 
Residency 
Evidences US Residency Evidence non-US Residency Ambiguous 
55 (75.3%) 8 (11.0%) 10 (13.7%) 
 
 
It was also noted that contextual factors (those unseen in the clinic) exist in the user 
narratives and add a vital layer of richness to the clinical details of patients.  Six (6) randomly-
selected narratives, referred to here alphabetically, were annotated for contextual factors and 
these factors noted in Table 4 below using the contextual factor categorization framework of 
Holden et al.67 
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Table 4. Contextual Factors Across Six User Narratives 
 
Factor 
Category 
User: Detail Factor 
Category 
User: Detail 
Economic 
C: Currently employed 
 
D: Employed in medical field 
Psycho- 
logical 
C: Considers self to be religious 
C: Can understand some scientific 
literature 
 
D: Considers self highly health literate 
D: Advocate for rare disease patients 
and causes 
Health 
Behavioral 
C: On a low-glycemic diet 
 
D: Using a low-carbohydrate diet 
D: Trying to lose weight 
 
F: On gluten-free diet 
F: Abstains from carbonated 
beverages 
F: Abstains from alcohol 
Social 
A: Has a daughter and granddaughter 
 
B: Has a young child 
B: Is married 
 
C: Has grandchildren 
 
E: Is married 
E: Has a daughter 
Functional 
C: Difficulty raising kids due to 
fatigue 
 
D: Recently able to take a 
camping trip 
Techno- 
logical 
C: Uses Internet to search for AIH-
related study information 
 
F: Good at and enjoys using Facebook 
 
Healthcare 
System 
A: Specialist doctors of user are 
not communicating well and 
disagreeing with each other 
 
D: Has difficulty getting 
appointments 
Other F: Has a puppy 
 
Overall, 24 contextual factors were discovered across the six users.  These were also used to 
enrich the clinical dossiers; User F’s clinical dossier is available in Figure 5. 
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Figure 5. Clinical Dossier Example 
 
The rater (clinician co-author AC) determined that the clinical detail presented in these 
dossiers was less than what is typically gained during an initial clinic intake appointment but 
stated that sufficient information for research purposes was gathered; furthermore, he believed it a 
major benefit that analyzing group data would bring patients (users) that his clinic would never be 
able to see in real life.   
Topic modelling with LDA through MALLET resulted in 50 key topics represented by 
respective baskets of words.  Below in Table 5 is represented an example of one of the key 
topics’ basket of words and the interpretation of its topic group by AC, and strengths of topic 
categories are noted in Table 6 thereafter. 
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Table 5.  LDA-Generated Topic Example with Interpretation116 
 
Key Topic Word Basket AC Group Interpretation 
euro acirc checked brvbar rosacea eye supplements set link gel hole 
pressure draw intolerant herbs metals janet hair broken bleeding 
Alternative 
Treatments 
 
Note: A list of all topics with key word baskets and AC’s assigned topic category is available in 
Appendix I. 
 
Table 6. Strengths of Topics and Categories Across the Corpus116 
 
AC-Assigned Category of Topic Sum of Topic Strengths in Category 
Treatment side effects 23.23% 
Caregivers 16.49% 
Treatment stories 16.03% 
Treatment goals 8.73% 
Comorbid conditions 7.69% 
New diagnosis 5.86% 
Support groups 4.88% 
Research 4.64% 
Alternative treatment 4.28% 
Religion 1.47% 
Disease associated phenomenon 1.32% 
Pathogenesis 1.24% 
Disease side effects 1.11% 
Pregnancy 0.74% 
Treatment - pediatric 0.70% 
Medication payment 0.64% 
Research trials 0.21% 
 
 
4.4 Discussion & Conclusions 
 
Group metrics revealed the remarkable sample size gained from the data acquisition and 
analysis.  During the initial qualitative analysis of 73 users, 55 users who live in the US were 
detected; this figure is over 1% of the total (less than 4,000) number of individuals in the US who 
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are diagnosed with AIH.  If the fraction is extrapolated (to 1,052 users, matching 792 as US 
residents), nearly 20% of the US population with AIH will have been observed solely through the 
data that were obtained.  A cohort of such size and coverage would be likely impossible to gather 
in the real world. 
A general sense of the health-related information shared in the online support group at 
study was also ascertained.  It appears that users are concerned with side effects of AIH 
treatment, because 23.23% of the topic weight centered upon this facet of discussion.  The topics 
of communications generated by caregiver (as opposed to patient) users and general treatment 
stories each held approximately 16% of the weight of discussion.   
Although the quantity and quality of medical factors found in the clinical dossiers, by 
AC’s assessment, were weaker than what can be assessed in the clinic, the geographical reach is 
far greater and medical factors in this case can be ascertained for individuals who would never 
even be seen in the clinic.  While it is valuable to gain confirmation of clinical insight from users, 
it is more noteworthy that contextual factors were elucidated.  From the sample of clinical dossier 
users (N=6), 24 contextual factors were found.  These factors, in particular those categorized as 
social and psychological, are very unlikely to be elicited in the clinical visit setting and provide 
richness to the histories of patients and the AIH population as a whole. 
Inherent limitations of social media research exist.  User communications are taken at 
face value and assumed to be honest and not fabricated.  The limitation is inherent in social media 
research, although it should be observed that patients can fabricate personal histories in the clinic, 
as well.  Furthermore, social media venues (including Facebook) prohibit page administrator 
contact with users (except through surveys where users can voluntarily opt in to contact), creating 
a challenge in connecting individual users’ social media data with official clinical information.  It 
is therefore recommended that health-related data from social media is better applied to 
population-level health rather than individual-level health research. 
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It is also noted that the demographics of the population at study may not reflect the 
demographics of the AIH population. The gender ratio (an estimate of the sex ratio) in the 
group’s patients was estimated in related research116 by the author to be 13.2:1 (female); most 
traditional studies suggest a sex ratio of around 3.6:1 (female).121  Although 75.3% of annotated 
narratives evidenced US residency116, AIH has shown a significant prevalence in other countries 
such as South Korea122, Norway, and Sweden.121  These limitations are expected to be inherent in 
any study involving online social media, whose content is considered dominated by females (with 
an estimated ratio of 1.5:1 for online support groups123) and English speakers.124 
The dominance of the coauthor-administrator (AC) is discussed, particularly because he 
was the most prolific poster and his posts were subjects of 10.8% of comments received.  The 
intense degree of gravitation could raise the speculation that discussion is driven into reflecting 
medical and clinical information rather than contextual factors; however, this conjecture is not 
sufficiently provable and it is further noted that that contextual factors were successfully 
ascertained in other cases. 
The most important points of discussion pertain to future research: The purpose of this 
phase of dissertation work was only to determine proof of concept of extraction and estimate the 
reliability of user-generated content from this Facebook support group.  The current research has 
been on a relatively small sample (73 or less) of 1,052 users.  Future research will include 
analysis of clinical and lay terminology indicating contextual factors, medication, and signs and 
symptoms experienced, resulting in socio-medical folksonomies where user misspellings and 
slang usage are accounted for.  With this folksonomy, automated term extraction via natural 
language processing (NLP) may be executed, allowing for large-scale mining of user/patient-
generated online content for knowledge that will inform workflows of researchers and clinicians. 
Overall, the research at hand shows great promise in benefitting the rare disease 
community’s bodies of clinical and patient knowledge.  Because these patients are difficult if not 
impossible to reach in quantity in real life but yet often post generously about their condition(s) 
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on social media, the ability to ethically extract and utilize social media information generated by 
cohorts of such users represents significant progression in rare disease research.  Finally, it is 
noted via qualitative analyses that this user-generated content was demonstrated to provide 
clinically actionable information regarding the medical, and more importantly contextual, factors 
experienced by patients and populations with rare diseases including AIH. 
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CHAPTER 5. DETERMINING THE FEASBILITY OF DETECTING SELF-REPORTED 
XENOBIOTIC (DRUG) USAGE 
 
5.1 Introduction & Background 
 
Having obtained a suitable corpus of AIH patient-generated communications from social 
media in the previous chapters, an analysis of clinical factors is in order; I proceed first to discuss 
pharmaceutical medication drug products, also known as xenobiotics.  The liver is a hub for 
processing xenobiotics and subject to damage caused by said chemicals, and AIH patients 
consume xenobiotics in the form of prescription therapeutics in order to control their disorder.  
Finally, in order to survive, humans (as with all living organisms) must consume some form of 
xenobiotic material in the form of vitamins and minerals. 
I have already noted that the research body believes that various classes of antibiotics 
may mediate AIH risk. 16, 17 Statins, a commonly-prescribed class of drugs for high cholesterol, 
were also discussed as  potential culprits. 16, 18-20  Other medications implicated by the literature in 
AIH pathogenesis include nitrofurantoin, carbamazepine, chlorpromazine, methotrexate, 
valproates, and even the common analgesic ibuprofen. 21, 22  Furthermore, the development of 
syndromes biologically similar to, and considered partially overlapping with AIH, are noted in 
some liver toxicity cases regardless of the alleged causative xenobiotic.26, 27,28  AIH-associated 
biological liver damage features are also correlated with the use of non-prescription xenobiotics 
in the form of herbal supplements, including black cohosh23, ginseng, ephedra, chamomile, milk 
thistle, kava kava, and pennyroyal. 22 
Xenobiotics in the form of pharmaceutical products prescribed for AIH treatment include 
a wide array of immunosuppressants, including corticosteroids.30  The high side effect burden of 
immunosuppressant treatment may lead to an even higher load of xenobiotic burden when 
medications are added to control adverse drug effects (ADEs). 29   
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The progress of researching AIH, including its pharmaceutical and xenobiotic 
demographics, has been severely hampered by an inability to recruit sufficient numbers of 
patients for studies; this inability is inherent due to the rareness of AIH.    Preliminary content 
analysis via computational topic modeling has revealed that users in this group frequently discuss 
medications of intake as well as the side effects thereof.116   
Therefore, I now explore the use of social media venues to study larger populations of 
AIH-affected individuals to determine the types of pharmaceutical products and dietary 
supplements that they claim to take.    
 
5.2 Methods 
 
Using nth-member sampling (n = 10), 105 user narratives (created as described in 
Chapter 4) were sampled via alphanumerical order of encrypted Facebook™ screen names.  
These narratives were then randomly ordered and split into 73 training set entries and 32 testing 
set documents. 
The lead author (AK) and a coauthor (JSP), both with extensive academic natural science 
backgrounds, annotated the 73 training set narratives in order to observe mentions of medication-
related terminology.  For each post or comment made by each user, each volunteer was to note 
the following aspects: 
1. Literal.  The literal independent clause showing that (2), (3), and (4) were evidenced in 
the user’s communication.  This will include literal evidencing of xenobiotic use and 
therefore any misspellings that may occur.   
2. Xenobiotic. Shows the actual xenobiotic drug. Components: 
a. Name of xenobiotic (US generic/USAN) 
b. Unified Medical Language System (RxNorm Concept Unique Identifier (RxCUI) 
system.125) corresponding to USAN 
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3. Experiencer. Categorizes the mention of a xenobiotic (not the user themselves) as to the 
user’s use of the xenobiotic-related term. Classes: 
a. Patient 
b. Caregiver/relative of patient 
c. Observer: Mentioning xenobiotic but not due to taking it (e.g. as a suggestion or 
question).   
i. If the experiencer in the sentence is judged as observer, the annotation is 
omitted.   
ii. Non-observer users who act as observers will have only the observer 
annotations omitted. 
Note: Users may have mentions of multiple distinct xenobiotics, and in many cases, the redundant 
mentions of the same xenobiotic.  
4. Temporal-Negation (not recorded if Experiencer is an observer).  Classes: 
a. Currently taking 
b. Taken in the past 
c. Denies taking (negation) 
5. Type of spelling (annotated only by AK).  Classes: 
a. Generic name, spelled correctly 
b. Generic name, clinical abbreviation 
c. Generic name, non-clinical abbreviation or misspelled 
d. Brand name, spelled correctly 
e. Brand name, abbreviated or misspelled 
f. Class of drug, spelled correctly 
g. Class of drug, misspelled 
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6. Literal split.  From (1) above, split into – Components: 
a. Subject-verb portion 
b. Object (xenobiotic) portion 
 
A consensus procedure was performed after annotation to ensure 100% agreement of the 
two annotators respect to each xenobiotic as mentioned by each user.    The 35 testing set 
narratives were also annotated with post-annotation consensus, but without noting misspelling 
class.  Therefore, a folksonomy of user-generated terms used to represent drugs and their intake 
can be generated.   
The folksonomy, in turn, can then be structured in a set of synsets; the synset is a concept 
referring to the matching concepts with all possible synonymous (folksonomic) terms. 126   When 
a set of synsets (i.e., a thesaurus) is used to search a group of documents, the process is known as 
named entity recognition (NER).  Synsets consist of one preferred term and multiple synonymous 
terms; the latter of which are misspellings, abbreviations, and synonyms of the preferred term.  If 
a document (in this case, a user communication) mentions any member of the synset, the 
document (or communication) is tagged with having mentioned the concept represented by the 
preferred term. 
The pharmaceutical compound dexamethasone (a xenobiotic used to treat AIH) can 
similarly be represented as a synset, with dexamethasone itself being the preferred term because 
the USAN nomenclature was used in earlier annotation, as seen in Figure 6. 
 
Dexamethasone: _dexa_; _dex_; decadron; dexamethasone; intensol 
Figure 6.  Synset Representing the Pharmaceutical Dexamethasone 
 
A xenobiotic folksonomy is therefore created via addition of drug name misspellings and 
brand nomenclatures are matched as synonyms to the respective generic compounds. 127, 128   A 
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combination of NER with rules-based searching further enhances the accuracy of detecting 
whether a xenobiotic drug is mentioned as actually taken by the user or just mentioned in passing 
(as an observer).  Fuzzy matching via basic local alignment search (BLAS)129 may have the 
capability to reveal misspelled xenobiotic generic and brand names.   Furthermore, portions of 
user-generated communications over SM have been considered sufficient for extraction of self-
admission of various use of xenobiotics via NER and hybrid methods.130  
To develop a compendium of all possible xenobiotics that users could have been exposed 
to, an initial synset consisting of over 2,000 pharmaceutical and over-the-counter/supplement 
xenobiotic substances (with over 7,000 related brand and compounded preparation names) was 
retrieved from the United States Food & Drug Administration (US FDA)’s Orange Book131 
master database file. 
The file was then parsed to separate multi-compound brands (e.g., the product 
MUCINEX was originally listed as containing “dextromethorphan and guaifenesin”; the entry 
was converted to MUCINEX,dextromethorphan and MUCINEX,guaifenesin).  Anion references 
in salt compounds were removed from generic and brand names (e.g., paroxetine mesylate 
became simply paroxetine; duloxetine hydrochloride became simply duloxetine; etc.).  These 
modifications truncated the original Orange Book file into having 1,479 unique pharmaceutical 
xenobiotic compounds named, with 4,467 associated brand name pairs. 
Most important is the fact that the synsets were enriched with every misspelling and 
abbreviation found during manual annotation of the training set.  Over 100 unique drug 
misspellings were discovered via annotation and appropriately mapped to the synset.  In addition, 
30 observed instances of foreign brand name usage (virtually all United Kingdom-market names) 
were added. 
Nonetheless, even with the enrichment of synsets with user-generated misspellings and 
abbreviations, NER via the synsets still contains one major weakness: It can only find the 
mention of a xenobiotic substance and cannot affirm whether the user claimed to have used it.  
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Therefore, a risk of elevated type I error (false positive) may exist, whereby users are falsely 
assumed to have been taking a substance simply because they mention it.  Similar risks have 
already been identified in the processing of clinical narratives (the free-text of electronic medical 
records and published clinical case study text).132 
 
True positive: 
I have been on aza for 6 months now 
 
False positive A (observer): 
I heard aza causes agranulocytosis 
 
False positive B (negation): 
I never took aza 
 
Figure 7. NER True and False Positive Examples 
 
 
As seen in Figure 7 above, term aza is correctly used in the NER synset to refer to 
azathioprine, but false positives occur because (A) a communication was simply mentioning the 
xenobiotic substance in passing or because (B) the communication indicates denial of the user 
taking the substance. 
Therefore, in the previous steps, the entire phrase (complete with subject, verb, and 
object) was recorded, as the subject and verb content are important to determine whether the user 
was actually taking the substance in question.  The subject and verb were taken as prefix and the 
actual manner in which the compound was referred to taken as the target.  Prefixes recorded both 
the experiencer and temporal aspects of the xenobiotic’s mention in a single element.  Examples 
of actual prefixes discovered are shown in 4.1.2 (Results, Prefixes).  Furthermore, suffixes, of few 
of which were discovered in annotation, were added to create an affirmative (albeit experiencer-
ambiguous) class. 
55 
Finally, increased Type II error can occur during literal matching via user-generated 
misspellings (other than those encountered in the training set) missed by the synsets.  Therefore, a 
basic local alignment search (BLAS; BLAST)129, similar to that used for alignment of genetic 
sequences, is utilized in order to match non-identical but likely similar strings.  For each synset 
member, if the communication fails to contain it literally, the member is then compared pairwise 
across every possible frame through the entire communication.   
The prefixes and suffixes were integrated into NER by enhancing an existing Java Virtual 
Machine (JVM) synset detector that was the earlier work of the author and colleagues (AK; JJ).133  
Prefixes and suffixes are searched for in a 45 character geographical neighborhood of the synset 
member.  Therefore, the first phase of search is pure named entity recognition, and further search 
steps are a hybrid of NER and rules-based search (RBS). 
Finally, as indicated in the following diagram, a step to implement BLAS (Fuzzy) search 
is carried out in case of a synset member not being found literally.  Such instance occurs a 
majority of the time, because most communications do not contain many individual synset 
members. 
 
Figure 8. NLP Hybrid Methodology Workflow 
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The algorithm, depicted in Figure 8, was then run on the testing set of 40 user narratives.  
Precision and recall were judged on correctly identified user-xenobiotic pairs.  Although tense 
and specific experiencer are recorded by the algorithm, they are not analyzed here as they are not 
significant to the aims of the research at hand and serve only to classify the communication as 
evidencing xenobiotic intake and not simply observation of chemical consumption. 
With testing set analysis successful, a corpus-wide search of all 1,052 user narratives is 
performed to describe and quantify xenobiotic usage in this virtual cohort.  This search was 
performed by executing the aforementioned algorithm across the corpus of over 18,000 group 
communications. 
 
5.3 Results 
 
The 73 narratives in the testing set contained a total of approximately 2,000 posts and 
comments that were subject to annotation.  599 pairs of users referring to xenobiotics were noted, 
of which 461 pairs indicated the user (or patient user was caregiver for) actually taking the 
xenobiotic in question. 
One very significant change to the structure of the experiment was effected due to what 
was observed during training set annotations: The two common AIH treatment compounds 
prednisone and prednisolone were both determined to be frequently referred to as pred by the 
patients, and had to be merged into one ambiguous term because it was often impossible to 
differentiate them on the basis of lexical expression, the only available hint. The following 
metrics in Table 7 describe the different kinds of medication spellings (assessed post-
adjudication) used by patients, caregivers, and observers: 
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Table 7.  Types of Xenobiotic/Drug Spellings Utilized 
 
Spelling type Patient Caregiver Observer Total 
Correct 
Brand 125 (30.6%) 10 (15.9%) 26 (21.3%) 161 (27.2%) 
Generic 150 (36.8%) 32 (50.8%) 60 (49.2%) 242 (40.8%) 
Drug Class 20 (4.9%) 1 (1.6%) 9 (7.4%) 30 (5.1%) 
Clinical 
Abbreviation 
Brand 1 (0.3%) 1 (1.6%) 0 (0.0%) 2 (0.3%) 
Generic 69 (16.9%) 14 (22.2%) 13 (10.7%) 96 (16.2%) 
Misspelling 
Brand 19 (4.7%) 0 (0.0%) 7 (5.7%) 26 (4.4%) 
Generic 21 (5.2%) 5 (7.9%) 6 (4.9%) 32 (5.4%) 
Slang 3 (0.7%) 0 (0.0%) 1 (0.8%) 4 (0.7%) 
 
Some common prefixes are noted below in Table 8.  These prefixes hint the machine that 
the quoted user is actually taking (or caring for someone taking) a xenobiotic, and is neither 
casually mentioning the product or outright denying usage of it. 
 
Table 8. Drug Intake Prefixes 
 
Experiencer Temporal Prefix(es) 
Patient 
Present 
Am taking Take 
Am on Still on 
Past Took Was taking 
Negated Was never on Never had 
Caregiver 
Present She is on Husband takes 
Past He was on Wife took 
Negated Daughter never took She never had 
 
Prefixes for observers (casual mentions) were not created because the exclusion of the 
experiencer prefixes in rules-based search would automatically create the assumption that the 
xenobiotic mention was only an observation. 
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Natural language processing (NLP) was performed on the testing set (35 users who made 
approximately 500 communications) utilizing named entity recognition hybridized with RBS both 
with and without and BLAS.  Pairs of users and xenobiotic intake affirmations were compared 
between the annotated gold standard set and the result set derived from NLP.  Results for recall, 
precision, and F-score were noted to be as shown in Table 9. 
 
Table 9. Performance of the NER Algorithms 
 
Protocol Precision Recall F-score 
NER + RBS  
(No BLAS; Literal Only) 
0.707 0.693 0.700 
NER + RBS +  
BLAS (Literal + Fuzzy) 
0.704 0.769 0.735 
 
 
In order to benchmark the methodology against more comparable studies (i.e., ones that 
only studied one variable), the precision, recall, and F-score measures were calculated for the four 
most popular xenobiotics (azathioprine, prednisone/prednisolone, mycophenolate, and 
budesonide) seen in the annotated gold standard set; benchmark results are shown in Table 10. 
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Table 10. Performance over Common Xenobiotics   
 
Xenobiotic/Drug Precision Recall F-Score 
(Taking any drug at all) 1.000 0.958 0.979 
Azathioprine 0.769  1.000 0.870 
Prednisone & Prednisolone 0.923 0.800 0.857 
Mycophenolate 1.000 0.667 0.800 
Budesonide 0.800 1.000 0.889 
 
Error analysis, the qualitative judgment of false positive and negatives, was conducted in 
order to observe the most common reasons for NLP either failing to match a taken xenobiotic or 
mistakenly matching one that was not taken.  All instances of false results were a result of one of 
the following conditions: 
 (Ambiguity) Prednisone and prednisolone could not be disambiguated because many 
users conflated the two medications simply as pred.  Therefore, users could only be 
tagged with the fact they were using one or both medications with no further 
specification.  Note that NLP quality metrics exclude this limitation. 
 (False Negative) In one user instance, the user was judged by both annotators to have 
implied intake of multiple xenobiotics due to having mentioned them all in a row without 
having used any term explicitly indicating intake.  The annotators believed that the users 
were giving out personal medication lists in response to an inquiry about their medication 
regimen; the current NLP does not detect when multiple xenobiotics are mentioned in a 
row. 
 (False Negatives) Two users with exceptionally high tendencies to misspell words 
misspelled drug product names to a BLAS similarity score of < 0.50, evading tagging. 
 Prednicarbate (False Positives) 
o Resembles prednisone to a BLAS similarity score of 0.75, resulting in false 
matches when a user says prednisone literally. 
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o Sold as DERMATOP, which closely enough resembles dermatologist for a false 
match to be returned when a user mentions dermatologist preceded by words 
indicating taking a xenobiotic.   
 
After validation of the testing set, the corpus of all 1,052 users was searched for 
medication usage via the NER + RBS hybrid algorithm.  608/1,052 (57.79%) of users mentioned 
intake of at least one studied xenobiotic.  The most popular xenobiotics, by users claiming having 
taken them, were therefore revealed and are shown in Table 11. 
 
Table 11. Sample: Xenobiotics Taken by at least Twenty Users 
 
Rank Xenobiotic N % Users 
% Users 
Reporting 
 (Reported any xenobiotic intake) 574 54.6% 100.0% 
1 Azathioprine 339 32.2% 59.1% 
2 Prednisone & Prednisolone Combined 285 27.1% 49.7% 
3 Mycophenolate (All Forms) 99 9.4% 17.3% 
4 Budesonide 89 8.5% 15.5% 
5 Ursodiol 59 5.6% 10.3% 
6 6-Mercaptopurine (6-MP) 48 4.6% 8.4% 
7 Acetaminophen (Paracetamol) 44 4.2% 7.7% 
8 Vitamin D (All Forms) 42 4.0% 7.3% 
9 Tacrolimus (Fujimycin) 36 3.4% 6.3% 
10 Calcium 31 3.0% 5.4% 
11 Diuretic (NOS) 27 2.6% 4.7% 
12 Magnesium 23 2.2% 4.0% 
13 (T) Amoxicillin 20 1.9% 3.5% 
13 (T) Ibuprofen 20 1.9% 3.5% 
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5.4 Discussion & Conclusions 
 
Percentage-wise differences were discovered in how users as patients, caregivers, and 
observers of xenobiotics referred to these products.  The communication group most likely to use 
correctly spelled brand names was observed to be those communicating as patients.  Generic drug 
names were most likely to be used by those acting as caregivers, while correctly spelled drug 
classes were seen disproportionately frequently among communications that mentioned the 
xenobiotic only in passing.   
Clinically acceptable abbreviations of brand names were relatively rare, and more 
common for generic names.  Misspellings, overall, were surprisingly infrequent (9.8% of all 
mentions), raising speculation that group members could be affected by a white coat syndrome 
and use proper medical terminology due to AC’s presence. Alternately, it is possible, but likewise 
not confirmed, that they may be what are considered expert users due to their extensive 
experiences with the medical system.  Furthermore, it is noted that slang usage was less common 
than even misspellings, further hinting at possible backgrounds and motives of the users in the 
group. 
While typical NLP studies prescribe target F-scores in excess of 0.80, such research has 
only attempted to classify the existence of one variable through a corpus and attempting to do 
multinomial classification at this level would not be feasible.  Many of these studies were also 
performed solely on electronic medical record (EMR) free text, where brand name usage is less 
common, misspelling extremely rare, and the mere mention of a medication is sufficient to 
assume that administration occurred.  The closest similar recent study (Klein et al, 2017)130 
demonstrated an F-score of 0.67 for a hybridized approach to detecting multinomial xenobiotic 
usage across a social media corpus,  and the techniques in this dissertation demonstrate a 
composite F-score of 0.731, higher than the previous effort by those authors.   
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Even though only 9.8% of all xenobiotic mentions were noted as misspelled in gold 
standard annotation, adding a fuzzy (BLAS) step to the search algorithm increased recall to 0.766 
from 0.693 with only a modest drop in precision.  The F-score increased in turn from 0.700 to 
0.734.  Despite the fact that the addition of BLAS increased the wall clock execution time from 
15 minutes to approximately 45 minutes to process the entire corpus, BLAS is still considered 
valuable for increasing recall and overall quality due to the increase in F-score. 
Finally, a comparison to single-compound detection studies can be performed by 
reducing the results to a univariate format, comparing precision and recall using only singular 
xenobiotics.  Detection performances of azathioprine, budesonide, mycophenolate, and 
prednisone/prednisolone usages were above 0.800.   
With a sufficiently valid methodology developed to analyze xenobiotic usage over social 
media, the corpus of all 1,052 group users could be analyzed.  The most common xenobiotics 
indicated as taken were therapeutics for AIH and its most common sequelae.  
Hydroxychloroquine is an anti-malarial drug that is also used to modify the progression 
of a common autoimmune comorbidity (rheumatoid arthritis) 11 of AIH.  Lactulose is typically 
used to relieve the etiological factors behind hepatic encephalopathy (HE), a known AIH sequela.  
Other xenobiotics estimated to be consumed, such as acetaminophen, ibuprofen, and amoxicillin, 
are very commonly used in the general population.  Furthermore, amoxicillin is commonly used 
by the general population; it and other antibiotics, especially in combination preparations with 
clavulanic acid have been linked by researchers to hepatic injury. 17  Finally, the role of pain in 
AIH symptomatology may be suggested by the high rankings of tramadol (an opioid pain 
reliever) and gabapentin (a neuropathic pain drug) intake, in addition to claimed intake of more 
common analgesics. 
Furthermore, common vitamin/mineral supplements mentioned as taken included vitamin 
D (all forms), magnesium, and calcium products.  In addition, the less commonly used 
supplement melatonin, used commonly as a sleep aid, was mentioned often as taken.  Intake of 
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these substances might suggest treatment of untoward AIH (or comorbidity) symptom treatment 
and possibly polypharmacy of AIH medication side effects, although more data, in addition to 
consults with clinicians, are required to elucidate this relationship. 
One significant issue discovered during gold standard annotation was that the compounds 
prednisone and prednisolone could not be differentiated in automated search due to many users 
conflating them by using the term pred.  It is possible that contextually searching the remainder 
of the user’s communications can reveal which xenobiotic the user is actually referring to, but the 
NLP method does not analyze user postings in such a manner. 
Furthermore, a broader limitation is noticed: The information derived faces the same 
problems electronic medical record (EMR)-derived medication lists.  A primary issue was 
incomplete reporting, noted in that only 337 out of 1,052 group users reported intake of 
azathioprine, a medication used to treat a far higher proportion of AIH patients.  Furthermore, the 
overall figure for users having claimed to have taken any xenobiotic at all was 574/1,052 (54.6%) 
which is also likely to be an underestimate of the real figure.  The other significant issue shared 
with EMR-derived research was the inability to reliably judge when a patient (user) stopped or 
started a medication.  While past and current medication usage are differentiated with the 
algorithm in order to differentiate patients/caregivers from mere observers, the tense-based 
portion of classification has not been subject to quality assurance.  Future research therefore 
should involve more detailed study into temporal attributes of medication usage in this and 
similar cohorts.   
Finally, the algorithm utilized is computationally inefficient due to its use of literal text 
matching and moreover, lack of BLAS time optimization.  Wall clock time of scanning all 
18,000+ communications was under 15 minutes without BLAS but increased to over 2 hours 
when BLAS was added.  Future research must consider ways in which the BLAS portion can be 
optimized for more efficient and expedient throughput. 
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Despite the limitations encountered, the proposed executed methodologies are valid for 
detecting xenobiotic usage and thus performing surveillance on a virtual cohort of over 1,000 
users of an autoimmune hepatitis (AIH)-related online support group.  The reliability has 
surpassed that of the most recent similar study. 130  As per prefix detection in section (4.1.3), 
combined with synsets involving brand names and a BLAS-based correction for potential 
misspellings, the research at hand has also created an effective folksonomy to classify xenobiotic 
usage via consumer- (patient-) generated corpora of communications.  With the research that has 
been generated, the potential exists for the examination of any user-generated text corpus, in 
particular one relating to health, for intake of xenobiotics and drugs. 
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CHAPTER 6. DETECTING CLINICAL FACTORS EXPRESSED OVER THE AIH 
GROUP 
 
6.1 Introduction 
 
Drug (xenobiotic) intake, as analyzed in the previous chapter, is considered only one 
clinical concern in Autoimmune Hepatitis (AIH).  AIH is shown to have significant 
gastrointestinal sequelae of hepatic destruction and has been associated with highly associated 
gastrointestinal and systemic autoimmune comorbidities. 9, 10, 33-36   Frequently experienced 
sequelae include, edema, hepatic cirrhosis, and hepatic encephalopathy.  AIH may co-occur with 
and has the potential to be exacerbated by other liver-related diseases, including Diabetes 
Mellitus (DM). 37-39  Other signs and symptoms are likely due to these sequelae as well as the 
adverse effects of treatments: Changes in weight, impaired white blood cell (WBC) function, and 
severe pain in and around affected regions of the body are frequently noted .40 is therefore of 
significant interest to classify AIH patients by sequelae and symptoms experienced. 
Symptoms may, per clinician judgement, also be due to adverse drug effects (ADEs; e.g., 
side effects).  Corticosteroids, a mainstay of AIH treatment, are documented to have heavy burden 
of ADEs, some of which (such as edema, weight changes, and impaired WBC function40) are 
common to original disease symptoms and were found in one study to in fact decrease AIH 
patient quality of life.41    Such drugs and regimens are known to aggravate the paralyzing fatigue 
and psychological risks42 already observed in untreated disease.  As noted in the next section, 
pain is a common indirect sequela of AIH treatment. 
Regardless of alleged cause, the important symptom of pain (physical and psychological), 
along with fatigue, is a major concern in patient quality of life (QOL).  Pain has been noted at 
elevated rates in the AIH population; mycophenolate44, 45 usage may be one correlate. 
Corticosteroid use is known to correlate with pancreatitis,47 soft tissue injuries42 and 
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osteonecrosis-induced bone fractures,46 which can all be painful.  Autoimmune comorbidities of 
AIH also include painful syndromes of arthritis.11 
Pain in the form of psychological distress (and potentially psychosomatic physical pain) 
is seen in AIH, potentially at an elevated rate compared to control populations.48-50   Mental 
depression is in particular considered common in AIH49, 50  furthermore, immunosuppressant 
therapies (in particular, corticosteroids51) are associated with similar adverse neuropsychiatric 
effects.  Furthermore, the mental trauma incurred due to the exceptional symptom burden and 
resultant decreased quality of life contribute to psychological distress.70   
Fatigue, a biopsychological symptom, is also noted but the etiology considered cryptic; it 
has been attributed by some researchers as an ADE.42, 52, 53   Cognitive impairment is observed 
and has been attributed to hepatic encephalopathy, a condition where the brain is overloaded with 
toxic metabolic byproducts due to the liver failing.32, 54 
Batteries of liver function tests (LFTs) are conducted regularly on AIH patients in order 
to gauge biological disease severity.55  In addition, various auto-antibodies are assayed despite the 
fact that they are not always considered diagnostic of AIH.56   
For all of these signs, symptoms, comorbidities, and even test results, social media can be 
amenable to syndromic surveillance (SS), a public health-based technique of recording symptoms 
without observing patients directly.  Social media has been used for gathering reference data for 
epidemiologic studies134 and environmental and sociodemographic factors into infectious disease 
prediction models.135  In fact, the author’s earlier114 and forthcoming43 research ha suggested that 
signs, symptoms, comorbidities, and serum monitoring (lab) results are frequently discussed on 
the AIH group in question. 
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Therefore, the purpose of this phase of dissertation research is to determine the feasibility of 
conducting online surveillance of: 
 Signs & Symptoms 
 Diagnosed Comorbidities 
 Laboratory test results 
…associated with autoimmune hepatitis (AIH) over an AIH-oriented social media support group. 
 
6.2 Methodology 
 
Initially, a qualitative analysis on a testing set of the entire communications of 73 users 
(over 1,500 communications) was performed in order to determine the manner in which signs, 
symptoms, diagnosed comorbidities, and lab test results were expressed by the online cohort in 
question.   
Annotations were standardized using the Systematic Nomenclature of Medicine 
(SNOMED-CT).  Each annotation was mapped to a preferred SNOMED-CT finding-class term 
with 264 SNOMED finding-class concepts discovered. Afterwards, the preferred finding-class 
terms were clustered by mutual agreement of both annotators into 49 different classes of findings. 
Appendix IV contains a list of all SNOMED concepts whose experience was discovered 
during training set annotation.  In addition, it contains the mapping of these concepts to the 
authors’ 49 chosen higher-level concepts.  
After annotation, literal mentions of these factors were also qualitatively clustered by 
semantic regular expression traits and the following semantic clusters (not identical to the 49 
SNOMED clusters) of mentions determined as shown in Table 12. 
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Table 12. Regular Expressions by Algorithm 
 
Factor Expression (Any Order) Expression List In 
Pain-related 
sign/symptom 
Body Part (AND) Term Indicating Pain.  
(Sequential regular expressions; please see below 
figure) 
Appendix V 
Non-pain-related 
sign/symptom 
(Experiencer Term) (AND) Term Indicating Sign 
or Symptom 
Appendix VI 
Diagnosed Comorbidity (Experiencer Term) (AND) Term Indicating 
Comorbidity 
Appendix VI 
Lab Test Result Name of Test (AND) Indicator of Value Appendix VII 
 
Each cluster is characterized by a regular expression, a set of features that are required in 
order to indicate the user was experiencing the problem in question.  Note that the order of 
elements in each expression is not binding, but the presence of all elements is. 
 
Therefore, the most suitable way to search the wider corpus of postings was determined 
to be via three separate algorithms, with each algorithm using its own expression content: 
 Pain 
 Diagnosed comorbidity & non-pain-related signs and symptoms 
 Lab test results 
 
As per the cardinal expression (#1) detailed in (6.3.1), evidence of experiencing pain was 
searched by the hybrid named entity recognition (NER) and rules-based search (RBS) algorithm 
described in Figure 9. 
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Figure 9. Sequential Pain Detection Algorithm 
 
Depending on the body part and type of pain, the pain classification was reduced from 
(10 * 5) = 50 to 10 classifications by clinical judgment of the second annotator, subject to 
approval by the primary author.  The classifications and logic thereof are seen in Figure 10. 
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Figure 10. Higher Level Classification of Pain and Injury 
 
 
The algorithms for non-pain-related signs and symptoms and diagnosed comorbidities are 
far simpler and therefore not diagrammed.  The analogous classification table is available in 
Appendix IV. 
The following lab test results, important in the monitoring of the disease, were sought: 
 Liver Function Tests (LFTs) 
o Bilirubin 
o Alanine transaminase (ALT) 
o Aspartate transaminase (AST) 
o Alkaline phosphatase (ALP) 
o Gamma-glutamyl transpeptidase (GGT) 
Neuropathy 
(Burning, Tingling, 
Parasthesia)
Fracture 
(Breaking a bone)
Soft Tissue Injury 
(Sprains, Strains, 
Bruises, 
Dislocations)
Myalgia (Cramps, 
Soreness, Fibro)
Physical Pain NOS 
(Hurting, Aching)
Lower Limb (Excl. 
Joints)
Upper Limb (Excl. 
Joints)
Back/Spine
Dental/Oral
Painful Mouth 
(102616008) [NB3]
Thorax
Muscle Pain 
(68962001)
(Physical) Pain 
(22253000)
Head
Abdomen (Including 
Quadrants)
Not Observed
Bone (Any) Not Observed
Joint (Any)
Arthralgia 
(57676002) [NB2]
Pain but no body 
part
Neuropathic Pain 
(247398009)
Muscle Pain 
(68962001)
(Physical) Pain 
(22253000)
NOTES [NB1]
[NB2]
[NB3]
[NB4]
Type of Pain or Injury
Bo
dy
 P
ar
t/
Re
gi
on
Headache (25064002)
Muscle Pain 
(68962001)
(Physical) Pain 
(22253000)
Fracture of Bone 
(125605004)
Soft Tissue Injury 
(282026002)
Neuropathic Pain 
(247398009)
Neuropathic Pain 
(247398009)
Abdominal myalgia classified as abdominal pain due to cramps
Burning/tingling in abdomen typically due to organomegaly associated compression
Painful Mouth (102616008) [NB3]
Burning sensation in joints typically due to arthritis, so classified as arthralgia
Oral myalgia classified as mouth pain due to soreness typically being not muscle related
Bone Pain (12584003)
Abdominal Pain (21522001) [NB4]
Arthralgia (57676002)
Fracture of Bone 
(125605004)
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 Autoimmune antibody (AAB) titers 
o ANA 
o PANCA 
o LKM 
 White blood cell (WBC) titers 
o Lymphocytes 
o Neutrophils 
 Red blood cell (RBC) titer 
 
Based on patient self-report as test result high, low, abnormal, or normal, the annotators agreed 
upon higher-level classifications for test results as schematized in Figure 11. 
 
 
Figure 11. Higher Level Classification of Lab Test Results 
 
 
Liver Function (LFT) Autoantibody (AAB) Red Blood Cell (RBC)
White Blood Cell 
(WBC)
High
LFT Abnormal / AIH 
Flare (707724006 / 
408335007.FLARE)
Autoantibody Titer 
Positive (165878000)
RBC Normal 
(165421004)
WBC Normal 
(165507003)
Low
LFT Normal / Serum 
AIH Remission 
(166602006 / 
408335007.STAB)
Autoantibody Titer 
Negative (165878000)
Abnormal
LFT Abnormal / AIH 
Flare (707724006 / 
408335007.FLARE)
Autoantibody Titer 
Positive (165878000)
Normal
LFT Normal / Serum 
AIH Remission 
(166602006 / 
408335007.STAB)
Autoantibody Titer 
Negative (165878000)
RBC Normal 
(165421004)
WBC Normal 
(165507003)
Le
ve
l
Test Type
Anemia (271737000)
Leukopenia (NOS) 
(419188005)
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To validate the findings, a test set of 35 users was then analyzed for signs, symptoms, 
pain signs, pain symptoms, comorbidities, and laboratory test results.  The aforementioned 
algorithms were then run over this new corpus of users and measures for sensitivity, specificity, 
and F-score calculated. 
 
6.3 Results 
 Performance results varied depending upon the algorithm, granularity of detection 
sought, and specific problem to be detected. Relevant results are detailed in the below tables 
(Tables 13 and 14). 
 
Table 13. Algorithm Performance: Pain and Injury 
 
Note: Only combinations that evidenced a gold standard N of >=5 are discussed. 
Observation 
Granularity  
Variable Granularity  Precision Recall F-score (N +) 
User (35) Any type of pain or injury  0.778 1.000 0.875 15 
Communi- 
cation (277) 
Any type of pain or injury 0.722 0.813 0.765 135 
 
User (35) Correct type of pain or injury (20 
types) 
0.667 0.667 0.667 15 
Arthralgia only 0.800 0.889 0.842 11 
Physical Pain NOS only 0.625 0.625 0.625 8 
Abdominal pain only  0.600 0.600 0.600 5 
 
The next table represents the detection of non-pain signs, non-pain symptoms, and diagnosed 
comorbidities. 
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Table 14. Algorithm Performance: Signs, Symptoms, Comorbidities 
 
Variable SNOMED-CT 
Code 
Precision Recall F-score (N +) 
(/35) 
Correct sign, symptom, 
comorbidity type  
N/A 0.694 0.767 0.729 31 
Cirrhosis 19943007 0.909 1.000 0.952 10 
Comorbid autoimmune disorder  85828009 0.889 0.800 0.842 10 
Fatigue 84229001 0.600 0.667 0.632 10 
Infectious disease 40733004 0.667 0.667 0.667 9 
Mood issue 271596009 0.643 1.000 0.783 9 
Gastrointestinal upset 162059005 0.667 0.800 0.727 7 
Fibromyalgia 203082005 1.000 1.000 1.000 5 
Cognitive Impairment NOS 386806002 1.000 0.750 0.857 4 
Disorder of Pancreas 3855007 1.000 0.750 0.857 4 
Jaundice 18165001 0.667 1.000 0.800 4 
Note: Only entities that achieved a rate of at least 4 gold standard testing set positives are shown 
here.  The observation granularity is always by user (never by communication). 
 
 
Finally, results pertaining to the detection of specific aspects of laboratory results are shown in 
Table 15. 
 
Table 15. Algorithm Performance: Lab Test Results 
 
Variable Granularity  Permu-
tations 
Precision Recall F-
score 
(N +) 
(/35) 
Correct test performed on user  3 0.818 1.000 0.900 27 
Correct test with correct result  12 0.605 0.676 0.639 27 
Liver function test (LFT) with correct result  4 0.692 0.720 0.706 19 
Autoantibody (AAB) titer with correct result  4 0.429 0.600 0.500 5 
White blood cell count with correct result  4 0.400 0.500 0.444 4 
Note: The observation granularity is always by user (never by communication).   
 
Common patterns of errors were elucidated that hampered precise detection of the studied 
factors.  The following errors were known to occur at least twice upon further examination: 
 Psychological pain/mental distress would be referred to with terms such as it hurts, in 
pain, hurts me, and other false positive n-grams that the algorithm coded as physical pain. 
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 The abdominal pain dictionary included various abdominal organs.  Users often 
mentioned abdominal organ damage followed by pain in another part of the body.  In this 
case, the algorithm tagged users as having pain both in the abdomen (false positive) and 
the other body part (true positive). 
 In detection of AAB titer self-reports, positive and negative readings were often 
conflated.  Two instances were found where the user mentioned one antibody as positive 
and one as negative within the same sentence; the combination of antibody readings into 
one variable made these users default to self-reporting negative AAB titer status. 
 
The algorithm was then run on the entire corpus in order to gain population estimates of 
patient self-reports of these signs, symptoms, comorbidities, and lab test results.  Only aspects 
that attained a test set (gold standard) N of at least 4 are listed in summary Tables 16, 17, and 18, 
below. 
 
Table 16. Pain & Injury over the Wider Corpus 
 
Pain Type, Classified SNOMED-
CT Code 
N Users 
(/1052) 
% Users % Report Users 
Any type of pain or injury N/A 365 34.7% 100.0% 
Physical Pain NOS 22253000 205 19.5% 56.2% 
Arthralgia 57676002 137 13.0% 37.5% 
Abdominal Pain 21522001 96 9.1% 26.3% 
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Table 17. Signs, Symptoms, and Comorbidities over the Wider Corpus 
 
Variable SNOMED-CT 
Code 
N Users 
(/1052) 
% Users % Report 
Users 
Any sign, symptom, comorbidity N/A 687 65.3% 100.0% 
Mood issue 271596009 249 23.7% 36.2% 
Infectious disease 40733004 222 21.1% 32.3% 
Fatigue 84229001 219 20.8% 31.9% 
Comorbid autoimmune disorder  85828009 137 13.0% 19.9% 
Cirrhosis 19943007 136 12.9% 19.8% 
Gastrointestinal upset 162059005 112 10.6% 16.3% 
Cognitive Impairment NOS 386806002 112 10.6% 16.3% 
Jaundice 18165001 82 7.8% 11.9% 
Fibromyalgia 203082005 42 4.0% 6.1% 
Disorder of Pancreas 3855007 22 2.1% 3.2% 
 
 
Table 18. Lab Test Results over the Wider Corpus 
 
Variable N Users 
(/1052) 
% Users % Report 
Users 
Liver function test (LFT) result reported 386 36.6% 100.0% 
Normal LFT (AIH Serum Stabilized) 203 19.3% 52.6% 
Abnormal LFT (AIH Flare) 323 30.7% 83.7% 
Only Normal LFT Reported 63 6.0% 16.3% 
Only Abnormal LFT Reported 183 17.4% 47.4% 
Both Normal & Abnormal LFTs Reported 140 13.3% 36.3% 
 
 
6.4 Discussion 
 
Our research has shown evidence for the feasibility, via targeted natural language 
processing (NLP), of the extraction of various clinical factors self-reported to have been 
experienced by patients of autoimmune hepatitis (AIH).  Multiple algorithms allowed for the 
automated discovery of self-reported signs, symptoms, comorbidities, pain-related issues, and 
disease monitoring results across a corpus of 1,052 members of an AIH-oriented support group.   
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In terms of detecting pain symptoms and injury, the algorithm performed best in 
detecting self-reported arthralgia (i.e., joint pain), with an F-score of 0.842.  Detection of 
expressed general physical pain (not otherwise specified as to nature or location) 136 and 
abdominal pain were satisfactory, with F-scores of 0.625 and 0.600, respectively.  Furthermore, 
the detection of any user (or in fact any communication) evidencing any sort of pain or injury was 
reliable at F = 0.875 for users and F = 0.765 for individual communications.   
Set upon the wider corpus of users, the pain detection algorithm demonstrated that 
unspecified physical pain was most commonly self-reported (19.5% of all users, or 56.2% of 
pain-reporting users).  Arthralgia was also noted by 13.0% of all users (37.5% of pain-reporting 
users).  Unspecified pain is expected to be most common due to its physical generality; on the 
other hand, arthralgia is more remarkable because is not as common in the general population and 
is still nascently being researched as an AIH symptom that may be due to autoimmune-mediated 
joint destruction.136   The reporting rate of abdominal pain was at 9.1% of all users (26.3% of 
pain-reporting users) and therefore lower than the self-reported rate of arthralgia in this cohort 
despite the inherently abdominal nature of the disease.  The rate of self-reported arthralgia in this 
group, if corroborated by survey evidence, may support the sparse literature on the topic of 
arthralgia in AIH, and more research to uncover the relevant links would have to be conducted. 
Several non-pain signs, symptoms, and comorbidities were also deemed amenable to 
automated extractions.  The pilot testing analysis showed that mood issues, infectious disease, 
fatigue, comorbid autoimmune disorders, cirrhosis, gastrointestinal upset, and cognitive 
impairment were detectable at satisfactory F-levels.  In addition, for all possible non-pain-related 
recognized signs, symptoms, and comorbidities, the overall F-score for detection was satisfactory 
at 0.729. 
The corpus-wide analysis revealed that 65.3% (N = 687/1052) users expressed one of the 
sought signs, symptoms, or comorbidities.  The most commonly observed self-reported factor 
pertained to mood issues (which are defined by the annotators and recorded by the algorithm as 
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all mood-related psychiatric diagnoses along with expressions of profound sadness or grief), 
which were expressed and/or self-reported by 23.7% of individuals (36.2% of those who 
expressed any sign, symptom, or comorbidity at all).  In addition, infectious disease and fatigue 
were reported by over 20% of all group users.  
Anomalous detection rates were also observed.  A diagnosis of cirrhosis, a late-stage 
complication of AIH, was self-reported by 12.9% of all group users.  In comparison, researchers 
estimate that 25% of AIH patients have cirrhosis at initial disease presentation (with a much 
higher lifetime prevalence)31, suggesting that cirrhosis may be underreported by users in the 
cohort currently at study.   Gastrointestinal upset may also be underreported (10.6% of all users; 
16.3% of all reporting users), especially viewed in comparison to cognitive impairment, which 
was self-reported at an identical frequency.   
Of the laboratory test results, only self-reported liver function tests (LFTs) were 
demonstrated to be reliably ascertainable; this detection feature allowed for partial classification 
of users claiming to have experienced disease flares and/or remissions.  
The limitations inherent in this research may form a basis for future research that should 
be conducted on the subject.  A chief limitation that occurred in classification was the fact that 
although SNOMED-CT contains unique concept mappings for clinical entities, these entities are 
technically subject to type constriction, with entities typically typed as sign/symptom, finding, 
entity, and diagnosis.   
The prime limitation was noted with regards to non-pain signs, symptoms, and 
comorbidities.  Specifically, although the F-score measure of reliability was satisfactory (0.729), 
there existed a limited span of covered issues.  Similarly, the small size of the testing set (N = 35 
users) limited the overall study to pilot status. 
While this research demonstrates the feasibility of extracting certain clinical signs and 
factors from a cohort of people affected with AIH, it cannot demonstrate the correlations these 
factors have with each other or with other clinical factors such as medication intake.  Associative 
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analyses will be an important part of future research and while they will not definitively create 
relationships with treatments and effects, can still help inform clinical workflows. 
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CHAPTER 7. DETECTING CONTEXTUAL FACTORS EXPERIENCED BY AIH 
PATIENTS 
 
7.1 Introduction & Background 
 
While I have already well-entertained the spectrum of factors already ascertainable in the 
AIH clinic, it is necessary to examine the AIH patient beyond the traditional clinical knowledge 
environment. Contextual factors for purposes of this discussion are non-clinical factors present in 
any individual or population thereof.  Contextual factors include (but are not limited to) 
demographics, quality of life (QOL), physical and social environments, and lifestyle-related 
factors.  At this point, I speculate and research the prospect that social media can be suitable for 
the potential of ascertaining non-clinical factors of a body of AIH patients.   
A two-search systematic review and synthesis of the literature, detailed in the overall 
background (Chapter 2) of this dissertation, discovered multiple categories (i.e., themes) of 
contextual factors that have been researched in AIH patients.  These themes were diet-related 
factors, treatment noncompliance (patient-initiated treatment withdrawal), physical environment, 
psychological quality of life (QOL), recreational substance usage, and research advocacy 
(ADVOC) for further contextual factors research. 
The existing themes from the literature review form part of the framework needed for 
classification of contextual factors as potentially observed on the AIH-related Facebook™ group 
that is the subject of this dissertation’s research.  Furthermore, a thesaurus-based format of 
classification as prescribed by Holden et al67 is utilized, where each category (theme) and each 
component (sub-theme or factor) that makes it up are also explicitly and unambiguously defined.   
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I therefore wish to investigate the creation of tools that would be required for the 
automated tagging of user-generated communications in a fashion that is relevant to improving 
the user’s health.  Therefore, customizing an algorithm with which multifaceted user text corpora 
may be classified is of essence to achieving the goal of tagging potentially health-related user-
generated content.   
 
7.2 Methodology 
 
A top-down thesaurus-based approach was utilized to synthesize and classify all factors, 
clinical and non-clinical, experienced by patients.  Although the focus of the research is with 
contextual factors, information conveyed by patients in a real-life online support group may also 
be clinical, be in inquiry for advice, or be of support to another user.  Therefore, all facets of all 
communications (be they clinical, support-related, or non-clinical/contextual) are studied while 
indexing with the thesaurus. 
Annotation was performed with a single annotator (the lead author).  Every fragment of 
every communication was annotated and assigned a thesaurus code.  Annotation ceased at 
saturation (when the annotator had gone through 50 communications in a row without 
encountering any new concepts at all), resulting in a total of 676 annotated communications split 
into 882 fragments.  Annotation validation was performed by single-blinded re-annotation, the 
author using the existing list of codes to blindly annotate the corpus once again. 
 Because the purpose of the research at hand involves automated detection of the 
contextual factors facing patients (support group users), a computational approach is favored to 
attempt automated detection of these important facets of patient life.  Due to the high number of 
observed categories (16 top-level domains with over 210 subdomains; see section 7.4.1 for more 
details), a machine learning approach (a form of complex analysis that takes multiple numeric 
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and nominal factors to characterize observations and predict future ones) was utilized to explore 
automated detection of contextual factors. 
 In order to perform machine learning, textual data must be processed into numerical (or 
Boolean) vectors (with each vector being the values of a set of variables).   
For example, let Fruits be a set of variables:  
𝐹𝑟𝑢𝑖𝑡𝑠 = [𝐴𝑝𝑝𝑙𝑒, 𝐵𝑎𝑛𝑎𝑛𝑎, 𝑇𝑜𝑚𝑎𝑡𝑜, 𝑂𝑟𝑎𝑛𝑔𝑒, 𝐿𝑒𝑚𝑜𝑛] 
 
And let Sentence be a sentence: 
𝑆𝑒𝑛𝑡𝑒𝑛𝑐𝑒 = [𝐼𝑛 𝑚𝑦 𝑔𝑎𝑟𝑑𝑒𝑛 𝐼 𝑝𝑙𝑎𝑛𝑡𝑒𝑑 𝑓𝑜𝑢𝑟 𝑡𝑜𝑚𝑎𝑡𝑜 𝑏𝑢𝑠ℎ𝑒𝑠 𝑎𝑛𝑑 𝑎𝑛 𝑎𝑝𝑝𝑙𝑒 𝑡𝑟𝑒𝑒] 
In this example, neither Sentence nor Fruits are readily computable because they consist of text.  
However, Sentence can be expressed as a Boolean vector of the variables seen in Fruits: 
𝑆𝑒𝑛𝑡𝑒𝑛𝑐𝑒(𝐹𝑟𝑢𝑖𝑡𝑠) = [1, 0, 1, 0, 0] 
…because it contains tomato as well as apple.  Similarly, Sentence can be compared to another 
vector: 
𝐴𝑛𝑖𝑚𝑎𝑙𝑠 = [𝐶𝑜𝑤, 𝐻𝑢𝑚𝑎𝑛, 𝑃𝑖𝑔, 𝑆ℎ𝑒𝑒𝑝] 
 
In that case, 
𝑆𝑒𝑛𝑡𝑒𝑛𝑐𝑒(𝐴𝑛𝑖𝑚𝑎𝑙𝑠) = [0, 0, 0, 0, 0] 
 
And is fully represented by 
𝑆𝑒𝑛𝑡𝑒𝑛𝑐𝑒 = [𝐹𝑟𝑢𝑖𝑡𝑠(1, 0, 1, 0, 0);  𝐴𝑛𝑖𝑚𝑎𝑙𝑠(0, 0, 0, 0)] 
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As well as in relation with respect to Sentence’s length: 
𝑆𝑒𝑛𝑡𝑒𝑛𝑐𝑒 = [𝐹𝑟𝑢𝑖𝑡𝑠(0.083, 0.0, 0.083, 0.0, 0.0);  𝐴𝑛𝑖𝑚𝑎𝑙𝑠(0.0, 0.0 0.0, 0.0)] 
 
As well as in relation with respect to the number of Fruits and Animals combined: 
𝑆𝑒𝑛𝑡𝑒𝑛𝑐𝑒 = [𝐹𝑟𝑢𝑖𝑡𝑠(0.111, 0.0, 0.111, 0.0, 0.0);  𝐴𝑛𝑖𝑚𝑎𝑙𝑠(0.0, 0.0, 0.0, 0.0)] 
 
Finally, the two vectors expressed as in relation may be combined to form a normalized 
Term Frequency-Inverse Document Frequency (TF-IDF) matrix, which expresses the frequency 
of words in Sentence in a direct ratio to the relative frequencies of all words in Fruits and 
Animals.  There are multiple ways of calculating TF-IDF, the simplest of which is dividing the 
probability of the word within a sentence to the probability of the word within the classification 
array: 
𝑇𝐹𝐼𝐷𝐹(𝑆𝑒𝑛𝑡𝑒𝑛𝑐𝑒) = [𝐹𝑟𝑢𝑖𝑡𝑠(0.748, 0.0, 0.748, 0.0, 0.0);  𝐴𝑛𝑖𝑚𝑎𝑙𝑠(0.0, 0.0, 0.0, 0.0)] 
 
The vectors of Sentence, in turn, can be used to determine what it is about.  Because 
Sentence does match to Fruits to some degree but not to Animals at all, it is safe to say that if a 
machine had to choose which of those two topics Sentence was about, it would most likely 
choose Fruit as the topic.  Overall, the TF-IDF vector normalization of different groups of text 
facilitates computational learning by converting text representations into simpler numerical 
formats. 
Preprocessing of text was performed by using a customized dictionary and original Java 
virtual machine (JVM)-based subroutine to do the following actions: 
 Stemming of words (removing common endings such as -ing, -er, and also de-pluralizing 
words) 
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 Stopword removal (removal of entire words, e.g. and, or, the, and special characters such 
as amp and quot that do not enhance the semantic meaning of a sentence) 
 Standardization  
o Replacement of all web links with url 
o Replacement of all AIH pharmaceutical therapy drug names with aihrx 
o Replacement of all references to AC with referencetoAC 
o Replacement of indicators of first, second, and third person with the standard 
terms fpindicator, spindicator, and thpindicator respectively 
o Replacement of all verbs of being (be, am, are, etc.) with verbofbeing 
o Replacement of all possessive verbs (have, got, having, etc.) with 
verbofpossession 
In this particular study, communication fragments were grouped by top level domain as 
the outcome variable because grouping by thesaurus coding would require in excess of 40,000 
communications to be annotated.  Weka (University of Hamilton, Waikato, New Zealand)116, an 
open-source machine learning platform, was utilized in order to perform analysis on the corpus of 
communications.  Each communication fragment was normalized to standardize common 
stopwords and its content truncated to leave words as stems.  Afterwards, TF-IDF conversion was 
automated by Weka’s Filtered Classifier String2WordVector function, which calculated the 
frequencies of both words and bigrams (two-word chains) relative to corpus frequency for each 
communication fragment.  Finally, the mathematically-transformed communications were 
analyzed via several methods that all employed Sequential Minimal Optimization (SMO), a 
transformer that allowed machine learning to be performed a per Figure 12’s workflow on data 
with many possible categories (e.g., the 16 top level domains of contextual factors at study).137   
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Figure 12. Workflow Schema for ML Contextual Factors Classification 
 
 Multiple methods (i.e., algorithms) were used in conjunction with SMO.  Each algorithm 
underwent 10-fold cross-validation to determine its reliability.  The methods employed by SMO 
in detection of contextual factors included: 
 Fisher Linear Discriminant Analysis (FLDA): An implementation of principal component 
analysis that is highly suitable for delineating multiple classes.138 
 Voted Perceptron (VP): An algorithm that specializes in maximizing the distance 
(difference) between classes.139 
 Classification via Regression (CVR): A traditional linear model algorithm that can be 
tuned to detect multiple classes of different proportions. 
 Bayesian Logistic Regression (BLR): Similar to CVR but operates solely on binary trees 
(and will decompose numbers into said trees) 
 Multilayer Perceptron (MLP): An advanced classification algorithm that has shown 
capability in detecting sparse entities due to its ability to recurse over previously read 
items.140 MLP is one of the more common types of neural network (NN) analysis and is 
somewhat related to VP. 
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7.3 Results 
 
Qualitative annotation analysis revealed 172 subdomains that were classified under 16 
top level domains.  Of these subdomains, 156 described actual communications while the 
remainder served solely as parent domains.  The discovered top-level domains are listed below in 
Table 19 along with their codes and definitions.  A full classified schedule of all 172 subdomain 
codes and their definitions is included in Appendix VIII. 
 
 
Table 19. List of Top-Level Domains with Definitions 
 
Domain Code 
Detailed Definition: The user is 
discussing… 
In 
Annotated 
Corpus 
Systematic 
review 
status 
Demographics DEMO 
Commonly elicited social characteristics of 
an individual 
18 (2.0%) NCF 
Physical 
Environment 
ENV 
The physical surroundings of a person, 
including geographical location and 
natural environment 
19 (2.1%) Y 
Family History FAMHX 
Medically-recognized symptoms and 
diagnoses of blood relatives 
15 (1.7%) NCF 
Finances FIN 
Pertaining to monetary instruments, 
acquirement thereof (e.g., employment) 
and sureties (e.g., insurance) 
20 (2.3%) Y 
Support Group 
Socializing 
GRSOC 
Greeting others within context of the group 
discussion itself 
18 (2.0%) NCF 
Healthcare 
System 
HCS 
Matters pertaining to the user’s interaction 
with healthcare, including clinic and 
clinicians/providers.  Excludes personal 
medical story (MEDXS) and insurance 
(FIN) discussions. 
41 (4.6%) N 
Information 
Sharing 
ISHR 
Sharing information for academic purposes 
with no support intended.  Indicates 
advanced knowledge of the subject matter, 
which is typically health. 
30 (3.4%) N 
Medical 
Stories/ 
Histories 
MEDXS 
Medically-recognized elements of health, 
including diagnoses, medication intake, lab 
test results, signs, and symptoms.   
Communications observed in this domain 
are primarily detected and classified by 
the algorithms in Chapter 6 of this work. 
248  
(27.9%) 
NCF 
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Domain Code 
Detailed Definition: The user is 
discussing… 
In 
Annotated 
Corpus 
Systematic 
review 
status 
Treatment 
Noncompliance 
NCOMP 
The act of not adhering to provider-
mandated treatments 
4 (0.5%) Y 
Quality of Life 
Factors 
QOLS 
Psychosocial factors ranging from 
emotions to coping to abilities to perform 
the daily activities to one’s personal 
satisfaction 
94 (10.6%) Y 
Research 
Participation 
RSPRT 
Participating as a subject in medical or 
social research related to the disorder 
4 (0.5%) N 
Social History 
& Environment 
SOC 
Factors pertaining to the individuals who 
physically surround the user.  Excludes 
marital status.  Excludes the provision and 
receiving of online support from other 
group members. 
28 (3.2%) N 
Self-treatment 
Stories 
STX 
Sharing stories about personal and self-
care treatments, including diet and 
exercise.  These treatments might or might 
not be at behest of a provider. 
44 (4.9%) Y 
Support SUP 
Communications made to request or 
provide assistance from or to another 
individual(s).  
 
This category is broken down into 
subcategories that are entertained and 
detected further in Chapter 8 of this work. 
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(31.2%) 
NCF 
Technology TECH 
The user’s relationship with electronic 
technology 
7 (0.8%) N 
Viewpoint VPT 
A personal opinion not necessarily 
grounded in fact. 
22 (2.5%) NCF 
Legend: 
Y = Contextual factor that was reflected in the literature review 
N = Contextual factor that was not reflected in the literature review 
NCF = For purposes of this research not considered a contextual factor; some contextual factors (e.g. 
demographics) easily ascertainable in the clinic are also given this category. 
 
 
 Within the annotations that form this thesaurus, it can be remarked on the prevalence of 
each top-level domain.  The most popular top-level topic domains of conversation were by far 
support (SUP) and medical stories/histories (MEDXS).  Together, these top-level domains 
comprised 526/889 (59.2%) of the annotated corpus.  Outside of those two top-level domains, 
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quality of life factors (QOLS) was the most popular, with 94 communication fragments (10.6% of 
the corpus).  The least popular top-level domains, reflecting the least popular topics of 
conversation in the sample, were Technology (TECH), Research Participation (RSPRT), and 
Treatment Noncompliance (NCOMP), each representing less than 1.0% of the corpus.  All other 
top-level domains were discussed at levels representing between 1.0-10.0% of the corpus. 
 
7.3.1 Literature Review Coverage Comparison 
The overall numbers and proportions of annotated communication fragments representing each 
literature review category can therefore be calculated and are expressed in Table 20. 
 
Table 20. Contextual Factors Compared to Literature Presence 
 
Literature review category # fragments % fragments 
Y (Contextual factor found in communications and in literature 
review) 
181 20.3% 
N (Contextual factor found in communications but not in 
literature review) 
10 12.4% 
NCF (Not considered a contextual factor) 599 67.3% 
 
 
7.3.2 Reliability & Performance of Detection Algorithms 
The reliability of each algorithm in classifying the identified categories of contextual factors was 
assessed by F1-score; results are noted in Table 21. 
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Table 21. Algorithm Performance Across Contextual Factor Types 
 
  Algorithm F1-Reliability Avg. F1 Best F1 Best Algo. 
TLD CF? FLDA VP CVR BLR MLP    
DEMO N 0.645 0.462 0.514 0.429 0.552 0.520 0.645 FLDA 
ENV Y 0.471 0.452 0.387 0.414 0.467 0.438 0.471 FLDA 
FAMHX N 0.348 0.400 0.222 0.381 0.400 0.350 0.400 VP/MLP 
FIN Y 0.438 0.500 0.529 0.345 0.160 0.394 0.529 CVR 
GRSOC N 0.414 0.414 0.286 0.320 0.231 0.333 0.414 FLDA/VP 
HCS Y 0.386 0.364 0.301 0.370 0.314 0.347 0.386 FLDA 
ISHR Y 0.000 0.048 0.195 0.000 0.000 0.049 0.195 CVR 
MEDXS N 0.663 0.638 0.665 0.657 0.652 0.655 0.665 CVR 
NCOMP Y 0.000 0.000 0.000 0.000 0.000 0.000 0.000 None 
QOLS Y 0.256 0.229 0.295 0.247 0.272 0.260 0.295 CVR 
RSPRT N 0.000 0.000 0.000 0.000 0.000 0.000 0.000 None 
SOC Y 0.489 0.508 0.423 0.356 0.545 0.464 0.545 MLP 
STX Y 0.301 0.282 0.386 0.290 0.305 0.313 0.386 CVR 
SUP N 0.671 0.640 0.645 0.647 0.656 0.652 0.671 FLDA 
TECH Y 0.444 0.444 0.444 0.444 0.444 0.444 0.444 All Tied 
VPT N 0.000 0.085 0.000 0.000 0.000 0.017 0.085 VP 
 
      
2/9 0/9 3/9 0/9 1/9 
# of Categories 
Best Algorithm (CF Only) 
0/9 2/9 1/9 0 1/9 
# of Categories 
F1 Above 0.500 (CF Only) 
 0.290 0.285 0.317 0.262 0.273 Wt. Avg (CF Only) 
Notes: 
 Some top-level domains are conventionally considered contextual factors but because they are 
typically ascertainable in the clinic are not considered such for purposes of this research. 
 
 
Overall, it is noted that optimization of detection of each top-level domain topic was 
heterogeneous, with different algorithms specializing in detection of different topics.  Across top-
level domains classified as contextual factors, FLDA and CVR achieved the highest number of 
domains classified as the best across all algorithms, while CVR maintained the best overall 
weighted average.  VP did not demonstrate top reliability in any specific category yet categorized 
the highest number (2) of contextual factor top-level domains at F1 >= 0.500.  More qualitatively, 
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despite MLP’s modest overall performance, it did by far classify social environment (SOC) the 
best (F1 = 0.545).  BLR was, overall, the least-well performing classification algorithm utilized. 
 
7.4 Discussion & Conclusions 
 
 The construction of the thesaurus in and of itself is significant in that it (as did Holden et 
al’s research67) provides a beginning step to the general classification of contextual issues; this 
research expands Holden et al’s findings to more contextual factors in a rarer disease that affects 
individuals of all ages.  Its top-level categories and many of its specific fine-grained codes can 
potentially be used to describe contextual factors across other chronic diseases. 
 Although the core purpose of the research at hand is to attempt delineating contextual 
factors faced by patients, it can also be commented as to the popularity of other topics of 
conversation.  As far as frequency of discussion top-level domains, it is unsurprising that support 
(SUP) was the most popular, given that the group at hand is in fact a support group.  The status of 
the second most popular top-level domain topic, MEDXS, may be a bit more unusual, as directly 
divulging personal medical histories is considered by most to be sensitive.  The higher presence 
of MEDXS, however, validates the fact that in an earlier chapter of this work, treatment stories 
and treatment side effects were two of the most popular ML-discovered categories when 
comparing user vs. user within this corpus.  Therefore, it is implied that AIH patients are more 
likely than what would be intuitively expected to disclose details of their medical histories over 
an online support group. 
 Similarly, the majority of topicality via top-level domain in the annotated set was not 
focused on contextual factors not ascertained in the clinic; only 291 (32.7%) fragments evidenced 
a topic top-level domain pertaining to such contextual factors.  Of these, 181 (20.3% of the 
corpus) fragments evidenced discussion of a topic identified in the literature review.   
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The most popular top-level domain contextual factor discussed was quality of life factors 
(QOLS); this observation is in harmony with the literature’s frequent identification of quality of 
life factors, in particular psychological quality of life, as important to AIH patients’ well-being.  
Self-treatment stories (STX), including those pertaining to diet, also formed a reasonable part of 
the corpus, aligning with the literature review results that nutrition may be a factor in the 
pathogenesis of AIH.  Furthermore, Finance (FIN), which for these purposes also includes 
insurance status, was also stated in the literature as a potential AIH-mitigating factor.  
Conversely, treatment noncompliance (NCOMP) was repeatedly suggested in the 
literature but found in only four (0.5%) of corpus communication fragments.  This finding may 
suggest (although cannot confirm) that due to AC’s presence in the group, a measure of white 
coat syndrome may occur, where patients do not disclose treatment noncompliance due to 
disappointing AC. 
On the other hand, gaps in literature coverage were also noted.  Technology (TECH), 
social history & environment (SOC), Healthcare System Relationship (HCS), and Information 
Sharing (ISHR, which may be considered evidence of enhance health literacy), all considered 
important contextual factors in Holden et al’s67 research, were discovered in the users’ 
communications but not in the literature review.  One reason for this discrepancy may be that the 
original search terms sought risk factors for AIH and that current research does not view and 
therefore does not seek these facets of patient life as potential risk modifiers in AIH. 
Perhaps more important than the literature review were the attempts at algorithm-based 
contextual factor classification.  Algorithm results were extremely heterogenous as to which 
algorithm performed the best in detecting which top-level domain topic of conversation.  The 
below drill-down (Table 22) re-emphasizes individual algorithm performance on each top-level 
domain. 
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Table 22. Best Algorithms for each Contextual Factor Category (Theme; Domain) 
 
Top-Level Domain Best Algorithm F1 of Best Algorithm 
ENV FLDA 0.471 
FIN CVR 0.529 
HCS FLDA 0.386 
ISHR CVR 0.195 
NCOMP None 0.000 
QOLS CVR 0.295 
SOC MLP 0.545 
STX CVR 0.386 
TECH All Tied 0.444 
 
 The overall impression is that algorithm performance tended to be poor-to-modest over 
detecting contextual factor-related discussion.  The best performing algorithm overall (CVR) by 
weighted score only performed at an F1 reliability of 0.317.  The only top-level domains 
detectable with reliability of at or above F1 = 0.500 were Finance (FIN), detectable by CVR at 
F1 = 0.529 and Social History & Environment (SOC), detectable by MLP at F1 = 0.545.  It is 
therefore recommended that any detection algorithms to be deployed in real-world patient health 
platform situations be employed in tandem, with specific algorithms used to seek specific top-
level domain topics of discussion. 
A sample of best-performing algorithm (i.e., CVR)-misclassified posts was selected and 
manually analyzed to determine the nature (and possible reason) for misclassification.  The 
following common misclassifications were noted, and the potential reasons speculated: 
 ISHR (Information Sharing) misclassified as SUP (Support): Many support posts 
evidenced competent use of medical terminology and thus confounded the algorithm into 
assuming that such communications were a part of SUP, the most common category. 
 ISHR misclassified as MEDXS (Medical Stories/Histories): Similar to the previous 
misclassification, with MEDXS being the second most commonly-annotated top level 
domain. 
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 NCOMP (Treatment Noncompliance) was universally misclassified as MEDXS due to 
semantic similarities discussing medical treatments and MEDXS being overall more 
popular. 
 Finance (FIN), although occasionally very well-classified, could be confounded with 
Healthcare System (HCS); this error is likely due to the fact that individuals may discuss 
insurance interaction with trouble finding healthcare services. 
 Technology (TECH) and HCS were occasionally misclassified with each other; this 
phenomenon is likely due to semantic similarity that owes to the technology (e.g., patient 
portal) being used in a healthcare system-associated setting. 
 
In summary, a majority of commonly-made classification errors were due to untoward 
semantic similarities between communications that a human annotator could easily distinguish as 
one top-level domain or the other.  The machine learning algorithms all focus on pure lexical 
semantic content and therefore will be vulnerable to making such errors, especially when one 
rarer topic is semantically similar to a more common one, causing regression towards the 
mean/median and thus misclassification as the more common topic. 
Finally, also remarkable is (not shown in the above drill-down table) the more impressive 
recognition of Support (SUP) and Medical Stories/Histories (MEDXS), two non-contextual factor 
domains detected by all algorithms at F1 >= 0.600.  The mathematical nature of these algorithms 
suggests that they tend to classify by regression towards mean or median characteristics, and 
when certain topics dominate conversation, machine algorithms would therefore regress towards 
matching communications of uncertain topicality to pre-existing dominant topics.  However, as 
per research documented in other chapters of this work, detection of support-related 
communications and detection of medical stories and histories (i.e., information directly relevant 
to the clinical record) were found to be better performed with dictionary-based literal search 
algorithms, with F1 exceeding 0.700 in both cases. 
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The limitations of the research at hand are significant and serve to form a framework on 
which follow-up research will greatly enhance.  The qualitative annotation and thesaurus 
generation must in the future be re-validated by at least one third-person annotator (preferably 
one with a clinical background).  Similarly, the literature review can be expanded to 
systematically analyzing non-risk factors that surround AIH patients, although the practical merit 
and productivity of such a review may be little.  Indeed, it is recommended that AIH researchers 
devote more attention to contextual factors that may not be archetypal disease risk factors; this 
way, a more complete knowledge provenance of AIH can be formed.  Furthermore, the generated 
thesaurus does not itself constitute an ontology, but the possibility exists for an ontology of not 
just AIH, but also other chronic rare diseases, can be constructed using the thesaurus as a base to 
define attributes of affected users. 
In thesaurus annotation and machine learning attempts, annotations were performed and 
communications machine-sorted by fragment and not entire communication.  Future research may 
benefit from (instead of using cross-validation) the utilization of separate testing and training sets.  
Such an arrangement would allow for the quality assurance analysis of real-world, real-time 
communication topic detection, as actual users do not split individual communications into 
fragments by topic. 
Many recommendations for future research rely upon algorithm improvement for 
automated detection as this was the least satisfactory portion of results obtained.  The detection 
reliability was low enough as to preclude any utilization of the algorithms for a corpus-wide 
classification of contextual factors.  Most importantly, proper detection and differentiation of 
even the top-level domains would benefit by going beyond pure semantic/lexical similarity and 
will likely require machine learning approaches that take into account other variables, such as 
context of post vs. comment, metadata of the user, and (for comments), metadata of the user 
being responded to.  More complex algorithms, such as serial ensembles, may also be of use.   
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In addition, classification by more fine-grained topics (e.g., the 210 topics that rest under 
the top-level domains) was not attempted here and will require approaches that range from 
dictionary support to the annotation of thousands of more communications by an expanded 
research team.  Alternately, similarly-annotated materials from other chronic disease support 
groups could be added to the existing corpus in an attempt to increase the fineness and reliability 
of automated classification. 
The research at hand has demonstrated a valid, thesaurus-based categorization system for 
classifying the communications (related to contextual factors and otherwise) of users of an AIH-
oriented online support group.  Contrasts between clinical research opinions and consumer (user) 
opinions of important contextual factors were successfully delineated by comparing literature 
review information with annotations of support group user communications. 
Machine learning methods were attempted to semantically characterize user-generated 
content via analysis of word vectors by support vector machine-optimized regression algorithms.  
While the machine learning attempts did not yield optimal results, they have instead suggested 
future options to improve classification of communications and therefore enhance detection of 
contextual factors expressed over online support groups for not just AIH, but also other rare 
and/or chronic conditions.   
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CHAPTER 8. CHARACTERIZING SUPPORT GIVEN AND RECEIVED OVER THE 
AIH GROUP 
 
8.1 Introduction 
 
Patients with rare diseases travel great distances to seek presence of a provider, both for 
treatment and advice. 4, 5  It is assumed that patients with AIH (and other rare diseases) will 
inherently face a shortage of support, both socially and informationally and will require forms of 
support outside the clinic. 
I performed a thematic analysis141 of the literature on support exchanged over health-
related social media venues and discovered that there were two dyadic directions (inbound and 
outbound) 104-107 as well as two types (emotional/social7, 92, 98, 101, 102  and advice/informational99, 7, 
90, 100).  While dyadic direction of support is a self-explanatory concept, I will specifically define 
social/emotional support (here abbreviated EMO) as support that does not have objective 
information or recommendations but instead are essentially kind words given to help someone’s 
emotional status, whereas advice/informational support (here abbreviated AIS) as the exchanging 
of ostensibly objective advice and information in hopes of support. 
I therefore propose to widen the spectrum of AIH patient knowledge gained by this 
dissertation by analyzing the feasibility of automated detection of types of support provided and 
requested on AC’s AIH-associated Facebook support group and then to characterize the 
communication structures that surround rare disease social support.  In the process, it is desired to 
estimate the adequacy and appropriateness of support exchanged over the group. 
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8.2 Methodology 
 
This analysis was performed on the parsed data set that was used throughout this dissertation.  
Initial classification was performed by a qualitative analysis of communications (posts and 
replies) on the target Facebook group.  From the literature review, the following baseline 
categories for annotation were derived: 
 Offering social/emotional support (OFF.EMO): The provision of support indicated solely 
for emotional fulfillment and not as practical advice.   
 Requesting social/emotional support (REQ.EMO): The requesting of support for 
emotional fulfillment and not requesting for advice 
 Offering advice/informational support (OFF.AIS): The provision of information and/or 
advice with clear intent to answering a fellow user’s question 
 Requesting advice/informational support (REQ.AIS): The requesting of advice or 
information; often phrased as an information-seeking question to the group. 
Note: The classification of REQ.EMO, requesting emotional/social support, was theoretically 
possible but never observed in the annotation set and is therefore not entertained in this analysis. 
 
Other annotation categories, which were derived in a top-down fashion from reading the 
communications, included: 
 Requesting advice/information from AC, the administering colleague (AIAC): Identical 
to REQ.AIS but directly invokes AC. 
 Personal Inquiry (PINQ): It was noticed that in the dyad of support, users would often ask 
each other personal questions (e.g. What dose were you on? or Are you feeling better?) in 
the act of offering support 
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 Gratefully acknowledging support (GRACK): In reception of support (regardless of 
type), stating that one is thankful for the support evidently provided.  It is assumed that 
any undirected gratitude expressed in the group is a signal of this category. 
 
Finally, all communications were assessed in a blind secondary run by the first author (AK), 
re-annotating each communication with the existing thesaurus according to the annotation 
categories and guidelines above.  The intra-rater annotation was considered agreed upon if the 
annotator agreed with his earlier opinion completely for each given communication.  The initial 
intra-rater reliability was 87.44%. Finally, self-adjudication was performed until an intra-rater 
agreement of 100% was reached. 
A qualitative dictionary was thereby created via annotation of 679 (/900 total) training set 
communications.  The dictionary contains terms that are by the annotator’s observation virtually 
unique to a specific type of support.  Some examples of dictionary terms are shown in Table 23. 
 
Table 23.  Explored Categories of Support 
Category Example Dictionary Terms 
AIAC (Requesting advice 
from AC) 
[Censored; various terms related to AC’s real name] 
GRACK (Gratefully 
acknowledging support) 
thank, TY, TYSM, thx, thnk, thnx, ty sm, ty vm, tyvm 
OFF.AIS (Offering advice) you should, you might, try this, I think you, you need, 
could work, might work, can help, might help, helped me 
OFF.EMO (Offering social or 
emotional support) 
hug, prayin, prayer, be ok, be alright, be all right, sorry, 
hearts, best wish, wish you, sending many, sending much, 
much love, good thoughts, aww 
PINQ (Personal inquiry) is your, do you, does your, what is your, who is your, are 
your 
REQ.AIS (Requesting advice, 
not from AC) 
please, does anybody, does anyone, would somebody, can 
you tell, can you give, can you help, I need help, tell me 
what 
 
Note: Some dictionary terms are partial words because the dictionary functioned by substring, 
and not whole word, matching.  A full list of dictionary terms is available in the Appendix. 
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The algorithm was designed in a fashion where the category with the least observed 
testing set frequency would be returned first.  For example, the dictionary terms in PINQ were 
observed frequently in REQ.AIS but the terms in REQ.AIS not frequently observed in PINQ.  
Therefore, REQ.AIS must be excluded well before PINQ will be returned.  In addition, the 
algorithm can only tag each communication with one kind of support, and the priority for tagging 
follows the priority order in the algorithm. The algorithm is depicted in Figure 13. 
 
 
 
 
Figure 13. Algorithm Flow for Support Type Detection.141 
 
The above algorithm, after validation, was finally performed upon the entire corpus of support 
group communications in order to characterize its extant types and directions of support. 
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Finally, in performing an analysis of the support type characterization that can be 
performed on this corpus, it is decided to correlate in an exploratory fashion network and user-
related characteristics with support types evident in communications.  This exploratory analysis 
will assist in validating the classification algorithm and potentially shed new light on support in 
this rare disease online support group.  Data were sorted in order to compare the support-related 
characteristics of the following: Type of communication (post vs. comment); whether or not the 
user was deleted from the group at the time of data collection (AC’s communications were 
excluded from this subcount); user role (clinician administrator AC vs. the remainder of the 
group); user tenure (duration since first communication in the group) at the time the posting was 
made (deleted users excluded). 
 
8.3 Results 
 
676 communications in total were annotated, of which 277 evidenced some form of 
support.  In the second round of annotation, there were 15 instances of support added to 
communications previously annotated as not involving support.  Furthermore, reasons for support 
were removed from further analysis (although kept on the record for archival purposes).  
Comparing the training set of 667 communications vs. the testing set of 223, the following 
reliability measures in Table 24 were observed and are reported as precision, recall, and F1-score.  
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Table 24. Algorithm Performance: Support Type Detection 
Support Type (By Communication) Precision Recall F1 
Score 
N (GS) 
Support vs. not support 
  
0.730 0.692 0.711 78 
AIAC  
(Asking administering colleague, AC, for 
advice) 
0.429 1.000 0.600 3 
GRACK  
(Expressing gratitude for support) 
 
0.533 0.571 0.552 14 
OFF.AIS 
(Offering advice) 
 
0.400 0.250 0.308 24 
OFF.EMO  
(Offering emotional/social support) 
 
0.700 0.700 0.700 20 
REQ.AIS 
(Requesting advice; not from AC) 
 
0.636 0.636 0.636 11 
 
The detection reliability (F1 = 0.711) of support-related communication vs. non-support-
related was higher than detection of individual support types.  Individually, the best-detected type 
of support was OFF.EMO, the offering of emotional (social) support (F1 = 0.700).  PINQ 
(personal inquiry in provision of support) and REQ.AIS (requesting of advice and informational 
support) were acceptably detected with F1-scores of 0.667 and 0.636, respectively.  Detection of 
grateful acknowledgement of support (GRACK) was more modest at F1 = 0.552; finally, the 
detection of OFF.AIS (the offering of advice/informational support) was the least satisfactory at 
F1 = 0.308. 
With the reliability of the algorithm assessed, it was then run over entire corpus of 
communications.  Therefore, the corpus-wide occurrence rate of each type of support (and the 
rate of non-support communications as well) can be, with greater or lesser degrees of error, 
estimated; these estimates are shown in Table 25.   Please note that the double asterisk (**) by 
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OFF.AIS indicates that relevant data are displayed despite the unreliability of the algorithm in 
detecting it. 
 
Table 25. Wider Corpus: Support Types Discovered 
Support Type Communications % of Corpus 
AIAC 633 3.32% 
GRACK 1,664 8.72% 
OFF.AIS** 1,283 6.72% 
OFF.EMO 1,186 6.21% 
PINQ 462 2.42% 
REQ.AIS 1,580 8.28% 
 
In order to better elucidate the social network structures and user properties that underlie support-
related communications, support type rates were also broken down via the following criterion 
sets: 
 Communication type (post vs. comment) 
 User social network metrics & structure characteristics: 
 Communications on Facebook™ groups are divided into two structural types: Top-level 
posts, and comments to these posts.  Support varied across communications dependent upon 
communication type, as shown in Table 26. 
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Table 26. Types of Support: Posts vs. Comments 
  Posts (vs. Comments) 
OR 
5% 
Odds 
Ratio 
OR 
95% 
Chi-
Square 
(df=1) 
P-value 
AIAC Req. Advice/Info. 
from AC 
5.454 6.445 7.616 613.2 <.001 
GRACK Gratefully 
Acknowledging 
1.565 1.800 2.017 69.4 <.001 
OFF.AIS** Offering Advice/Info. 0.644 0.789 0.968 5.2 .0225 
OFF.EMO Offering 
Emotional/Social 
0.126 0.186 0.276 88.6 <.001 
PINQ Personal Inquiry 0.365 0.540 0.799 9.8 .0017 
REQ.AIS Req. Advice/Info. 4.804 5.408 6.087 937.6 <.001 
 
Posts and comments often had striking differences in the types of support expressed in 
them.  Comments demonstrated a much higher rate of offering emotional support (OR for posts 
0.186, 95% CI 0.126-0.276, P<.001).  Finally, although the finding should be viewed with 
caution due to low detection reliability; it was noted that the offering of advice and informational 
support (OFF.AIS) was slightly more common in comments (OR for posts 0.789, 95% CI 0.644-
0.968, P=.0225). Unsurprisingly, these support types are located on the outbound end of the 
support dyad.  The algorithm therefore receives some validation via intuition. 
I then analyzed differences in support types by if the user was deleted (left the group, 
banned from the group, or left Facebook™ entirely, evidenced by a blank entry for user name in 
the XHTML) at the time of data collection.  Note that in this case, all deleted users are processed 
as one because such users cannot be differentiated.  These results are detailed in Table 27, below. 
 
 
 
 
 
 
 
 
 
 
 
103 
Table 27. Types of Support: Deleted vs. Non-Deleted Users 
 
  Deleted Users (vs. Non-Deleted) 
OR 
5% 
Odds 
Ratio 
OR 
95% 
Chi-Square 
(df=1) 
P-value 
AIAC Req. Advice/Info. 
from AC 
2.406 3.223 4.316 68.7 <.001 
GRACK Gratefully 
Acknowledging 
0.599 0.824 1.132 1.4 .2314 
OFF.AIS** Offering 
Advice/Info. 
1.339 1.751 2.289 17.2 <.001 
OFF.EMO Offering 
Emotional/Social 
0.069 0.155 0.348 27.1 <.001 
PINQ Personal Inquiry 0.000 0.000 0.000 14.7 <.001 
REQ.AIS Requesting 
Advice/Info. 
0.933 1.232 1.628 2.2 .1410 
 
 
 Users who were deleted from the network had comparatively high rates of asking AC for 
his advice (AIAC; OR 3.223, 95% CI 2.406-4.316, P<.001).  There is also evidence for the 
increased level offering of advice and informational support (OFF.AIS) in this cohort (OR 1.751, 
95% CI 1.339-2.289, P<.001), and in contrast, decreased evidence of offering emotional/social 
support (OFF.EMO; OR 0.155, 95% CI 0.069-0.348, P<.001). 
Certain observations could be made about user tenure as of the date of communication.  
There is a drop-off in REQ.AIS and GRACK combined with the concurrent rise in OFF.EMO 
through increasing tenure (visible in Figure 14).  For inbound support types, a U-curve formation 
is seen (Figure 15), except for AIAC, which shows a very mild increase over increasing tenure.  
Results are further detailed in Table 28. 
104 
 
Figure 14. Outbound Support Types vs. User Tenure 
 
 
Figure 15. Inbound Support Types vs. User Tenure 
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Table 28. Support Types by User Tenure (Tabular) 
 
Note: Percentage figures indicate percent of all communications in that user tenure time slot only 
and do not add up to 100% because non-support communications are excluded. 
 
 
User Tenure at Time of Communication % (N)  
First 
Day D2-90 
D91-
180 
D181-
270 
D271-
360 
D361-
450 
D451-
540 
D541-
630 
D631-
720 
D721 
+ 
Total 
By 
Type 
AIAC 
2.4% 
(12) 
3.6% 
(108) 
3.5% 
(83) 
3.6% 
(68) 
4.2% 
(48) 
4.1% 
(43) 
5.8% 
(40) 
3.3% 
(23) 
4.3% 
(22) 
4.1% 
(6) 
453 
GRACK 16.3% 
(82) 
10.6% 
(321) 
7.8% 
(186) 
7.3% 
(137) 
6.3% 
(72) 
7.7% 
(81) 
7.4% 
(51) 
9.2% 
(63) 
8.3% 
(42) 
7.4% 
(12) 
1,047 
OFF. 
AIS 
4.1% 
(21) 
6.8% 
(207) 
6.6% 
(156) 
7.6% 
(142) 
8.1% 
(92) 
9.2% 
(96) 
7.0% 
(49) 
10.8% 
(74) 
9.2% 
(47) 
12.3% 
(19) 
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OFF. 
EMO 
6.1% 
(31) 
5.8% 
(176) 
7.6% 
(181) 
7.3% 
(137) 
8.2% 
(93) 
7.6% 
(80) 
7.2% 
(50) 
7.8% 
(54) 
5.2% 
(27) 
10.0% 
(16) 
845 
PINQ 
1.7% 
(9) 
2.5% 
(76) 
3.3% 
(78) 
3.3% 
(62) 
2.7% 
(30) 
2.7% 
(28) 
1.0% 
(7) 
3.3% 
(23) 
2.6% 
(13) 
3.0% 
(5) 
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REQ. 
AIS 
11.5% 
(58) 
8.8% 
(267) 
9.1% 
(217) 
8.2% 
(154) 
8.9% 
(101) 
8.3% 
(87) 
10.3% 
(71) 
6.8% 
(47) 
6.9% 
(35) 
10.4% 
(16) 1,053 
 
 
The final important classification of users is the dichotomy between AC and the 
remainder of the users.  As expected, the offering of advice and informational support was 
significantly higher (OR 2.824, 95% CI 2.255-3.538, P<.001), although this finding must be 
viewed with caution due to that algorithm’s relatively poor performance). AC also appeared have 
less of a tendency to inquire users (PINQ) about their situations (OR 0.401, 95% CI 0.178-0.900, 
P=.0017).  In addition, being grateful for support (GRACK) was detected in significantly higher 
amounts (OR 1.477, 95% CI 1.150-1.896, P=.0021), in AC’s communications compared to the 
remainder of the user corpus.  These results are elaborated in Table 29. 
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Table 29. Support Types, AC’s Engagement.141 
  AC (vs. not AC) 
OR 
5% 
Odds 
Ratio 
OR 95% 𝑿𝟏,𝟏 P-value 
AIAC Req. Advice/Info. 
from AC 
0.192 0.388 0.782 7.539 .0060 
GRACK Gratefully 
Acknowledging 
1.150 1.477 1.896 9.440 .0021 
OFF.AIS** Offering Advice/Info. 2.255 2.824 3.538 88.817 <.001 
OFF.EMO Offering 
Emotional/Social 
0.569 0.820 1.184 1.125 .2888 
PINQ Personal Inquiry 0.178 0.401 0.900 5.251 .0219 
REQ.AIS Requesting 
Advice/Info. 
0.869 1.150 1.522 0.958 .3277 
 
 
8.4 Discussion & Conclusions 
 
Algorithm performance varied depending on the type of support being detected despite 
being satisfactory overall.    A qualitative post-hoc error analysis was performed, comparing 
annotated posts to the algorithm’s results, in order to note weak points in the algorithm. 
The poor detection of OFF.AIS may be explained by the fact that an annotator can find 
out when information is being shared in provision of support by the nature of the information 
while the machine sees no hints that support is being sought.   Likewise, the grateful 
acknowledgement (GRACK) of support searches for generic terms such as thanks and its 
synonyms, creating the observed probability of misclassifying a user who was thankful, but for 
something other than support.   
In the receiving end of the support dyad, the most commonly observed types of support 
were the requesting of advice/information (REQ.AIS) and being grateful for support 
(SUP.GRACK).  It is more significant that requesting advice and informational support is very 
common; such an observation strengthens the potential utility of detecting user requests for 
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advice on an active personal health platform with the goal of delivering the user customized 
patient health education materials.  Furthermore, the requesting of advice in this group 
corresponds with literature evidence that this type of support is a major component of online 
health-related support groups, with multiple sources92, 98, 100 discussing the importance both of 
giving and receiving this type of support.  
Also noted was the offering of emotional/social support (OFF.EMO), which is a type that 
is likely used in diseases (including AIH) that have no definitive cure.  Literature has observed 
this type of support being used commonly by patients of pulmonary fibrosis (PF)92 and the 
incurable status of breast cancer survivorship103.   Less common was PINQ (personal inquiry in 
the provision of support), indicating some weakness in the support dyads formed.  Deliberately 
asking the administering colleague (AC) for support (AIAC) was also less common than general 
requests for advice, bucking the trend of the clinician’s assumed dominance in the group.  
Posts and comments differed significantly in types of support discovered; comments were 
biased towards the outbound side of the support dyad.  In contrast, the other three types of 
support, coincidentally located on the inbound end of the support dyad, are noted at a higher rate 
in posts, creating further intuitive validation of the algorithm.  The algorithm therefore receives 
some validation via intuition. 
The more inherent characteristics (not related to social network structures) observed were 
user deletion from the network (due to leaving the group, leaving Facebook entirely, or being 
banned from the group due to conduct violation), tenure of the user as of the date of a 
communication, and the role of the user (administering colleague AC vs. all other users).  Unless 
otherwise stated, the conclusions made in this section are speculative and require further 
information as specified. 
Users who were deleted from the network more often asked AC for advice.  It is possible 
but not confirmed that they may have lost interest in the group after asking a single question and 
receiving AC’s advice.  If the conclusion of increased OFF.AIS discussion is validated by 
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algorithm improvement, the increased level of communication in that domain in this cohort may 
indicate the presence of fraudulent information (offered as advice) for which the user was banned; 
however, further investigation into the OFF.AIS posts is indicated in order to gauge user attempts 
at providing fraudulent and possibly harmful information as advice. 
The tenure of the user at time of communication (i.e., the number of days they have been 
in the group at the time they made the made the communication) is another facet of study due to 
the need to explore changes in support involvement across time.  This feature implies not just 
trends about communications, but also those inherent in users themselves.  The drop-off in 
REQ.AIS and GRACK combined with the concurrent rise in OFF.EMO through increasing tenure 
(visible in Figure 3) may be intuitively explained by the fact that users tend to shift away from 
requesting and receiving support and instead towards giving others support.  The potentially 
paradoxical tail end of the U-curve seen for the inbound support types (Figure 3) may be 
explained by long-time users facing more severe disease and having more support needs; this is a 
phenomenon that requires further investigation.  Another paradoxical increase in one type of 
inbound support (requesting from AC, AIAC) can only be speculated by the idea that users 
become more comfortable asking AC for advice the longer they stay in the group.  
AC was significantly more likely to offer advice (OFF.AIS), with relevant limitations for 
the algorithm.  More unusual is the fact that he appeared to have been more prone to offering 
gratitude (GRACK), although this finding may have been due to him thanking users for their 
participation and not for their advice or emotional support. Finally, judging by the lack of AC’s 
PINQ content, it appears that AC might be offering information without becoming too personal in 
investigating individual patient histories, suggesting that his conduct and advice are appropriate 
and legal in nature.   
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The discovered limitations of automated support type detection form a significant 
framework upon which future research can be based.  Detection of an important type of support, 
the offering of advice and information (OFF.AIS) was inferior to detection of other support types.  
It is possible that future research can investigate communication structures in order to increase 
detection of OFF.AIS: For example, health-related information shared in reply to a post that 
requested advice should also be (but is not) tagged as OFF.AIS. Similarly, detection of grateful 
acknowledgement of support (GRACK) could be enhanced by searching for previous outbound 
support within the post’s comments. 
Due to reasons of scope, the detection and categorization of support utilized also did not 
explicitly classify the reason support was being given or solicited.  For example, it is not known 
if emotional/social support was given due to another’s grief or if informational support was given 
to a question regarding medication side effects.  Further dictionary-based classification of 
communications (for REQ.AIS) and of neighboring communications (for offering subtypes) may 
elucidate reasons further. 
In addition, while detection of requesting advice and informational support (REQ.AIS) 
was sufficient, Facebook does not allow an automated intervention in response to detection of this 
type of support need.  It is therefore recommended that this algorithm in the future be 
implemented in an active patient health platform where users can post and comment with their 
communications (consentingly) monitored and then relevant advice in the form of patient 
education materials returned to them based on the remainder of their communication content. 
Finally, there are portions of the dictionary that are customized to the domain of AIH and 
even this group in particular.  Specifically, the synonym set for detecting invocation of the 
clinician (AIAC) functions based upon AC’s actual name, and future detection of clinician 
invocation should be customized to the clinician(s) in the respective group.  In addition, there is 
no dictionary for the detection of emotional support requests (REQ.EMO) because the support 
type was never observed in the training set.  
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The research at hand has demonstrated a pilot, proof-of-concept methodology for 
detecting certain types of support exchanged over an online support group for the rare disease 
autoimmune hepatitis (AIH).  The algorithm, which functions by a dictionary that is enforced by 
a binary tree, is able to detect with satisfactory reliability the requesting of advice, the invocation 
of the administering colleague, personal inquiry in the provision of support, and the offering of 
emotional (social) support.  Detection of grateful acknowledgement of support is modest, and the 
least detectable support type was the offering of advice and informational support.   
Through this methodology, the dynamics of support across cohorts of users and time has 
been successfully described, with both intuitive as well as surprising findings generated.  The 
generated algorithm finally has the potential to enhance a patient health platform that can be 
attentive of when a patient is seeking information (requesting advice/informational support) and 
return via further dictionary searching appropriate patient educational materials. 
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CHAPTER 9. CONCLUDING SYNTHESES & FINAL DISCUSSION 
 
9.1 Synthesis of Methods & Findings 
 
Across all aims and chapters comprising this dissertation, I have retrospectively identified 
the following themes pertinent to methodology: Qualitative Classification, Methodology, 
Computational Methodology, Reliability, and Reusability of Method.  The following synthesis 
brings together these themes across all research aims and chapters in order to form a suitable 
conclusion for the research work at hand. 
The first theme across which the aims will be compared is qualitative classification 
methodology, which for purposes of this discussion consist of the subjective criteria and objective 
level by which communications are classified.   
Classifications of information exchanged and support, despite their temporal distance in 
when research was performed, both utilized a thesaurus-based methodology in classifying the 
subjectivity of user communications.  The research in both aims was initiated from a top-down 
read of user communications, which was followed by internal validation.  The research in 
classifying types of information shared was more consistent with the initial research in thesaurus 
classification of patient contextual factors67; later on, I renamed Economic to Financial (FIN) and 
Health Behaviors to Self-Treatment Stories (STX).  More significantly, the original Psychological 
domain was largely re-classified into the psychological sub-domain of Quality of Life Factors 
(QOLS.PSY) due to results from the literature review in the latter aim.   
Somewhat similarly, issues of signs, symptoms, and comorbidities – including pain, 
injury, and laboratory test results were mapped not just to distinct SNOMED-encoded clinical 
entities, but to higher level coarser SNOMED entities that effectively clustered the finer 
SNOMED codes, in effect forming a hierarchy similar to that found in a thesaurus.  In contrast, 
xenobiotic/drug usage classification was done with extremely fine granularity (i.e., to compound 
112 
identity and not therapeutic class), chiefly in the interest of potential hepatic effects of these 
chemicals.  One chief exception is that classification of xenobiotic products as AIH-related 
therapeutics was also informally performed in order to qualitatively validate the study’s results. 
 In contrast to qualitative methodology, which in this dissertation is human-curated, 
computational methodology is automated.  Computational (defined here as automated computing-
based) methodology differed significantly across aims, with clusters of aims having similar 
methodology utilized.  Research methods used in overall group characterization and contextual 
factor analysis were similar in that they both used black box computational approaches, allowing 
off-the-shelf machine learning software products to analyze the data with relatively little 
researcher interference.  In the former, the lack of existing knowledge of patient communication 
content drove the choice of methodology; in the latter, it was the known sheer complexity of data 
(with 172 variables found qualitatively). 
 In contrast, detection of drug (xenobiotic) usage, signs/symptoms/comorbidities, and 
types of supports exchanged all utilized recognitions of named entities (named-entity recognition, 
aka dictionary-based search or simply NER) combined with rule sets.  A fixed and typically lower 
number of observed categories allowed for qualitative synthesis of customized dictionaries that 
could then be run across the wider corpus of communications.  The exception to this logic was the 
analysis of AIH patient xenobiotic (drug) intake, chiefly due to the fact that it was intended to 
detect the consumption of over 7,500 xenobiotic products (and in fact detected consumption of 
over 250).  Because of the US Food & Drug Administration (FDA)’s Orange Book131 of generic 
and brand names – and an added step to account for misspellings – an NER-based search was still 
feasible. 
 Computational methods, in turn, are judged by reliability.  Reliability, for purposes of 
this discussion, is defined as the harmonic mean (F1-score) of precision and recall for any 
detection algorithm.  Reliability varied significantly across aims and aspects sought in each aim.  
Literature thresholds for F1-based reliability vary greatly; for purposes of this discussion, 
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moderate reliability will be considered 0.500 <= F1 <= 0.670 and high reliability F1 > 0.670.  
Below is a reference table of F1 reliability values across aims and aim components.  A reliability 
summary is demonstrated in Table 30. 
 
Table 30. Algorithm Performance Summary: F1-Scores 
 
Aim Component F1-Score Notes 
B1 All drug intakes 0.731 Correct xenobiotic & usage by user 
B2 
Pain & Injury 0.667 Correct injury & location by user 
Signs, Symptoms, & 
Comorbidities 
0.729 
Correct sign/symptom/comorbidity class 
by user 
All Lab Test Results 0.639 Correct test & result by user 
B3* 
All Contextual Factors 0.317 
Correct factor by communication; best 
algorithm 
Finance (FIN) 0.529 By communication; best algorithm 
Social (SOC) 0.545 By communication; best algorithm 
C* 
All 0.730 
By communication; is support vs. not 
support 
Offering emotional support 
(OFF.EMO) 
0.700 By communication 
Personal Inquiry (PINQ) 0.667 By communication 
Requesting Advice 
(REQ.AIS) 
0.636 By communication 
Asking AC for support 
(AIAC) 
0.600 By communication 
Expressing gratitude for 
support (GRACK) 
0.552 By communication 
*Not all data are shown for B3 or C due to the high number of variable types discoverable 
 
 Some user facets evidenced high reliability.  Drug/xenobiotic usage, down to the correct 
compound (B1), was reliably detectable, as were an array of signs, symptoms, and comorbidities 
(B2).  The chief similarity between these facets (and analyses) is that they were calculated by user 
and not by communication.  The calculation, although appropriate for the purpose of the 
respective study, may implicitly deflate the reliability achieved in per-communication analyses.  
However, some communication-specific metrics evidenced high reliability; such metrics included 
the detection of communications that were vs. were not support-related, and also the offering of 
emotional support (OFF.EMO).  All of these facets were explored by named entity (NER; 
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dictionary-based) search, indicating better performance of this algorithm vs. black box machine 
learning approaches. 
 More modest reliability, in contrast, was found for pain and injury (B2), all lab test 
results (B2), finance (FIN) as a contextual factor (B3), social history as a contextual factor (B3), 
and several types of support (C).   Except for those in B2, these were all sought on the 
communication level, potentially deflating the reliability estimates.  Many of these facets were 
sought using a black box machine learning approach, and it is important to consider that such an 
approach, while often the only option, may not yield the results that an NER/dictionary-based one 
would. 
 Reliable algorithms are useful, but only if reusable (i.e., interoperable in separate but 
related use cases).  The reusability of methods varied by the exact algorithm and aim.  In this sub-
section, the reusability of sufficiently-performing (F1 >= 0.500 in all cases) algorithms is 
elaborated. 
 Some utilized algorithms are likely to be highly reusable because they operate on 
assumptions that are common to all social media communication content.  Latent Dirichlet 
Allocation (LDA) operated via the Machine Learning Language Toolkit (MALLET)119, being an 
off-the-shelf and black box solution, is by nature reusable (and not a product of this research).  
More significantly, however, the named entity-rules-based hybrid search for xenobiotic/drug 
usage, which is original to the research at hand, would be usable in other corpora of user-
generated online support group content.  As such, it may be useful for pharmacovigilance 
analyses in commonly-available social media information.  Finally, detection of certain forms of 
support (in particular the requesting of advice and information, REQ.AIS), was sufficiently 
reliable and the algorithm dictionary used for it could potentially be implemented in real-time 
patient health platforms to help determine when a user was actively seeking health advice. 
 The algorithm for detection of contextual factors, in its better performing top-level 
domains, would require some modification in order to be reusable across different disease 
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domains.  Normalization takes into account only AIH treatments and would have to be modified 
to normalize common treatments for the disease at hand.   
 Finally, the least reusable methodology is likely that which detects signs, symptoms, and 
comorbidities.  While a few signs and symptoms (e.g., mood issues) will be found in corpora 
across many disease domains, diagnosed comorbidities in the dictionary are almost exclusively 
autoimmune in nature.  The dictionaries for this algorithm would therefore require that extensive 
re-annotation of any new corpora be performed. 
 
9.2 Synthesis of Other Limitations & Future Research 
 
 The purpose of this sub-section is to synthesize, across the different aims, common 
limitations that were not covered in the synthesis of findings and extend these limitations to what 
future research will best help this research cause.  These limitations include those pertaining to 
semantic ambiguities, user underreporting, small sample sizes, and the lack of an 
associative/predictive model. 
The first general limitation to be discussed is semantic ambiguity, which for purposes of 
this discussion is defined as the literal lexical content of a communication deviating from its 
logical content.  Semantic ambiguity most often caused problems in black box machine learning 
approaches.  For example, The aza [azathioprine] keeps me in bed was annotated as 
QOLS.NEG.NRG (poor energy as a quality of life factor) but because of the presence of a drug 
name was matched by the machine learning algorithm to MEDXS (discussion of medicine intake 
and medical symptoms).  Such a deviation may also occur when a user is commenting on another 
user’s post, and either an annotator who understands disease context – or the other user’s posting 
text – is required to determine the actual logical meaning of a communication.   
Other portions of this research discovered semantic ambiguities, albeit at a much lower 
rate.  Rare cases of drug US brand names were within 75% spelling similarity to commonly used 
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words.  Further discussion on this type of error is available in Chapter 5’s Discussion section, to 
which the reader is encouraged to refer. 
Future research to mitigate semantic ambiguity as it results from black box algorithms 
will require enhancing the data given to the machine.  A clear potential exists to enhance 
comment communication TF-IDF data with the TF-IDF data from respective parent posts.  In 
addition, the identity of the user who was replied to may also assist machine learning-based 
classification of comments.  Previous mistakes can also be coded and given to the algorithm.  In 
the previous example, another field can supplement the communication’s TF-IDF matrix; this 
field can state whether the machine earlier classified it correctly, and if incorrectly, state the 
incorrect class.   
 Even if lexical content mapped directly to the semantic, there still will exist user 
underreporting, which for purposes of this discussion is defined as the online support group users 
not reporting every problem experienced, every question thought of, every answer considered, 
and every medication taken.  
 Measures of underreport could be quantitatively defined with regards to the detection 
studies for drug (xenobiotic) intake and signs/symptoms/comorbidities (SSCs).  For drug intake, 
it was noted that 337/1052 (32.0% of) users declared intake of azathioprine.  In reality, a majority 
of AIH patients (50.0% or greater) are treated with this drug41, 121, 142, implying an underreport rate 
of at least 36% for azathioprine intake.  Underreport of intake of non-AIH-associated medication 
is also a likely scenario, with (for example) the very common pain reliever Ibuprofen (ADVIL, 
MOTRIN, etc.) only reported by 2.0% of group users as taken. 
In the studies to detect SSCs, the underreport of symptoms and comorbidities, including 
cirrhosis, was hypothesized. Conservative estimates have put the prevalence of cirrhosis at AIH 
presentation of 25%31 with rates in established AIH much higher.  In contrast, it was found that 
only 10.6% of online support group members declared having cirrhosis.  The gap observed for 
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comorbidities less associated with AIH was even more striking: For example, 222/1052 (21.1% 
of) users reported having had an infectious disease; the actual rate is most likely closer to 100.0%. 
 In these cases, future research, if restricted to social media, may not enhance detected 
report rates because the algorithms in question already possess sufficient recall; solutions may 
exist to mitigate these issues.  Assuming that less active users (with lower communication degree) 
are the chief under-reporters, the data set can be trimmed to either users making over a threshold 
number of communications or users reporting a minimum threshold number of clinically-related 
factors (signs, symptoms, comorbidities, and drug intakes).  Preliminary post-hoc analysis of the 
data, conducted after the under-reporting was recognized, demonstrated that users who reported at 
least ten clinically-related factors (N = 151) showed a 51% rate of claimed azathioprine intake 
and a 39% rate of cirrhosis diagnosis claims.   
Furthermore, for signs, symptoms, and comorbidities, it is possible but unproven that 
xenobiotic/drug usage can be used in absentia of their primary disorder of treatment as surrogate 
markers of pathology (e.g., antidepressant intake used as a surrogate for mood issues; ibuprofen 
intake used as a surrogate for physical pain).  However, the best practice for optimal data 
coverage for these clinical factors will likely be traditional researcher-patient (or provider-patient) 
interview sessions and surveys, as evidenced in previous research.88 
 The underreport phenomenon begets an issue of small sample size.  Although the sample 
sizes discovered and utilized were generally superior to those obtainable in real life studies of rare 
disease patients, they still restricted many of the studies at hand to pilot status. 
 In particular, the sections on drugs/xenobiotics and SSCs were limited to reliability 
validation performed on the user level, with only 35 gold standard testing set users.  The F1-
reliability scores generated, while often high, are nonetheless subject to standard error.  However, 
it is also noted that these reliability scores were generated across multiple classes (i.e., multiple 
drugs and multiple signs, symptoms, and comorbidities), technically increasing the sample size 
between 2- and 10-fold depending on the evaluand being studied. 
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 When the studied communications were studied by communication and not by user (and 
further broken down into fragments), the sample size was also greatly increased as per the 
research portions regarding contextual factors and exchanged support.  890 communication 
fragments were analyzed for contextual factor and communication topic content; in detecting 
support content, the testing set was in excess of 200 communications.  Nonetheless, in the case of 
rarer top-level contextual factor domains as well as rarer support types, not only did the sample 
size become small, but the responsible algorithms also tended to perform poorly. 
 Future research therefore should focus on the annotation of larger portions of the corpus 
as well as annotation of other, similar chronic disease support group corpora in order to gain 
sample sizes sufficient enough to narrow the margin of error of F1-reliability scoring and 
potentially improve the performance of machine learning-based algorithms. 
Despite the valuable self-reported information gained (often with reasonable sample size 
and a high degree of reliability) from the work at hand, association of such factors is not 
entertained in this dissertation.  In fact, this limitation was deliberately imposed because it was 
not known whether all such factors could even be reliably detected over social media support 
group postings.  The only associative analysis performed was on the characterization of support 
exchanged; correlations were performed between support types and various user facets. 
Future research to remedy utilizing the data that was successfully derived through this 
dissertation’s research could potentially be used to construct associative and predictive models for 
disease.  Clinical factors such as xenobiotic/drug intake and signs/symptoms/comorbidities 
(including pain and lab test results) can all be cross-associated to determine hundreds of pairwise 
and multiple-logistic association strengths from the data.43  Contextual factors, on the other hand, 
would likely require better detection algorithms in order to be featured in associative analysis. 
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9.3 Final Conclusion 
 
The research at hand has demonstrated satisfactory-to-high reliability in detecting general 
types of health information shared; xenobiotic/drug intake; experienced pain, signs, symptoms, 
diagnosed comorbidities, and lab test results; types of support exchanged; and select patient 
contextual factors, all over an online autoimmune hepatitis (AIH) support group.   
It is expected that this research has generated significant impact by proving pilot 
feasibility of extracting clinical and non-clinical patient factors from social media.  In addition, 
the research has successfully surveyed an AIH patient/caregiver “digital cohort”85 (p. 618) of 
previously unattainable size (1,052 users, of which 687 mentioned at least one clinical factor).  
The research has also impacted knowledge of non-clinical factors experienced by support group 
users; in particular, exchange of support was well-characterized and pilot methodology for 
detection of an array of patient contextual factors was established. 
Most importantly, the research at hand was necessary to facilitate future research in rare 
and chronic diseases.  Many of the developed algorithms are expected to be cross-domain in 
nature, executable on any support-oriented social media communication corpus.  The data derived 
from the more clinical research portions (e.g. xenobiotic/drug intake; symptoms) can be used in 
associative models to shed more light on potential drug-disease correlates, putative drug adverse 
events, and symptom-symptom correlations.  Finally, the attempted detection of contextual 
factors creates a framework on which its own performance can be improved and used in wider 
disease corpora. 
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APPENDIX I. TOPIC MODELLING-GENERATED TOPICS, WITH WORD BASKETS 
AND AC’S CLASSIFICATIONS 
 
Used with permission from research of the author’s original work: Kulanthaivel A, Lammert CS, 
Jones JF.  (2018).  A novel approach using social media to investigate patient-centric data in 
autoimmune hepatitis.  (Poster). Washington, DC, USA: Digestive Diseases Week 2018.116 
 
Mallet 
ID 
Strength Topic Keywords 
Clinician 
(AC) Group 
Classification 
0 0.28% 
euro acirc checked brvbar rosacea eye supplements set link gel 
hole pressure draw intolerant herbs metals janet hair broken 
bleeding  
Alternative 
treatments 
1 0.66% 
pred post teeth yeah lol yep kids dentist fine bad weeks stuff 
migraines allowed pre refused oral gums house chest  
Treatment 
side effects 
2 0.24% 
chirrohis predisone mine lol teeth stage hepatologist yrs drs 
imuran alot agree heard fine alittle vertigo lenox fatty awesome 
idk  
Treatment 
side effects 
3 0.74% 
pregnancy pregnant baby risk flare pregnancies diseases doctor 
healthy gum postpartum qualify related born boys income fluid 
adhd birth ginger  
Pregnancy 
4 0.70% 
quot inflammation fibrosis low post point levels therapy igg 
increased impact evidence speaking increase small specifically 
immunosuppression activity speak talk  
Treatment 
5 4.54% 
doctor doctors liver taking blood diagnosed prednisone 
medication medications skin check good make numbers 
insurance diseases dont caused prescribed lab  
Treatment 
6 2.16% 
aih liver disease patients study risk treatment patient follow pbc 
diseases medication things history based drug members clinical 
community medications  
Treatment 
7 4.20% 
liver biopsy normal test high results negative inflammation 
damage blood elevated positive enzymes tests tested diagnosis 
interesting showed upper treatment  
Treatment 
goals 
8 4.50% 
great group information support autoimmune important 
questions hepatitis sharing make share rare research care long 
interesting treatment glad agree news  
Support 
groups 
121 
Mallet 
ID 
Strength Topic Keywords 
Clinician 
(AC) Group 
Classification 
9 0.89% 
emoticon smile frown feel calcium thistle coffee magnesium 
wink vit pains hormone thankful vomit hormones supplements 
shakes request mood milk  
Alternative 
treatments 
10 0.85% 
transplant spleen disease platelets low enlarged count blood 
wasnt aza diabetes case sugar itp removed metformin due fluid 
weight pred  
Comorbid 
conditions 
11 0.71% 
cellcept prednisone switched fibromyhellgia works imuran 
stomach raise mgs easier rituximab sucks teaching hours adjust 
cyclosporin shots diarrhea fantastic copd  
Treatment 
12 1.24% 
immune system people trigger med heard illness specific stress 
steroid track steroids heres term amount general bone 
developed doses link  
Pathogenesis 
13 0.76% 
yuml eth tilde rsquo trade acirc oelig euro bull lsquo permil 
iuml amazing cedil news rsaquo bdquo curren raquo cent  
Entirely stop 
characters; 
discarded 
14 3.47% 
aih lammert craig hope hepatologist side diagnosis time flare 
effects lfts research feeling experience opinion dont antibiotics 
conference question agree  
Research 
15 7.30% 
years aih ago side time months aza effects drug life times dose 
put live week hair thoughts age past drugs  
Treatment 
side effects 
16 0.10% 
yrs count pancreatitis stage white azathioprine 
hashimotoshypothyroidism weekly nite ulcers landed shots drs 
neupogin reply youssef trace switzerland burning daughter  
Treatment 
side effects 
17 4.29% 
prednisone imuran doc started taking month labs numbers flare 
start test levels lfts docs fatigue results week weaned hoping 
stopped  
Treatment 
18 0.82% 
son type immune auto year diabetes diseases psc sons dylan 
headaches chronic hes gastritis tacrolimus doesnt overlap 
prednisolone melatonin couple  
Comorbid 
conditions 
19 5.86% 
diagnosed aih week weeks ive azathioprine months hospital bit 
daily levels question great wondering due yesterday curious 
appointment type doctors  
New 
diagnosis 
20 0.32% 
mayo provider lobe medical necrosis left local studies scan lab 
live patient finland mass clinic story phos cardiac leg dismiss  
Comorbid 
conditions 
21 0.30% 
products daily results immunoglobulin copies level tests 
globulin hepatologist herbal nurse mgm quit benadryl regular 
hurt yrs medical lotion sarna  
Treatment 
22 11.20% 
dont good pain people find feel disease read family found hard 
lot love understand told makes havent luck fatigue helps  
Caregivers 
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Mallet 
ID 
Strength Topic Keywords 
Clinician 
(AC) Group 
Classification 
23 1.32% 
weight brain lost lose fog gained lbs pounds easy illness fun 
taste caused matter sucks hungry loose carb fat sense  
Disease 
associated 
phenomenon 
24 13.51% 
liver back meds year time work day days bad mine feel didnt 
blood started issues ago weeks things long night  
Treatment 
side effects 
25 1.47% 
god hope prayers praying pray happy blessed listen itching 
bless wonderful thankful skin awesome healing merry amen life 
finally worry  
Religion 
26 0.49% 
amp medical fibroscan dna awareness stress yrs drs area 
treatments community denial leg advil reducing protein educate 
rub monday reaction  
Research 
27 0.33% 
levels mouth thyroid dry possibly bump inr egd generally 
sodium pretty related hang yeah mmp occur ranges learned 
people facility  
Comorbid 
conditions 
28 1.64% 
alt normal ast range flare budesonide numbers labs remission 
immune lab slightly lower doesnt routine completely flares 
gastro period short  
Treatment 
goals 
29 0.33% 
budesonide lammert steroids myfortic probiotics medicine 
mouth issue dry cleveland lucky equine puppy depression 
insurance acupuncture moms nodes ursodiol missing  
Alternative 
treatments 
30 0.36% 
lupus plaquenil rheumatologist symptoms sjogrens arthritis 
rheumy psoriatic inflammatory add joint mos suppressant 
azathioprine debbie syndrome hands insulin ais symptom  
Comorbid 
conditions 
31 0.70% 
daughter daughters shes school prograf pred diagnosed takes 
tacrolimus drs advagraf vitamin college day worried child 
childrens reduce mum ruptured  
Treatment - 
pediatric 
32 0.64% 
insurance drugs enzymes pharmacy health store 
gastroenterologist price pay problems change yoga subject 
paying cost grocery deductible complete estrogen california  
Medication 
payment 
33 0.38% 
conference aiha weekend meeting indianapolis laurie indiana 
hellip hope hotel email june auction ebv attending indy relapse 
wonderful aware considered  
Support 
groups 
34 0.21% 
lfts study trial dxd posted part florida love update feeling 
women joy acirc anxious ill updates asked injection ladies spif  
Research 
trials 
35 1.30% 
water drink tea helps green yrs drugs dont iron bladder eat cool 
gall ice cancer switched wont coconut sensitive salt  
Alternative 
treatments 
36 0.13% 
cyclosporine dosage empathy ddd meditation addition turmeric 
sympathy myth cravings spine condition alcohol spec eye 
handle fry compassion physiologically toledo  
Alternative 
treatments 
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Mallet 
ID 
Strength Topic Keywords 
Clinician 
(AC) Group 
Classification 
37 1.19% 
ive youre ill wow lucky youve hey nurse theyre increased 
wondering relief lot rhuematoid yep beginning imagine hes 
shouldnt breathing  
Comorbid 
conditions 
38 2.89% 
hep aza pred months dose remission numbers taking day higher 
tests gain treatment doesnt concerned added weight small raised 
aware  
Treatment 
goals 
39 0.65% 
hashimotos hip knee replacement legs lucky surgeon shoulder 
synthroid spine honest shots replaced permanent convinced 
occasional tongue artist videos knees  
Comorbid 
conditions 
40 0.75% 
pbc ursodiol urso overlap aihpbc stage bile primary hepatologist 
clinic mayo hepa itching biliary ama skin intense ducts referred 
bloodwork  
Comorbid 
conditions 
41 0.40% 
tacrolimus generic medicare insurance medical approved 
prograf denied med pay fda seattle insulin drug send city pocket 
virginia vaccine supply  
Treatment 
42 1.36% 
diet eat free gluten food sugar foods oil eating vitamin paleo 
avoid medicine supplements dairy clean processed aip 
alternative organic  
Alternative 
treatments 
43 1.11% 
cirrhosis liver stage transplant portal severe varices ultrasound 
procedure meld hypertension hepatic failure bleeding 
considered lactulose encephalopathy standard ammonia 
diabetes  
Disease side 
effects 
44 0.10% 
patients question good data aiha number tests approach 
important commonly time related conference media approaches 
association typically findings ldquo  
Research 
45 2.41% 
pain joint diagnosed fatigue muscle disability fibromyalgia 
extreme nausea feels due joints arthritis vomiting october 
experience gallbladder failure level healing  
Comorbid 
conditions 
46 1.43% 
quot early switched removed heard doc appointment youre 
stronger touch wear cup alternative agree connective spot lucky 
cataracts put tub  
Treatment 
side effects 
47 0.58% 
bloods prednisolone consultant coeliac bit scan craig scans 
understand steroids biopsies sbquo alt tablets london reduced 
perspectum sjorgrens heal mri  
Research 
48 2.94% 
autoimmune disease diagnosis symptoms hepatitis common 
months treated hepatologist helpful diagnosed azathioprine plan 
issues conditions chronic easy daily genetic list  
Treatment 
49 5.30% told sick husband couple didnt hospital thing flu ill shot asked lol pretty times good gave drink eat home give  Caregivers 
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APPENDIX II.  LIST OF ALL DICTIONARY TERMS CONFIRMING DRUG INTAKE. 
 
Note: Underscores indicate spaces in real life communications. 
 
Negations 
"never_took", "never_had", "nt_take", "cannot_take", "never_tried", 
"nt_have", "not_given", "not_prescribe", "not_been", "not_prescribing", 
"refuse", "never_taken", "you", "your", "you_re", "youre", 
"not_prescribe" 
 
Caregiver Indicators 
"he_","daughter", "son", "father", "hubby", "wife", "hes", 
"my_daughter", "my_son", "my_hubby", "my_wife", "my_child", "year_old", 
"toddler", "boy", "girl", "baby" 
 
Caregiver Present Intake 
“takes", "is_taking", "takes", "is_on", "trying", "on", "being_given", 
"was_prescribed", "was_given", "hates", "can_take", "chooses", 
"uses","upped_his", "upped_her", "hates" 
 
Caregiver Passive 
"gave_him", "gave_her", "gave_my", "prescribed_him", "prescribed_her", 
"gave_her", "prescribing_him", "prescribing_her", "prescribing_my", 
"giving_my","giving_her", "giving_him", "gives_him", "gives_her", 
"gives_my", "started_him", "started_her", "raised_his", "raised_her", 
"had_her", "had_him", "prescribe_her", "prescribe_him" 
 
 
Patient Present Intake; Patient Suffixes 
"_on", "anyone_else", "any_one_else", "trying", "im", "i_m", "i_am", 
"im_on", "using", "taking", "take", "started", "been_on", "was_given", 
"has_me", "makes_me", "makes_my", "me_on", "up_my", "could_take", 
"missed","titrate", "taper", "lower", "raise", "raised", "lowered", 
"tapered", "titrating", "lowering", "tapering", "raising", "causes_me", 
"causes_my", "causing_me", "causing_my", "just", "hate", "hating", 
"prescribing", "gives_me", "prescribe", "dont_like", "do_not_like", 
"don_t_like", "added",“weaning", "choose", "have", "_can", "starting", 
"going_on", "use", "using", "now", "not_to_mention", "being", 
"starting", "stopping", "will_start", "will_stop", "prescribed", 
"prescribing", "prescribes", "can_only", "can_do", "have_me_on", 
"still_on", "allergic_to" 
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Patient Past Intake 
"took", "was_on", "stopped", "tried", "off", "was_on_", "d_been_on", 
"hated", "gave_me", "had_me", "nt_tolerate", "not_tolerate", "gave_me", 
"no_more", "never_again", "ve_taken", "made_me", "made_my", 
"caused_me", "caused_my",  "did_not_like", "didnt_like", "did_nt_like", 
"d_taken", "was_taking", "had_been", "chose", "tried", "used", 
"was_put", "took", "no_more", "used" "had_me_on", "discontinued", 
"allergic_to" 
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APPENDIX III. LIST OF XENOBIOTICS/DRUGS CONSUMED WITH FREQUENCIES 
 
Note: Only xenobiotics/drugs with a detected rate of N >=5 are shown.
 
  Xenobiotic N 
# 6-Mercaptopurine 48 
A 
Acetaminophen 43 
Allopurinol 6 
Alpha lipoic acid 7 
Alprazolam 5 
Amitriptyline 6 
Amoxicillin 20 
Aspirin 10 
Azathioprine 338 
Azithromycin 6 
B 
Beta blocker NOS 6 
Budesonide 88 
Bupropion 11 
 
  Xenobiotic N 
C 
Calcium 31 
Chloroquine 5 
Clavulanic Acid 14 
Clindamycin 12 
Cortisone 8 
Cyclosporine 16 
D 
Diclofenac 5 
Diphenhydramine 15 
Diuretic NOS 27 
Doxycycline 8 
Duloxetine 7 
 
  Xenobiotic N 
F Fluoxetine 7 
G Gabapentin 14 
 
  Xenobiotic N 
H Hydroxychloroquine 17 
I Ibuprofen 20 
L 
Lactulose 16 
Levonorgestrel 6 
 
  Xenobiotic N 
M 
Magnesium 23 
Melatonin 11 
Metformin 9 
Minocycline 7 
Morphine 8 
Multivitamin 8 
Mycophenolate 99 
N 
Naproxen 9 
Neomycin 6 
Nitrofurantoin 5 
O Oxycodone 8 
 
  Xenobiotic N 
P Prednisone Prednisolone 284 
R Rifaximin 6 
S Sertraline 5 
 
  Xenobiotic N 
T Tacrolimus 36 
Tramadol 11 
 
  Xenobiotic N 
U Ursodiol 58 
V 
Vancomycin 5 
Vitamin C 8 
Vitamin D 42 
Z Zolpidem 6 
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APPENDIX IV.  LIST OF ALL SNOMED CODES WITH PARENT TERMS  
 
Issue SNOMED Parent Issue Parent SNOMED 
Parent Issue 
Comment 
Abdominal Pain 21522001 
Abdominal Pain 21522001   LUQ Pain 301715003 
RUQ Pain 301717006 
Abnormal Hair 
Growth 85305001 
Abnormal Hair 
Growth 85305001   Alopecia 56317004 
Alopecia 
Universalis 86166000 
Abnormal LFT 707724006 
Abnormal LFT 707724006 
In the setting of 
AIH, an abnormal 
LFT is always 
assumed to be 
high. 
AIH Flare 408335007.FLARE 
Bilirubin Elevated 14783006 
Elevated Alkaline 
Phosphatase 274770006 
Elevated ALT 707724006.ALT 
Elevated AST 160931000119108 
Elevated Bilirubin 14783006 
Elevated CPK 432352001 
Elevated GGT 707724006.GGT 
Elevated LFT 707724006 
Unstable ALT 75183008 
Abnormal 
Menstruation 386804004 
Abnormal 
Menstruation 386804004   
Amenorrhea 14302001 
Menopause 161712005 
Premature 
Menopause 373717006 
Abnormal Stool 271840007 
Abnormal Stool 271840007   Acholic Stool 70936004 
Diarrhea 62315008 
Acne 11381005 
Acne 11381005   
Steroid Acne 201222006 
Advanced Stage 
AIH 408335007.ADV 
Advanced Stage 
AIH 
408335007.
ADV   Stage 3 AIH 
408335007. 
STAGE3 
Stage 4 AIH 408335007. STAGE4 
Excipient Allergy 
NOS 438784000 Allergy Disposition 609328004   
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Issue SNOMED Parent Issue Parent SNOMED 
Parent Issue 
Comment 
Allergy Disposition 609328004 
Penicillin Allergy 91936005 
Urticaria 126485001 
Anemia 271737000 Anemia 271737000   
Anorexia 79890006 Anorexia 79890006 
Refers to low 
appetite of any 
cause 
Arthralgia 57676002 
Arthralgia 57676002   
Back Pain 161891005 
Elbow Pain 74323005 
Finger Pain 18876004 
Hip Pain 49218002 
Knee Pain 30989003 
Leg Pain 15634511000119108 
Limb Pain 90834002 
Noise from Sternum 250119000 
Toe Pain 285365001 
Asplenia 51242008 Asplenia 51242008 
Post-splenectomy 
patients 
automatically 
assumed to have 
this condition 
Asthma 195967001 Asthma 195967001   
Ataxia 20262006 
Ataxia 20262006   
Motor Ataxia 59546009 
Autoantibody Titer 
Negative 165878000 
Autoantibody Titer 
Negative 165878000   
Autoantibody Titer 
Positive 165879008 
Positive ANA 
Antibody Titer 444551008 
Positive ANA titer 165850001 
Positive LKM 
Antibody 720330001.POS 
Positive LKM titer 720330001.POS 
Positive PANCA 
Titer 401078001.POS 
Benign Tumor 3898006 
Benign Tumor 3898006   
Breast Papilloma 99571000119102 
Bone Fracture 125605004 
Bone Fracture 125605004 Broken tooth is included because it Fracture of body of 
vertebra 445734009 
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Issue SNOMED Parent Issue Parent SNOMED 
Parent Issue 
Comment 
Rib Fracture 45910007 is a fracture of 
bone tissue 
Broken Tooth 36202009 
Bone Pain 12584003 Bone Pain 12584003   
Bruising 125667009 
Bruising 125667009   
Bruising Diathesis 424131007 
Cancer 363346000 
Cancer 363346000   
Cervical Cancer 363354003 
Cataracts 193570009 Cataracts 193570009   
Advanced Cirrhosis 123717006 
Cirrhosis 19943007   
Cirrhosis 19943007 
Aphasia 87486003 Cognitive 
Impairment NOS 386806002 
Includes mild or 
perceived cognitive 
impairment 
Cognitive 
Impairment NOS 386806002 
Ankylosing 
Spondylitis 9631008 
Comorbid 
Autoimmune 
Disease 
85828009 Excludes Diabetes Mellitus Type 1 
Autoimmune 
gastritis 84568007 
Autoimmune 
Urticaria 402397006 
Celiac 396331005 
Comorbid 
Autoimmune 
Disease 
85828009 
Hashimoto 
Thyroiditis 21983002 
Lupus 200936003 
Psoriatic Arthritis 156370009 
Rheumatoid 
Arthritis 69896004 
Sjorgen Syndrome 83901003 
Idiopathic 
Thrombocytic 
Purpura 
32273002 
Cough 49727002 Cough 49727002   
Dark Urine 720001001 Dark Urine 720001001   
Degenerative Disc 
Disease 77547008 Degenerative Disc 
Disease 77547008   Herniated Disc 2304001 
Dental Caries 80967001 
Dental Disorder 234947003 
Excludes broken 
tooth, which is 
considered a bone 
fracture Dental Disorder 234947003 
Diabetes Mellitus 
NOS 73211009 
Diabetes Mellitus 
NOS 73211009 
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Issue SNOMED Parent Issue Parent SNOMED 
Parent Issue 
Comment 
Diabetes Mellitus 
Type I 46635009 
Disorder of 
Pancreas 3855007 Disorder of 
Pancreas 3855007   Pancreatic Cyst 31258000 
Pleural Effusion 60046008 Disorder of Pleura 3855007   
Droopy Eyelid 11934000 Droopy Eyelid 11934000   
Dysglycemia 166922008 
Dysglycemia 166922008 Excludes declared Diabetes Mellitus Hypoglycemia 302866003 
Edema 267038008 Edema 267038008   
Ehlers Danlos 
Syndrome 398114001 
Ehlers Danlos 
Syndrome 398114001 All subtypes 
Adrenal 
Insufficiency 386584007 Endocrinopathy 362969004 
Excludes 
Hashimoto 
(autoimmune) 
thyroiditis Endocrinopathy 362969004 
Eruption of Skin 271807003 
Eruption of Skin 271807003 Excludes acne 
Pityriasis Rosea 77252004 
Failure to Thrive 54840006 Failure to Thrive 54840006   
Fatigue 84229001 Fatigue 84229001   
Fever 386661006 Fever 386661006   
Fibromyalgia 203082005 Fibromyalgia 203082005   
Cholecystectomy 38102005 
Gall Bladder 
Problem 
28231008. 
PROB 
SNOMED has no 
code for generic 
gallbladder 
problem 
Cholestasis 33688009 
Gall Bladder 
Problem 28231008.PROB 
Gallstone 2359190008 
Gastric Ulcer 429040005 Gastric Ulcer 429040005   
Bloating Symptom 248490000 
Gastrointestinal 
Upset 162059005 
Excludes 
abdominal pain 
with no assumed 
cause 
Gastritis 4556007 
Gastrointestinal 
Upset 162059005 
GERD 235595009 
Nausea 422587007 
Vomiting 422400008 
Gilbert Syndrome 27503000 Gilbert Syndrome 27503000   
Gingivitis 66383009 Gingivitis 66383009   
Gluten Allergy 
Non-Celiac 414285001 Gluten Sensitivity 441831003 
Excludes 
autoimmune celiac 
disease Gluten Sensitivity 441831003 
Gynecomastia 4754008 Gynecomastia 4754008   
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Issue SNOMED Parent Issue Parent SNOMED 
Parent Issue 
Comment 
Cluster Headache 193031009 
Headache 25064002   
Headache 25064002 
Headache Chronic 431237007 
Migraines 37796009 
Heart Disease 56265001 
Heart Disease 56265001   
Myocarditis 50920009 
Hepatic 
Encephalopathy 13920009 
Hepatic 
Encephalopathy 13920009   
Acute Hepatic 
Failure 19720009 Hepatic Failure 59927004   
Hepatic Failure 59927004 
Hyperammonemia 9360008 Hyperammonemia 9360008   
Hypercholesteremia 13644009 Hypercholesteremia 13644009   
Hyperhidrosis 312230002 Hyperhidrosis 312230002   
Hypoferritinemia 165623008 Hypoferritinemia 165623008   
Hypotension 45007003 Hypotension 45007003   
Hysterectomy 236886002 Hysterectomy 236886002   
Common Cold 82272006 
Infectious Disease 40733004   
Dientamoeba 
fragilis Infection 240367005 
Fungal Skin 
Infection 14560005 
Helicobacter pylori 
Infection 721730009 
Infectious Disease 40733004 
Infectious 
Mononucleosis 271558008 
Influenza 6142004 
MRSA Infection 266096002 
Mycosis 3218000 
Otitis 43275000 
Pneumonia 233604007 
Sepsis 91302008 
Sinusitis 39671009 
Skin Infection 108365000 
Urinary Tract 
Infection 68566005 
Varicella Zoster 
Infection 38907003 
Viral Hepatitis 3738000 
Insomnia 193462001 Insomnia 193462001   
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Issue SNOMED Parent Issue Parent SNOMED 
Parent Issue 
Comment 
Irritable Bowel 
Syndrome 10743008 
Irritable Bowel 
Syndrome 10743008   
Jaundice 18165001 Jaundice 18165001   
Injury to Anterior 
Crucial Ligament 127292004 Joint Injury 125610000 Includes all sprains and strains Joint Injury 125610000 
Kerato-
conjunctivitis Sicca 302896008 
Kerato-
conjunctivitis Sicca 302896008   
Kidney Stones 95570007 Kidney Stones 95570007   
Knee injury 1256010008 Knee injury 1256010008   
Lactose Intolerance 2764325008 Lactose Intolerance 2764325008   
Leukopenia 419188005 
 Cytopenia  508200005   Lymphopenia 48813009 
Thrombocytopenia 302215000 
Hepatic Fibrosis 62484002 
Liver Damage NOS 243978007 
Used when these 
types of liver 
damage are 
reported but by 
unknown cause.  
Typically assumed 
AIH-induced 
Hepatomegaly 80515008 
Liver Cyst 85057007 
Liver Damage NOS 243978007 
Mole 400096001 Mole 400096001   
Anxiety 48694002 
Mood Issue 
(Dysphoric Mood) 271596009 
Includes any hint 
of negatively 
altered mood; not 
just diagnosed 
psychiatric issues 
Depressed Mood 366979004 
Dysphoric Mood 30819006 
Feeling Stressed 224974006 
Labile Mood 18963009 
Mood Issue 271596009 
Panic Attack 225624000 
Reactive Depression 87414006 
Muscle Twitch 60238002 Muscle Twitch 60238002   
Muscle Spasm 221360009 
Myalgia 68962001   
Myalgia 68962001 
NAFLD 197315008 NAFLD 197315008   
Bilirubin Normal 166611006 
Normal LFT 250119000   Stabilized AIH 408335007.STAB 
Stabilized AIH 
Serum 
408335007.STAB.
SER 
Osteoarthritis 396275006 Osteoarthritis 396275006   
Osteopenia 312894000 Osteopenia 312894000   
Ovarian Cyst 79883001 Ovarian Cyst 79883001   
 
 
133 
 
Issue SNOMED Parent Issue Parent SNOMED 
Parent Issue 
Comment 
Ruptured Ovarian 
Cyst 95598005 
Numbness of Lower 
Limb 309537005 Paresthesia 91019004   
Paresthesia 91019004 
Primary Biliary 
Cirrhosis 31712002 
Primary Biliary 
Cirrhosis 31712002   
Physical Pain 22253000 Physical Pain 22253000 
Coded only when 
no further nature 
of the pain is 
known. 
Lung Collapse 46621007 Pleural Disorder 77252004   
Polymyositis 31384009 Polymyositis 31384009   
Portal Hypertension 34742003 Portal Hypertension 34742003   
Positive Lyme Titer 310567000 Positive Lyme Titer 310567000 
Not included with 
other antibody 
titers due to lack of 
hepatic 
involvement 
Caesarean Section 11466000 
Pregnancy 289908002 
A user with history 
of Caesarean 
section is assumed 
to have been 
pregnant. Pregnancy 289908002 
Primary Sclerosing 
Cholangitis 197441003 
Primary Sclerosing 
Cholangitis 197441003   
Pruritus 418363000 Pruritus 418363000   
Raynaud 
Phenomenon 266261006 
Raynaud 
Phenomenon 266261006   
Infertility 6738008 
Reproductive 
Disorder 362968007 
Excludes menstrual 
issues 
Polyuria 28442001 
Reproductive 
Disorder 362968007 
Odynypnea 75483001 
Respiratory 
Disorder   50043002 
Excludes 
respiratory 
infections, which 
are considered 
infectious diseases 
Respiratory 
Disorder 50043002 
Rhabdomyolysis 240131006 Rhabdomyolysis 240131006   
Splenomegaly 16294009 Splenomegaly 16294009   
Asymptomatic AIH 408335007. ASYMP Stabilized AIH 408335007. STAB 
Excludes AIH 
known to be LFT-
stable (see normal Compensated AIH 408335007.COMP 
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Issue SNOMED Parent Issue Parent SNOMED 
Parent Issue 
Comment 
Stabilized AIH 
Antibody 
408335007.STAB. 
AB 
LFT) and 
symptomatically 
stable AIH Stabilized AIH 
Gross 
408335007.STAB. 
BIOP 
Constipation 14760008 Stool Abnormal 201222006   
Stroke 230690007 Stroke 230690007   
Tachycardia 3424008 Tachycardia 3424008   
Hypothyroidism 40930008 
Thyroiditis 82119001 
Excludes 
autoimmune 
thyroiditis 
Thyroid Disorder 
NOS 82119001 
Type 2 AIH 721712002 Type 2 AIH 721712002   
Esophageal Varices 28670008 
Varices 128060009   Gastric Varices 91109007 
Varices 128060009 
Vertigo 399153001 Vertigo 399153001   
Vision Disorder 95677002 Vision Disorder 95677002 
Only includes 
anomalies 
correctable with 
optometric means 
Vitiligo 56727007 Vitiligo 56727007   
Moon Facies 67967009 
Weight Gain 8943002 
Moon facies are 
assumed to be a 
weight gain issue Weight Gain 8943002 
Weight Loss 89362005 Weight loss 89362005   
Xerostomia 87715008 Xerostomia 87715008   
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APPENDIX V. PAIN & INJURY REGEX MEMBER DICTIONARY 
 
Negations 
"never", "do_not", "don_t", "you", "i_wonder", "heard", "wondered", 
"understand", "not_had", "nt_had", "n_t_had", "i_think", "was_thinking" 
 
Pain/Injury Type: General Physical Pain 
"pain","hurt", "ache", "aching", "troubl", "cramp", "sting", "tear", 
"issue","sore", "feeling_in", "felt_my" 
   
Pain/Injury Type: Neuropathic Pain 
"_burn", "tingl", "_sting", "paresth" 
     
Pain/Injury Type: Fracture 
"broke", "fractur", "break", "snap", "shatter" 
   
Pain/Injury Type: Soft Tissue Injury 
"sprain", "strain", "tear", "tore", "bruis", "torn", "dislocat" 
   
Pain/Injury Type: Muscle Pain & Injury 
"sore", "cramp", "spasm", "knot", "tight", "spastic" 
   
Location: Joint (non-Hip) 
“cartilage”,”joint”,”tendon”,”tendinitis”,”knee”,”meniscus”,”meniscal”,
”_acl_”,”knuckle”,”thumb”,”ankle”,”heel”,”shoulder”,”elbow”,”bursitis”,
”bursa” 
 
Location: Hip 
pelvis,_hip_”,”_hips_”,”pelvic" 
 
Location: Lower Limb 
“toe”,”leg”,”thigh”,”femur”,”_shin_”,”tibula”,”fibula”,”calf”,”calves”,
”foot”,”feet" 
 
Location: Upper Limb 
"arm”,”humerus”,”hand”,”finger",”thumb”,”pinky”,”pinkie” 
 
Location: Back & Spine 
“_back_”,”lumbar”,”spinal”,”neck”,”thorac”,”spine”,”sacral”,”tailbone”,
”verteb”,”disc" 
 
Location: Oral & Dental 
"tooth”,”teeth”,”gum”,”mouth”,”oral”,”tongue" 
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Location: Abdomen 
"tummy”,”stomach”,”gut_”,”llq”,”luq”,”ruq”,”rlq”,”gastro”,”abdom”,”quad
rant”,”kidney”,”pancrea”,”bowel”,”colon”,”midsection”,”mid_section”,”be
lly”,”navel”,”spleen”,”pancrea”,”urq”,”ulq”,”lrq”,”flank”,”left_lower”,
”left_upper”,”right_lower”,”right_upper”,”lower_right”,”lower_left”,”up
per_right”,”upper_left" 
 
Location: Thorax 
"thora”,”chest”,”lung”,”_rib_”,”_ribs_”,”ribcage" 
 
Location: Muscle (NOS) 
"_myalg”,”muscl”,”muscul" 
 
Location: Bone (NOS) 
"bone”,”bony" 
 
Location: Head (Cranium) 
"head”,”skull”,”eye”,”face”,”facial”,”migrain”,”bell_" 
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APPENDIX VI. REGEX MEMBERS FOR DETECTION OF NON-PAIN RELATED 
SIGNS, SYMPTOMS, AND COMORBIDITIES 
 
Note: This appendix only contains the distinguishing terms for experiencers of all noted signs, 
symptoms, and comorbidities.   
 
Negations  
"dont", "do_not", "don_t", "has_not", "hasnt", "hasn_t", "has_nt", 
"never_had", "never_have", "negative", "normal", "doesnt", "does_not", 
"doesn_t" 
   
Experiencers  
"has", "dx", "having", "feeling", "suffer", "diagnosed", "becoming", 
"getting", "i_am", "i_m", "_im_", "any_one", "anyone", "any_body", 
"anybody","also", "is_", "have", "my_", "his", "her", "sons", "son_s", 
"hes", "he_s", "he_is", "for_", "going_through", "get_", "dx" 
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APPENDIX VII. LAB TEST REGEX MEMBER DICTIONARY 
 
Test Type Indicators 
Test Type: Liver Function Tests (LFTs) 
“_ast_”,”_alt_”,”astalt”,”altast”,”spt”,”sgot”,”liver_function”,”liver_
test”,”liver_lab”,”liver_level”,”hepatic_level”,”enzyme”,”livers_”,”lft
”,”hft”,”ggt”,”alkaline”,”alp_”,”phosphatase”,”_asts”,”_alts”,”_bun_”,”
nitrogen”,”numbers”,”creatinin”,”altsasts”,”astsalts”,”alpast”,”alpalt”
,”astalp”,”altalp”,“ammonia”,”ammone”,”bili_”,”bilirub”,”billirub”,”cre
atinin”,”creatine”,”cpk” 
Test Type: White Blood Cell Tests (WBC) 
“bloods”,”wbc”,”white_”,”whites_”,”count_”,”blood_cell”,”cell_count” 
Test Type: Red Blood Cell Tests (RBC) 
“red_blood”,”rbc”,”eryrthrocyte”,”iron”,”_fe_” 
Test Type: AIH Autoantibodies (AABs) 
“lkm”,”anca”,”_ana_”,”_anti_”,”_ab_”,”antibod”,”antianc”,”antiana” 
 
Test Value Indicators 
Value Indicators: Low Prefixes/Suffixes 
"low_", "depress", "lower", "only", "drop", "fell" 
Value Indicators: High Prefixes/Suffixes 
"raise", "raising", "rise", "rising", "elevate", "high", "nonresp", 
"non_resp", "jack" 
Value Indicators: Normal Prefixes/Suffixes 
"_normal", "ok_", "okay", "good", "great", "perfect", "fine", 
"no_problem", "negative", "_stable", "_stabili", "respond", 
"wonderful","acceptab", "not_a_problem", "nt_a_problem", "not_problem", 
"nt_problem", "to_normal", "back_normal", "improv", "better" 
Value Indicators: Abnormal Prefixes/Suffixes 
"bad", "abnormal", "not_good", "not_fine", "_off", "positive", 
"unstable", "unstabil", "all_over", "horribl", "terribl", "awful", 
"not_respond", "nt_respond", "problem", "issue", "wrong", "screw", 
"not_normal", "worse" 
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APPENDIX VIII.  CLASSIFIED SCHEDULE OF ALL DOMAINS & SUBDOMAINS OF 
USER COMMUNICATION 
 
Domain Name Description & Scope Notes N 
DEMO Demographics 
Commonly elicited social 
characteristics of an individual 
(N/A) 
DEMO.AGE Age Chronological age-typically in years 14 
DEMO.AGE.CGMIN Caregiver For Minor 
The user is posting on behalf of 
someone who is under the age of 
majority 
1 
DEMO.GEN.FEM Female Gender 
Affiliating with the female (woman or 
feminine) gender 
1 
DEMO.GEN.MALE Male Gender 
Appearing to affiliate as a male gender 
(man or masculine) individual 
1 
DEMO.MARR Married 
In an ideally permanent and 
monogamous relationship 
1 
ENV 
Physical 
Environment 
The physical surroundings of a 
person, including geographical 
location and natural environment 
(N/A) 
ENV.PET Having pets 
In possession of non-human animal 
companion 
3 
ENV.PROB 
Problems in the 
physical 
environment 
Problems with one's physical 
surroundings 
1 
ENV.RSLOC 
Geographical 
residence location 
Geographical residence location 1 
ENV.RSLOC.AUS Australian Resident Lives in Australia 1 
ENV.RSLOC.US US Resident Lives in the United States 11 
ENV.WSMK 
History of Wood 
Smoke Exposure 
A history of wood smoke being in the 
person's surroundings 
2 
FAMHX Family History 
Medically-recognized symptoms and 
diagnoses of blood relatives 
(N/A) 
FAMHX.AI 
Family History of 
Autoimmune 
Disease 
Evidencing a blood relative with a 
disease where the immune system 
attacks the body 
12 
FAMHX.CA 
Family History of 
Cancer 
Evidencing a blood relative with a 
disease that involves an uncontrollable 
malignant growth of cells 
1 
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Domain Name Description & Scope Notes N 
FAMHX.ID 
Family History of 
Infectious Disease 
Evidencing a blood relative that had a 
communicable disease 
1 
FAMHX.PSY 
Family History of 
Psychological Issues 
Evidencing a blood relative who had 
problems and-or diagnoses of mood 
issues 
1 
FIN Finances 
Pertaining to monetary instruments, 
acquirement thereof (e.g., 
employment) and sureties (e.g., 
insurance) 
(N/A) 
FIN.POS 
Positive financial 
status 
Favorable financial factors (N/A) 
FIN.POS.INS 
Favorable Insurance 
Status 
Favorable health insurance status 2 
FIN.POS.INS.MEDS 
Favorable 
Medication 
Insurance 
In possession of what is believed to be 
a good medication coverage plan 
1 
FIN.PROB 
Problems with 
finance 
Unfavorable financial factors (N/A) 
FIN.PROB.INS Insurance Problems Having problems with insurance 3 
FIN.PROB.INS.MEDS 
Insurance Problems: 
Medications 
Having problems getting medications 
due to insurance 
13 
FIN.PROB.MEDS 
Problems Affording 
Medications 
Having problems affording medications 
- Not attributable to insurance issues 
1 
GRSOC 
Support Group 
Socializing 
Greeting others within context of the 
group discussion itself 
7 
GRSOC.CONF 
Support Group 
Annual Conference 
Socialization relating to the annual 
group AIH conference 
1 
GRSOC.GRE 
Giving greetings to 
group members 
Simple greetings exchanged over the 
online support group 
6 
GRSOC.HUMOR Group Humor 
Humor shared over the online support 
group 
1 
GRSOC.INTRO 
Introducing Oneself 
on the Group 
A new user introducing themselves to 
the online support group 
1 
GRSOC.IRL 
Group members in 
real life 
Meeting or knowing group members in 
real life 
1 
GRSOC.PRIV 
Privacy issues on 
group 
Respecting a group member's privacy 1 
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Domain Name Description & Scope Notes N 
HCS Healthcare System 
Matters pertaining to the user’s 
interaction with healthcare, 
including clinic and clinicians-
providers.  Excludes personal 
medical story (MEDXS) and 
insurance (FIN.INS) discussions. 
(N/A) 
HCS.POS 
Healthcare System: 
Pros 
Positive aspects of healthcare system 1 
HCS.POS.CLIN 
Positive Clinician 
Experiences 
Having had positive experiences with 
clinicians-providers 
5 
HCS.POS.CLIN.COOP 
Clinicians 
cooperating 
The user's clinicians are in fact 
cooperating 
2 
HCS.POS.TECH 
Benefits of 
Technology in 
Healthcare 
Positive technological aspects of 
healthcare system 
1 
HCS.PROB 
Healthcare System: 
Problems 
Negative experiences with the 
healthcare system 
1 
HCS.PROB.CLIN 
Problems with 
Clinicians 
Problems with clinician 4 
HCS.PROB.CLIN.COOP 
Clinicians Not 
Cooperating 
Problems with clinicians unable to 
cooperate 
1 
HCS.PROB.CLIN.DAGR 
Disagreeing with 
Clinician 
Disagreeing with a clinician 1 
HCS.PROB.CLIN.IGN 
Clinician Ignoring 
Patient 
Problems with clinician ignoring 
patient 
1 
HCS.PROB.CLIN.INCMP 
Clinician Being 
Incompetent 
Problems with clinician being ignorant 
or incompetent 
2 
HCS.PROB.DXLAB 
Problems getting  a 
diagnosis 
Problems and conflict arising from 
diagnosis and-or lab tests 
4 
HCS.PROB.GEO.MOVE 
Problems with 
clinicians due to 
frequent moving 
Problems with clinicians due to 
frequent moving 
1 
HCS.PROB.WAIT 
Excessive Waiting 
for Healthcare 
Problems having to wait for healthcare 8 
HCS.PROB.WRHEP 
Healthcare thinking 
wrong hepatitis 
Problems with healthcare system 
believing that the user has viral or 
alcoholic hepatitis 
9 
 
 
142 
 
Domain Name Description & Scope Notes N 
ISHR 
Sharing 
Information 
Sharing information for academic 
purposes with no support intended.  
Indicates advanced knowledge of the 
subject matter, which is typically 
health. 
1 
ISHR.CAM 
Academic interest in 
CAM 
Academic (not necessarily personal) 
interest in complementary-alternative 
medicine 
1 
ISHR.HCS 
Academic discussion 
on healthcare system 
Sharing factual information about the 
healthcare system-not as a form of 
support 
2 
ISHR.HLTH 
Academic discussion 
on health and 
medical issues 
Sharing factual information about 
health and medicine - not as a form of 
support 
25 
MEDXS 
Medical 
stories/histories 
Medically-recognized elements of 
health, including diagnoses, 
medication intake, lab test results, 
signs, and symptoms.   
19 
MEDXS.AI 
Histories of 
autoimmune disease 
Histories of autoimmune disease 
including AIH 
27 
MEDXS.DXLAB 
Discussing lab 
results and diagnoses 
pertinent 
Discussing lab results and diagnoses 
pertinent 
61 
MEDXS.GENE 
Discussing genetic 
test results 
Revealing one's genetic test results 1 
MEDXS.HOSP 
History of 
hospitalization 
History of hospitalization 4 
MEDXS.MEDS Medication intake Affirming medication intake 56 
MEDXS.MEDS.COMP 
Treatment 
compliance 
Adhering to treatment and lifestyle 
recommendations given by the clinician 
or provider 
2 
MEDXS.MEDS.EFF 
Medication effective 
after intake 
Evidencing that a medication had a 
desired effect after intake 
1 
MEDXS.MEDS.FEAR Fear of Medications Expressing fear of medications 2 
MEDXS.MEDS.INEFF 
Medications 
Ineffective 
Discussing medications that did not 
have their intended effect 
3 
MEDXS.MEDS.LOWRX 
Lowering of drug 
dosages 
Discussing having lowered medication 
dosage.  Related to 
VPT.LOWRX.AGR 
1 
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Domain Name Description & Scope Notes N 
MEDXS.MEDS.WOR 
Worried about 
medication effects 
Worried about medications - usually 
side effects 
1 
MEDXS.NDC 
Not Diagnosed but 
Concerned 
Expressing worry due to concern about 
having a disease and not being 
diagnosed yet 
1 
MEDXS.PREG 
Discussing one's 
pregnancy 
Discussing one's pregnancy 3 
MEDXS.PROC 
Stories about 
procedures 
Discussing procedures and surgery - 
excludes diagnostic procedures e.g. 
biopsy 
6 
MEDXS.SYMP 
Medical symptoms 
and comorbidities 
Discussion of symptoms - ADEs - and 
comorbid diagnoses 
59 
MEDXS.TRNSP 
Liver Transplant 
History 
Stories and histories about liver 
transplant 
1 
NCOMP Noncompliance 
The act of not adhering to provider-
mandated treatments 
(N/A) 
NCOMP.MEDS 
Medication 
Noncompliance 
The act of not adhering to one's 
prescription drug regimen 
4 
QOLS 
Quality of Life 
Factors 
Psychosocial factors ranging from 
emotions to coping to abilities to 
perform the daily activities to one’s 
personal satisfaction 
(N/A) 
QOLS.DECL Declining QOL 
Evidencing a declining quality of life 
(QOL) 
(N/A) 
QOLS.DECL.EMP 
Declining 
Employment 
Declining ability to pursue employment 1 
QOLS.DECL.EXER 
Declining Exercise 
Capability 
Exercise capabilities declined or 
declining 
3 
QOLS.POS 
Favorable QOL 
Factors 
Favorable quality of life (QOL) factors (N/A) 
QOLS.POS.ADL 
Favorable ADL 
Abilities 
Favorable capabilities in performing 
activities of daily living (ADLs) 
1 
QOLS.POS.EMP 
Favorable 
Employment Status 
Discussing the ability to be employed 3 
QOLS.POS.NRG 
Favorable Energy 
Levels 
Discussing having more physical 
energy. Only use if there is no exact 
QOL measure (ADL, EXER, etc.) 
stated 
2 
QOLS.PROB Poor QOL Evidencing a poor quality of life 4 
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Domain Name Description & Scope Notes N 
QOLS.PROB.ADL 
Poor ADL 
Capabilities 
Poor quality of life due to inability to 
do activities of daily living (ADLs) 
6 
QOLS.PROB.DIET 
Inability to eat the 
desired diet 
Quality of life impaired due to inability 
to eat preferred foods 
1 
QOLS.PROB.EMO 
Emotional Issues 
interfering with 
QOL 
Poor quality of life due to emotional 
problems.  Only use if no other QOL 
(e.g. ADL) is affected 
2 
QOLS.PROB.EMP 
Poor Employment 
Status 
Poor quality of life due to lack of 
employment 
7 
QOLS.PROB.EMP.WRHEP 
Employment 
discrimination: 
Wrong Hepatitis 
Employment discrimination: Wrong 
Hepatitis 
1 
QOLS.PROB.EXER 
Poor Exercise 
Ability 
Poor quality of life due to inability to 
exercise 
1 
QOLS.PROB.HHD Hyperhidrosis 
QOL interfered with by excessive 
sweating 
1 
QOLS.PROB.NRG 
Energy/fatigue 
problems 
Energy-fatigue problems 2 
QOLS.PROB.SEX Sexual problems Sexual problems 1 
QOLS.PSY Psychological QOL 
Mental feelings and attitudes that affect 
life - Can be positive or negative 
1 
QOLS.PSY.ANTIC Feeling anticipation 
Expressing a feeling of looking forward 
to something 
1 
QOLS.PSY.CNFU Confused attitude Confused attitude 2 
QOLS.PSY.DOU.MEDS 
Doubting medical 
treatment 
Skepticism at traditional medical 
treatments  
1 
QOLS.PSY.FEAR.AIH Fear of AIH 
Expressing fear of autoimmune 
hepatitis 
1 
QOLS.PSY.FEAR.DEATH Fear of death Expressing fear of death 1 
QOLS.PSY.FEAR.HLTH Fear for health Being afraid for one's health in general 1 
QOLS.PSY.FEAR.MEDS Fear of medication 
Being afraid of medications (usually 
due to adverse effects) 
3 
QOLS.PSY.FRUST.AIH Frustrated With AIH 
Becoming particularly upset due to 
AIH and its sequelae 
4 
QOLS.PSY.FRUST.AIS 
Frustrated with 
informational/advice 
support 
Becoming upset due to poor quality of 
information or advice 
2 
QOLS.PSY.FRUST.MEDS 
Frustrated with 
Medications 
Being dissatisfied with medications 2 
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Domain Name Description & Scope Notes N 
QOLS.PSY.FRUST.PLYRX 
Frustration due to 
polypharmacy 
Expressing frustration due to taking too 
many medications (polypharmacy) 
1 
QOLS.PSY.FRUST.PPAIN 
Frustrated With 
Physical Pain 
Becoming particularly upset due to 
pain 
1 
QOLS.PSY.FRUST.SUP 
Complaining About 
Support 
Complaining about support quality 5 
QOLS.PSY.FRUST.WRHEP 
Frustration Due to 
Wrong Hepatitis 
Frustration due to public and-or 
professionals not understanding that the 
user's hepatitis is autoimmune - 
nonviral and nonalcoholic 
2 
QOLS.PSY.HOP Expressing Hope 
Expressng a positive sense that things 
will become better 
1 
QOLS.PSY.GRA.ADVOC 
Grateful for 
advocacy efforts 
Grateful for advocacy efforts in AIH 1 
QOLS.PSY.GRA.FAM Grateful for family Grateful for relatives and their actions 1 
QOLS.PSY.GRA.HLTH 
Grateful for Good 
Health 
Expressing thankfulness due to good 
health 
3 
QOLS.PSY.GRA.MEDS 
Grateful for 
Medications 
Expressing thankfulness due to 
medications working well 
5 
QOLS.PSY.GRA.PLM 
Grateful for similar 
patients 
Grateful for similar patients 4 
QOLS.PSY.JOY Joyous Expressing a sense of happiness 3 
QOLS.PSY.RLG Religious 
In belief of a dogmatic higher power 
and spirituality 
1 
QOLS.PSY.RSG Resignation Expressing a sense of giving up 5 
QOLS.PSY.SAD Sadness Expressing solemn negative emotion 1 
QOLS.PSY.WISH.CONF 
Wishing to attend 
conference 
Wanting to attend a conference 
(typically AIH related) 
1 
QOLS.PSY.WISH.HLTH Wishful about health 
Expressing the desire for one's health to 
improve 
1 
QOLS.PSY.WOR.DXLAB 
Worried about 
diagnosis or lab 
results 
Worried about diagnosis or lab results 1 
QOLS.PSY.WOR.HLTH Worried about health Worried about health 2 
RSPRT 
Research 
Participation 
Participates as a subject in AIH-
related research 
4 
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Domain Name Description & Scope Notes N 
SOC Social factors  
Factors pertaining to the individuals 
who physically surround the user.  
Excludes marital status 
(DEMO.MARR).  Excludes the 
provision and receiving of online 
support from other group members 
(SUP) 
(N/A) 
SOC.HGNDK Has Grandchildren 
Has offspring who in turn have 
offspring 
3 
SOC.HHA 
House Helper 
available 
Someone else is available to help do 
chores in and around the house 
1 
SOC.HKIDS Has kids Has offspring (regardless of age) 7 
SOC.HX.ABUSE History of abuse 
History of being a victim of physical-
sexual-or emotional abuse 
1 
SOC.HX.LSUP 
Social history of a 
lack of support 
Social history of a lack of support 1 
SOC.JOB.CLIN Works as a clinician 
Having a job as a nurse, doctor, or 
other medical provider 
8 
SOC.MARR Married 
Being in an ideally permanent and 
monogamous relationship with a 
romantic partner 
3 
SOC.PROB.SEX Sexual problems Sexual problems 1 
SOC.RLPLM 
Other similar 
patients in real life 
Knowing a similar patient in real life 
not from the group 
2 
SOC.TRAVL Travels 
Engages in visiting locations other than 
one's place of residence 
1 
STX 
Self-treatment 
stories 
Sharing stories about personal and 
self-care treatments, including diet 
and exercise.  These treatments 
might or might not be at behest of a 
provider. 
3 
STX.CAFF Caffeine usage Caffeine usage as self therapy 1 
STX.CAM 
Having CAM 
Treatment 
Discussion of engaging in 
complementary medicine treatment 
5 
STX.CAM.CEASE 
Stopping CAM 
treatment 
Cessation of complementary-alternative 
treatments 
2 
STX.CAM.CON 
Considering CAM 
Treatment 
Contemplating starting a 
complementary alternative treatment 
3 
STX.CAM.EFF 
Effective CAM 
Treatment 
CAM Treatment associated with 
improvement 
1 
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Domain Name Description & Scope Notes N 
STX.CAM.INTOL Intolerance of CAM 
The inability to tolerate a 
complementary-alternative therapy 
1 
STX.CHEMX 
Chemical exposure 
(avoiding) 
Avoiding exposure to environmental or 
foodstuff toxins for health purposes 
3 
STX.DIET 
Using Dietary 
Treatments 
Discussion of diet as a self-care 
treatment 
12 
STX.DIET.CON 
Contemplating 
Dietary Intervention 
Contemplating using a dietary 
intervention 
1 
STX.DIET.GF 
Using Gluten-Free 
Diet as Treatment 
Discussion of gluten-free diet as self-
care treatment 
2 
STX.DIET.LCARB 
Using Low-
Carbohydrate Diet as 
Treatment 
Using Low-Carbohydrate Diet as 
Treatment 
3 
STX.EXER 
Using Exercise as 
Treatment 
Discussion of exercise as a self-care 
treatment 
3 
STX.NOALC Avoiding Alcohol 
The avoidance of consumption of 
beverage ethanol 
1 
STX.VMIN 
Taking vitamins and 
minerals 
The act of self-care therapy with USDA 
recognized vitamins and minerals 
3 
SUP Support 
Communications made to request or 
provide assistance from or to another 
individual(s) 
(N/A) 
SUP.AIAC 
Requesting advice-
informational 
support from AC 
Requesting advice-informational 
support from AC - specifically 
mentioning him 
18 
SUP.GRACK 
Gratefully 
acknowledging 
Support 
Expressing thankfulness due to support 51 
SUP.OFF Offering Support The act of giving or offering support 5 
SUP.OFF.ADVOC 
Advocating the 
disorder 
Spreading the news about the disorder 
across the Internet and in real life.  Not 
searched for in support algorithms. 
5 
SUP.OFF.AIS 
Offering Advice-
Information 
(Assumed Health-
Related) 
Giving informational support or advice.  
Assumed to be health-related 
82 
SUP.OFF.EMO 
Offering Emotional-
Social Support 
Giving emotional (social) support 47 
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Domain Name Description & Scope Notes N 
SUP.PINQ 
Personal inquiry 
(used in support 
provision) 
Asking someone about themselves 19 
SUP.REQ.AIS 
Asking for Advice-
Information 
(Assumed Health-
Related) 
Asking for advice or information as a 
form of support.  Assumed to be health-
related 
51 
TECH 
Technological 
factors 
The user’s relationship with 
electronic technology 
(N/A) 
TECH.FRUST 
Frustration with 
technology 
Expressing negative emotions towards 
technology 
3 
TECH.SMUSE Use of social media 
Interest and competency in using online 
social media (not just using it per se) 
1 
TECH.UNFAM 
Unfamiliar with 
technology 
Not familiar or comfortable with using 
technology 
2 
TECH.WLRN 
Willingness to learn 
how to use a new 
technology 
Willingness to learn how to use a new 
technology 
1 
VPT 
Viewpoint 
(opinion) 
A personal opinion not necessarily 
grounded in fact. 
(N/A) 
VPT.ADVOC 
Expressing an 
opinion about 
advocacy efforts 
Demonstrating an opinion about efforts 
to shed light about AIH 
2 
VPT.AGR Agreeing Viewpoint Expressing agreement 7 
VPT.CAM Viewpoint on CAM 
An opinion about complementary-
alternative medicine therapies 
1 
VPT.CAM.AGR 
Agreement with 
CAM therapies 
Agreeing with or being biased towards 
complementary-alternative therapies 
2 
VPT.CAM.DOU 
Doubting CAM 
therapies 
Expressing skepticism that a 
complementary-alternative therapy may 
not work 
2 
VPT.HLTH 
Health-related 
viewpoint 
A viewpoint about health-related 
concerns, excluding complementary-
alternative medical therapies. 
2 
VPT.LOWRX.AGR 
Agreeing or for 
lowering 
prescription 
medication dosage 
Agreeing or for lowering prescription 
medication dosage 
1 
VPT.POL Political viewpoint Expressing a viewpoint on politics (N/A) 
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Domain Name Description & Scope Notes N 
VPT.POL.HLTH 
Health Politics 
Viewpoint 
Expressing health-related political 
viewpoints 
2 
VPT.RLG Religious viewpoint Religious viewpoint 2 
VPT.SUGG Making a suggestion 
The act of recommending something - 
not intended as support 
1 
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APPENDIX IX.  LIST OF SUPPORT DETECTION DICTIONARY TERMS 
 
Requesting Advice & Informational Support (REQ.AIS) 
 
"please", "does any", "need advice", "want advice", "what does", "can 
any", "will any", "please give","does any", "can i ", "should i ", 
"would i ", "could i ", "wanna know", "wanna find", "give me advice", 
"can my", "can we","should my", "must i ", "one tell", "do you know", 
"why is", "why does", "what is", "what does", "where are", 
"one tell", "one know", "body know", "to know", "can any", "will any", 
"can some", "will some", "would some", "would any", "why do","would 
you", "what is", "let me know", "lmk", "where are", "why is", "where 
is", "where can", "would my ", "will my ", "how can", "how should", "m 
clueless", "cant figure", "not figure", "nt understand", "not 
understand", "am i suppose","what am ", "why am ", "how am ", "where am 
", "where are ", "where is ", "how do", "will he ", "will she ", "will 
they ","is going on", " does", "dae ", "anyone else", "any one else", 
"anybody else", "any body else", "need an idea", "need ideas","could 
you", "would you", "wish i knew", "im asking", "am asking", "how 
would", "how should", "in advance", "wonder if", "want to learn","wanna 
learn", "want to know", "need to know", "any one can", "any body can", 
"anyone can", "anybody can", "one know", "body know","someone can", 
"some one can", "someone know", "some one know", "can someone", "can 
some one", "can somebody", "can some body","would someone", "would some 
one", "would somebody", "would some body", "would any body", "would 
anybody", "need advice", "have any of","body tell", "you tell", "just 
askin", "wanted to know", "want to know", "wanted to see", "want to 
see", "was askin", "be helpful", "be of help","need help", "want help", 
"help me", "can you give", "can you help", "anybody here", "any of 
you", "have a question", "question here","appreciated", "will this", "a 
question", "what have", "what has", "does somebody", "does someone", 
"can anyone", "can anybody","tell me why", "tell me how", "tell me 
what", "tell me which", "has anyone", "has any one", "has anybody", " 
is it ", "did they","any sugg", "any idea", "will this", "what has ", 
"what have", "was looking", "need info", "one have info", "body have 
info", "you have info","hellp", "helpp", "hellpp", "helppp", "helllp", 
"wtf", "what on ", "what the ", "why on ", "how on ", "in advance" 
   
 
Offering Advice & Informational Support (OFF.AIS) 
 
"you should", "my opinion", "read this", "check this", "should try", 
"http", "i read", "www", "pubmed","i think you", "you tried", "might 
want", "might need", "may want", "may need", "might wanna", "may 
wanna","try this", "you need", " imo ", "this link", "try this", "try 
to", "see and", "see if you", "if you can", "you really", "you 
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honestly","you do not", "dont you", "do you need", "just sayin", "you 
tried", "what you", "you want", "you might", "you should", "dude",  
"i think you", "can be", "could be", "should be", "can help", "could 
help", "should help", "need to", "might help","should help", "could 
work", "might work", "should work", "bad idea", "i recommend", "did it 
work", "any better","you tried", "try doing", "should try", "could 
try", "what you", "can you" 
 
 
Gratefully Acknowledging Support (SUP.GRACK) 
 
"thank", " ty ", "tysm", "thx", "thnk", "thanx", "tyvm", "tysm", "ty 
vm", "ty sm" 
 
 
Asking Administering colleague (AC) for Advice (SUP.AIAC) 
 
These terms have been censored because they are variants on the administering colleague (AC)'s 
name. 
 
 
Offering Emotional/Social Support (OFF.EMO) 
 
"hug", "prayin", "prayer", "be ok", "be alright", "be all right", 
"sorry", "hearts", "best wishes", "wish you luck", 
"sending many", "sending much", "aww", "sweetie", "honey", "hunny", 
"hon ", "congrat", "about you", "good thoughts", "sorry", "babe", "you 
thoughts", "best of luck", "hope it", "feel for", "with you","you can 
do", "good luck", "best wish", "hope things", "wishing", "in my 
thought", "in our thought", "i feel for", "i know how", "how it feels"} 
 
 
Personal Inquiry in Provision of Support (PINQ) 
 
"is your", "is his", "is her", "is he", "do you", "does he", "does 
she", "did you", "do you","have you", "can you", "you on", "you 
taking", "you take", "does your", "what is you", "what is his", "what 
is her", "whats you","whats his", "whats her", "whats their", "do 
your", "are your", "is your"; 
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